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ABSTRACT 
 
The objective of this dissertation is to design and optimize a nanoformulations 
(nanoparticle and nanofiber) delivery system loaded with anti-HIV topical microbicides for 
HIV prevention in women. 
In chapters 1 and 2, the overview of the problem, research objectives as well as the 
literature review of the technical and scientific background of this dissertation are introduced. 
In chapter 3, a study was designed to test the hypothesis that a triggered release of a 
topical anti-HIV microbicide (tenofovir: TFV) from hyaluronic acid based nanoparticles (HA-
NPs) can be achieved under the influence of hyaluronidase (HAase) enzyme. The Fractional 
Factorial Experimental Design (FFED) was employed to examine the formulation variables 
such as: molar concentrations of adipic acid dihydrazide (X1) and 1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (X2), volume of acetone (X3) and reaction 
time (X4), and their influence on the responses such as Y1; particle mean diameter: PMD (nm), 
Y2; polydispersity index: PDI and Y3; zeta (ζ) potential: (mV). The cross-linking efficiency of 
NPs was characterized by Fourier Transform Infra-Red (FT-IR), and 13C-nuclear magnetic 
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resonance (NMR) analyses. When formulated with X1; 2.49 mM, X2; 9.96 mM, X3; 60 mL, 
X4; 6 h, the HA-NPs exhibited a spherical shape with PMD, PDI, ζ potential, and drug loading 
of 70.6 ± 4.1 nm, 0.07 ± 0.02, -38.2 ± 2.8 mV, and 26.1 ± 1.2% w/w, respectively, (n = 3). 
Unlike for HA based gel, HAase notably triggered the drug release and HA degradation from 
the NPs after 24 h (~90% w/w and 65% w/w, respectively); whereas, in its absence, these 
values were ~39% w/w and 26% w/w, respectively. The NPs were non-cytotoxic to human 
vaginal VK2/E6E7 and End1/E6E7 cells and had no effect on Lactobacillus viability. These 
data suggested the possibility of using HA-NPs as a delivery system for intravaginal delivery 
of topical microbicides for the prevention of HIV transmission. 
In chapter 4, a study was designed to test the hypothesis that a stimuli-sensitive, safe 
and mucoadhesive thiolated hyaluronic acid (HA) based nanofibers (NFs) loaded with a topical 
vaginal microbicide (TFV) can be used for the prevention of HIV virus vaginal transmission 
in women. To test this, a novel thiolated sulfhydryl (-SH) group modified HA (HA-SH) was 
synthesized to fabricate the TFV loaded HA-SH-NFs (mean diameter ~75 nm) using 
electrospinning method. Sulfhydryl (-SH) group modified HA (HA-SH) were characterized for 
their size distribution, surface morphology, surface chemistry, crystallinity, mucoadhesion 
property, and in vitro drug release profile using size exclusion chromatography, powder X-ray 
diffraction, FT-IR, and 1H-NMR analyses. Mucin interaction and ellipsometer measurements 
confirmed that mucoadhesion of HA-SH-NFs was increased compared to that of native HA 
polymer based on an increase in the size (~4 fold), thickness (~3 fold) and adsorbed mucin 
amount (~2 fold) after 3 h incubation of HA-SH-NFs with mucin. A triggered drug release 
(~87% w/w) from NFs (drug loading ~17% w/w) occurred after 1 h in the presence of seminal 
hyaluronidase enzyme. It was observed that in the absence of HAase, the drug release from 
NFs followed the Peppas kinetic model whereas, in the presence of HAase, NFs followed 
Weibull model. The HA-SH-NFs were non-cytotoxic to vaginal VK2/E6E7 and End1/E6E7 
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cells and L. crispatus bacteria for 48 h. The results suggested that TFV loaded HA-SH-NFs 
templates developed in this study have the potential of vaginal delivery of topical microbicides 
for the prevention of HIV transmission. 
In chapter 5, in vivo evaluations of the developed HA-NPs and HA-SH-NFs were 
performed in female C57BL/6 mice. The histological analysis on the mice genital tract and 
other organs did not show any signs of damage upon once-daily administration of HA-NPs or 
HA-SH-NFs up to 7 days. Following 24 h exposure, HA-NPs or HA-SH-NFs did not show any 
significant immune (CD45) cell infiltration in mice vaginal tissues. The cytokines ((IL-1α, IL-
1β, IL-6, IP-10, IL-7, MKC, TNF-α) levels (pg/mL) in cervicovaginal lavage and 
cervicovaginal tissues were not significantly changed compared to control mice data analyzed 
after 24 h. The cytokine results confirmed the non-immunogenicity of developed 
nanoformulations. The in vitro anti-HIV activity of HA-NPs and HA-SH-NFs was analyzed at 
the MOI of 10,000, 5,000, and 1,000 using a luciferase assay. The pseudotyped HIV virus 
particles were generated using lipofectamine plasmid transfection method. The size 
distribution, mean diameter (~128 nm), and titer (~3.07×1010) of pseudotyped virus particles 
was analyzed using nanoparticle tracking analysis measurements. The in vitro anti-HIV activity 
data showed that the TFV loaded HA-NPs and HA-SH-NFs were able to inhibit the 
pseudotyped HIV virus replication. Moreover, the results also confirmed that the structural 
integrity and anti-HIV activity of TFV was preserved after the nanofabrication processes. The 
in vivo results illustrated that these nanoformulations (HA-NPs and HA-SH-NFs) are promising 
delivery systems and offered a safe delivery of anti-HIV microbicide candidates.  
Overall, the data presented here highlight the applicability and potential of TFV loaded 
HA-NPs and HA-SH-NFs templates for the topical vaginal delivery of anti-HIV/AIDS 
microbicide candidates. 
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CHAPTER 1 
INTRODUCTION 
 
1.1. Overview and Statement of the Problem 
 
Acquired immunodeficiency syndrome (AIDS) is a disease caused by Human 
immunodeficiency virus (HIV) infections. According to the recent report of the global AIDS 
epidemic, there are approximately 37 million people currently living with HIV/AIDS infections 
(Figure 1), corresponding to 0.8% of the total population of adults aged 15-49 years according 
to The Joint United Nations Programme on HIV and AIDS (UNAIDS) statistics (1). Since the 
epidemic began in the early 1980s, more than 75 million people have been infected and more 
than 30 million people have died of HIV-related infections. With 2.0 million new infections 
and 1.2 million deaths in 2014-2015, AIDS still remains the deadliest epidemic of our time (1). 
 
Figure 1. Global Estimates of People Living with HIV/AIDS 1990-2014. 
 
Unprotected heterosexual vaginal intercourse has become one of the major routes of 
HIV/AIDS infections and in general, women are at greater risk of heterosexual transmission of 
HIV virus (2). Women constitute over 50% of the HIV infected population, although in African 
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countries this percentage rises to approximately 60% (Figure 2A & 2B) (3). Moreover, young 
women aged 15-24 years are more likely (twice) to be infected with HIV compared to men of 
the same age.  
 
Figure 2. (A) People Living with HIV by Region as Percent of Global Total, (2014). (B) 
Women as Share of People Living with HIV by Region, (2014). 
 
There are multiple factors such as biological susceptibility, presence of other sexually 
transmitted diseases (STDs), hormonal contraceptive use and sociocultural discrepancies those 
amplify women's vulnerability to HIV infection (4). Moreover, among the efficiency of 
heterosexual transmission from male-to-female is 2 to 3 times greater under normal conditions 
and 8 times more in the presence of STDs as compared to that from female-to-male. Pregnancy 
is also shown to cause a two-fold increase in the risk of HIV due to thinned vaginal epithelium 
and exposure of columnar cervical epithelium.  Early efforts were focused on the use of 
physical barriers such as condoms. However, this approach has its own limitations such as 
expensive and cumbersome to use and is not a female controlled method of HIV prophylaxis 
(5). Moreover, condom effectiveness has been estimated to be approximately 80% against 
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heterosexual transmission and 70% against male-to-male sexual transmission of HIV infection, 
respectively, (6).  
Over the years, various delivery systems have been developed for prophylaxis of HIV 
(7, 8). Broadly, these systems can be divided into four categories viz. vaccines, macromolecular 
HIV entry inhibitors, antiretroviral (ARV) drugs, and nucleic acid-based therapeutics (3, 8, 9). 
Development of vaccines has been the most prominent prophylactic strategy for HIV virus 
infections. However, developing a safe and effective vaccine against HIV is a very challenging 
because of the vast genetic diversity and high mutation rate of HIV virus (9, 10). Several 
macromolecule entry inhibitors inhibit the binding of HIV to their target CD4 cells by 
interacting with envelope glycoproteins. These entry inhibitors showed a great promise in 
preclinical models, however, the clinical trials in humans failed to show any significant 
protection (9, 10). To date, despite a great deal of effort, there are no effective vaccines or 
prevention method against HIV infection is available. Thus, it is important to develop an 
effective method for prevention of HIV virus vaginal transmission that can be used by women. 
Currently, female-controlled prophylactic methods using microbicides are the major focus 
among HIV prevention strategies (3, 8, 9). These are agents applied within the vagina or rectum 
to prevent the transmission of sexually transmitted diseases including the HIV infections (11). 
A great variety of HIV microbicides candidates have been studied and tested (12-15). A lot of 
the emphasis has been put on the microbicide gel formulation, (16-20). however, such gel 
systems suffer from several disadvantages such as their limitation of encapsulating 
hydrophobic microbicides, the low retention time requires a high dosing frequency (21), poor 
acceptability and adherence. Also, to achieve a significant effect, the ideal microbicide 
formulation should have high vaginal retention time, higher drug loading and be able to release 
a high dose of microbicides in a short period of time when required (On-demand delivery 
systems). 
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With the recent advances in delivery system, nanotechnology provide one possibility of 
microbicide delivery due to their unique characteristics, such as small size, protection of native 
drug against harsh environment, ability to reduce irritation at the target site, and the ability of 
targeted and controlled release of drugs (22). Since, human semen is a potential carrier of the 
HIV virus during male to female intercourse (23), designing a semen-triggered 
nanoformulations delivery system would have the potential to inactivate or kill the HIV virus 
prior to exposure and penetration of the vaginal mucosa and systemic exposure. Human semen 
contains various specific enzymes in its content such as, hyaluronidase, acidic and alkaline 
phosphatases. Therefore, to develop a delivery system capable of giving response in the 
presence of specific enzymes of human seminal fluid will have the potential to inactivate or 
kill the HIV virus prior to exposure and penetration of the vaginal mucosa. 
 
1.2. Research Hypothesis 
 
 Based on the above mentioned facts, the research hypothesis of this work is to formulate 
a stimuli-sensitive and stable anti-HIV nanomicrobicides delivery system that will be safe and 
effective for HIV/AIDS therapeutics in women (Figure 3). 
 
1.3. Objectives 
 
The presented dissertation aims at exploring different nanoformulations strategies for 
HIV therapeutics in women. The objectives of this dissertation are: 
(1) To design and optimize a stimuli-sensitive nanoparticle formulation loaded with anti-
HIV topical microbicide. Design of experiments (DOE) is applied in the formulation 
and process variables screening and optimization. The developed formulations should 
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has a rapid/triggered release of microbicide drug under the influence of human seminal 
fluid enzyme.  
(2) The knowledge gained in previous aim is then applied in the development of stimuli-
sensitive mucoadhesive nanofiber formulations loaded with anti-HIV topical 
microbicide tenofovir.  
(3) In both the aims, the physicochemical characteristics of nanoformulations such as mean 
diameter, drug loading, surface morphology, stability, in vitro drug release profile and 
drug release kinetics were evaluated. The developed nanoformulations should be safe 
and thus, the in vitro cytotoxicity and cellular uptake are evaluated using vaginal 
epithelial and endothelial cells. Finally, nanoformulations were evaluated for their 
preclinical safety, non-immunogenicity, and in vitro anti-HIV activity in mice model. 
 
Figure 3. Microbicide Loaded Stimuli-sensitive Nanoformulations Delivery System for HIV 
Prevention and Treatment. 
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CHAPTER 2  
OVERVIEW AND PANDEMIC OF HIV INFECTIONS 
 
2.1. Steps Involved In HIV Life Cycle and Vaginal Acquisition of HIV Infection 
 
Unprotected heterosexual vaginal intercourse has become one of the major routes of 
HIV infection. To develop a delivery system for prevention of vaginal transmission of HIV, an 
understanding about the steps involved in HIV life cycle and its cervicovaginal (CV) mucosal 
transmission is required (Figure 4). There are multiple steps in the life cycle of HIV (24, 25) 
as explained below. 
 
Figure 4. Life cycle of HIV Virus. 
 
1. Binding and Fusion: The first step in the HIV entry process is binding of HIV gp120 to 
the host cell CD4 receptors, expressed on the surface of T lymphocytes, monocytes, 
macrophages and dendritic cells. Binding to CD4 is essential to the HIV infection process 
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because it induces conformational changes in the viral envelope that are necessary for 
membrane fusion and viral entry. The next step is the binding of gp120 to co-receptors 
CCR5 and CXCR4. After the first conformational change during the binding of gp120 to 
CD4 cell receptor, the viral gp120-gp41 glycoprotein complex undergoes further 
conformational changes, exposing the N-terminal domain of gp41 and allowing the fusion 
peptide sequence to insert into the cellular membrane of the host cell.  
2. Reverse Transcription: The fusion stage is followed by the reverse transcription and 
integration stages. The reverse transcriptase (RT) enzyme converts single-stranded HIV 
RNA into double-stranded HIV DNA through a process called reverse transcription, so it 
can be integrated into the host DNA. 
3. Integration: The new virus genetic material enters the nucleus of the CD4 cell and 
integrate itself into host genetic material with the help of integrase enzyme. Once the viral 
DNA has integrated into the host cell’s DNA, the host cell is infected for the remainder of 
its life. The integrated viral DNA is now called as a provirus. 
4. Transcription and Translation: The provirus DNA serves as a template for the creation 
of new viral RNA via a process known as transcription using the host cell enzymes. This 
results in the production of multiple copies of viral RNA. The newly formed viral RNA 
moves out of the infected cell’s nucleus. The viral RNA carries code for the synthesis of 
viral proteins and enzymes through the translation process. The code is translated into long 
chains of amino-acids (polypeptide chains), which fold to produce structural proteins such 
as the viral envelope and enzymes (reverse transcriptase, integrase, and proteases). 
5. Assembly, Budding and Release: The protease enzymes cut the longer HIV proteins into 
individual proteins. When these come together with the virus genetic material, a new virus 
bud has been assembled. Budding is the final stage of the HIV virus life cycle. In this stage, 
the virus pushes itself out of the host cell, taking with it part of the membrane of the cell. 
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This outer part covers the virus and contains all of the structures necessary to bind to a new 
CD4 cell and receptors and begin the process again. A single infected cell can release many 
new HIV particles which move on to infect other cells in various parts of the body, where 
the viral life cycle is repeated. The infected cells are eventually destroyed. 
 
Vaginal Acquisition of HIV Infection 
The integrity of vaginal and cervical epithelium has been highly associated as a risk factor in 
vaginal acquisition of HIV (26). It has been shown that the virus can penetrate through thin 
gaps between the squamous epithelial cells and pass several cell layers from the luminal side. 
The mucosal surface, when intact, serves as a natural barrier for HIV. The vaginal microbiota 
in healthy adult women is dominated by Lactobacillus species. Some features such as low pH 
in the environment and the hydrogen peroxide (H2O2) produced by vaginal Lactobacillus flora 
has a virucidal effect (27, 28). Therefore, the chance of vaginal acquisition of HIV is relatively 
low when the mucosal barrier is intact (29-31). If vaginal mucosal barrier is compromised, cell-
free HIV virion can easily gain access to the Langerhans cells (LC), which is a type of dendritic 
cells (DC) having dendritic projections (dendrites) that might extend to the mucosal surface 
(32, 33). This allows the DCs to directly entrap HIV when there’s only minor tissue damage at 
mucosal surface. Meanwhile, CD4+ T cells and macrophages, the primary target cells of HIV, 
usually reside in the lamina propria and columnar epithelium come closer to the CV mucosa. 
Within hours of infection, these target cells in the sub-epithelium are infected (26). The 
mechanism of vaginal acquisition of HIV infection was shown in Figure 5. 
There are several other factors which may can significantly increase the likelihood of HIV 
transmission by disrupting the integrity of vaginal mucosal. These factors including the dry or 
traumatic sex (34-36), bacterial vaginosis (37, 38), or inflammatory diseases of the vagina (39-
42). These factors enhance the HIV vaginal transmission through increasing the amount of 
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target cells to the vaginal mucosa, alteration of normal vaginal microbiota and vaginal pH, 
disruption of H2O2 producing Lactobacillus bacteria, thinning and disrupting the cellular lining, 
and recruiting a pool of target cells for local HIV expansion [17]. After HIV expands locally, 
dissemination of infection occurs and the movement of virus to lymph nodes and secondary 
lymphoid organs generates a systemic infection. 
 
Figure 5. Factors Affecting and the Mechanism of Vaginal Acquisition of HIV Infection. 
 
2.2. Topical Microbicides for HIV Prevention 
 
Microbicide candidates prevent or reduce the sexual transmission of HIV or other 
sexually transmitted infections (STIs) when used in the vagina or rectum. Currently, the leading 
microbicide candidates are the antiretroviral (ARV) drugs and there are more than 25 ARVs 
targeting different steps of the viral cycle have been approved by the U.S. Food and Drug 
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Administration (FDA) (3). There are several categories of ARV drugs that have been used as 
potential microbicides including Reverse-transcriptase inhibitors, Protease inhibitors, Integrase 
inhibitors, Entry/Fusion inhibitors and, Maturation inhibitors (Table 1) (9, 43). 
Table 1: Classification of Antiretroviral Drugs. 
Classifications Ref. 
Category: Reverse Transcriptase (RT) Inhibitors 
MOA: RT Inhibitors prevent the RT enzyme from converting single-stranded HIV 
RNA into double-stranded HIV DNA through a process called reverse transcription. 
Subcategory-1: Nucleoside/nucleotide RT inhibitors (NRTIs) 
MOA: NRTIs act by blocking RT enzyme. These drugs are preferentially 
incorporated into HIV DNA, leading to termination of DNA synthesis. 
Drugs: Tenofovir, Lamivudine, Emtricitabine, Zidovudine, Abacavir, Adefovir, 
Didanosine, Zalcitabine, Entecavir, Stavudine, Tenofovir disoproxil fumarate, 
Tenofovir alafenamide fumarate, Festinavir, Apricitabine. 
Subcategory-2: Non-nucleoside RT inhibitors (NNRTIs) 
MOA: NNRTIs bind to a pocket near the active site, which causes a conformational 
change of the enzyme and inhibition of reverse transcription. 
Drugs: Efavirenz, Nevirapine, Etravirine, Rilpiverine, Delavirdine, Doravirine 
(44-
46) 
Category: Integrase Inhibitors  
MOA: Block the action of HIV enzyme integrase, which the virus uses to integrate 
its genetic material into the DNA of the host cell. 
Drugs: Raltegravir, Elvitegravir, Dolutegravir 
(47, 
48) 
Category: Protease Inhibitors  
MOA: Inhibits virus-specific processing of viral Gag and Gag-Pol polyproteins in 
HIV infected cells by inhibiting viral protease. 
(49) 
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Drugs: Saquinavir, Lopinavir, Atazanavir, Darunavir, Ritonavir, Indinavir, 
Nelfinavir, Amprenavir, Fosamprenavir, Tipranavir 
Category: Entry Inhibitors 
MOA: Interfere with the virus ability to bind to gp120 receptors on the outer surface 
of the cell it tries to enter. 
Drugs: Maraviroc, Vicriviroc 
(50) 
Category: Fusion Inhibitors 
MOA: Binds to the HIV-1 membrane glycoprotein gp41 and prevents the 
conformational changes required for viral membrane fusion with the cells. This 
prevents HIV from entering a cell. 
Drugs: Enfuvirtide, Sifuvirtide 
(50) 
Category: Maturation Inhibitors 
MOA: Maturation inhibitors inhibit the last step in gag processing in which the viral 
capsid polyprotein is cleaved, thereby blocking the conversion of the polyprotein into 
the mature capsid protein. Because these viral particles have a defective core, the 
virions released consist mainly of non-infectious virus particles. 
Drugs: Alpha interferon, Bevirimat, Vivecon. 
(51, 
52) 
Category: Capsid Inhibitors  
MOA: Inhibitors of HIV-gag polypeptide assembly. Dismantles assembled HIV-1 
capsid assembly tubes. 
Drugs: under development 
(53) 
Newer categories under development: 
RNaseH inhibitors, Budding inhibitors, LEDGF-based inhibitors, Vpu/tetherin-
based inhibitors, Vif/APOBEC3G-based inhibitors, CA/TRIM5α-based inhibitors. 
(54) 
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The only topical microbicide candidate to show high efficacy to date is the Tenofovir 
(TFV) which belongs to the category of ARV drugs under the subcategory of NRTIs (17, 55). 
TFV is a BCS Class III drug with high solubility but low permeability (9). It is a small molecule 
(molecular weight of 287.213 g/mol), hydrophilic drug with a log P value of -1.6 and two pKa 
values of 2.0 and 6.7 (56). TFV formulations such as vaginal gel (57), vaginal ring (58), solid 
lipid NPs (59), mucoadhesive chitosan NPs (60, 61), pH responsive NPs (62) and, microspheres 
(63), intended for the prevention of HIV transmission, have been successfully engineered. 
Although, TFV has been successfully considered as a topical vaginal microbicide, the extreme 
hydrophilicity of the TFV poses a major problem for its encapsulation into formulations. 
 
2.3. Formulation and Delivery Considerations of Topical Microbicide Candidates  
 
In the case of prophylaxis using ARV drugs, oral, rectal and vaginal routes have mainly 
been explored (9, 64) (Table 2). Oral route is most convenient and preferred however, it 
presents several challenges in microbicide delivery compared to vaginal and rectal routes 
(Table 2). Since, the heterosexual transmission of HIV through CV mucosa is the major route 
of HIV infection, vaginal route has been explored vastly for anti-HIV drug delivery 
applications.  
Table 2: Anti-HIV Delivery System Routes. 
Delivery 
route 
Advantages Limitations Ref. 
Oral   Convenient and preferred.  
 Easy and economical.  
 Non-invasive. 
 High patient acceptability. 
 Therapeutic agent’s instability 
under harsh acidic environment of 
stomach and various digestive 
enzymes. 
(9, 
64) 
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 First-pass metabolism. 
Vaginal  Potential for non-invasive, 
controlled delivery of drugs 
intended for both local and 
systemic effect. 
 The avoidance of hepatic first-
pass metabolism.  
 The large surface area, 
permeability and rich blood 
supply of the mucous 
membrane of the vagina, 
provide significant potential 
for the delivery of a wide range 
of compounds, including 
peptides and proteins. 
 Large surface area and rich 
blood supply, provides a rapid 
drug absorption and quick 
onset of action. 
 As hormone levels (especially 
estrogen) change over the 
menstrual cycle, several 
alterations in vaginal conditions 
are induced involving the 
thickness of the epithelial cell 
layer, the width of intercellular 
channels, pH, and secretions. 
These all affect the drug efficacy 
and distribution. 
 Low retention to the vaginal 
epithelium. 
 Leakage and messiness, thereby 
causing poor patient compliance. 
 Limitation of volume of drug 
formulations to be used in small 
vaginal cavity. 
(64, 
65) 
Rectal  Non-invasive and relatively 
stable conditions such as pH, 
temperature and rectal fluid 
volume.  
 Rich blood and lymphatic 
drainage may allow significant 
 Erratic drug absorption.  
 Presence and traffic of stool.  
 Acceptability (cultural) issues. 
(64, 
66, 
67) 
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systemic levels for different 
drugs. 
 Low enzymatic activity 
compared to the GI tract. 
 Relatively high amounts of 
drug can be administered. 
 Rapid onset of effect. 
 Self-administration, painless 
delivery. 
 May cause irritation dependent on 
drug and drug product 
characteristics.  
 May cause discomfort, leakage.  
 Low patient acceptability. 
 Smaller surface area of the rectal 
mucosa limits its absorptive 
capacity. 
 
Characteristics of an Ideal Vaginal Microbicide Candidate 
In order to achieve a therapeutic concentrations of a microbicide drug at the target site, 
several factors should be taken into consideration as given below. Such factors may have an 
impact on the drug release from the delivery system and consequently on the drug 
concentration in the target cells, and thus they may influence their potential therapeutic effects 
(3, 8, 9). 
 Drug physicochemical properties: Solubility, ionization, molecular weight, logP, 
permeability, and crystalline/amorphous nature. 
 Formulation aspects: Compatibility, toxicity, release rate of drug, mucosal surface 
coverage, homogeneity of drug distribution in formulation systems. 
 Anatomical site characteristics: Vaginal fluid composition and pH before and after 
sexual intercourse, effect of seminal fluid, etc. 
 Physio-pathological conditions of vagina at the time of product administration: 
Menstrual cycle changes, presence of seminal fluid, bacterial vaginosis or other genital 
infections.  
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 Physio-pathological conditions applying at the time of administration such as menstrual 
cycle changes, presence of seminal fluid, bacterial vaginosis or other genital infections.  
 
Several important criteria for vaginal microbicide products with regard to their efficacy 
and safety have been established (3, 8, 9). The required characteristics of an ideal vaginal 
microbicide formulation product are shown in Table 3. 
Table 3: Characteristics of an Ideal Vaginal Microbicide Product (3, 8, 9). 
Property Description 
Acceptability/ 
feasibility of 
manufacturing 
 Products should be simple and have a convenient dosage regimen.  
 Products must be acceptable by high-risk populations. 
 Product should be non-irritating, effective, with a long-lasting action. 
 Formulation production must be feasible, allowing for the production in 
the amounts needed to meet projected needs. 
 Product that can be used in conjunction with sex should be developed. 
 Should also be compatible with the existing prevention strategy, the male 
condom, and have no adverse effects on reproductive health. 
Efficacy  Microbicides must be efficient in preventing HIV transmission. 
 Active against a range of sexually transmitted pathogens 
 Should provide a long-term efficacy. 
It is also essential that the product is not inducing any drug resistance. 
Low cost  Microbicides must be affordable by high-risk populations. 
The product must be economically feasible as well as easy to use without 
interfering with sexual pleasure. 
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Safety  Products should be safe, with no localized/systemic toxicity.  
 Product should not have any effect on fertility and/or fetal abnormalities. 
 Have no-effect on the normal vaginal microbiota. 
 Must show inertness towards the vaginal epithelium. 
Stability  The microbicide products should be stable under diverse environmental 
conditions of vagina such as low pH of 3-4.5 and pH of about 7-8 during 
the sexual intercourse and in the presence of hydrogen peroxide released 
from Lactobacilli. 
 The product must have adequate shelf-life, with tropical conditions and 
the potential for lack of proper storage being considered. 
Drug delivery  A microbicide product should provide a significant drug level at the target 
site. 
 Product should provide a controlled, sustained or stimuli sensitive drug 
release as required. 
 Higher compatibility with different types of drugs having different 
physicochemical properties. 
 The dosage forms should allow the active drug to distribute through the 
vaginal epithelium for adequate time in order to be able to penetrate and 
reach the target cells. 
 Prolonged residence time on vaginal site 
 
Safety Consideration of an Ideal Vaginal Microbicide Candidate 
An ideal topical microbicide would not only be effective to prevent the vaginal 
transmission of HIV-1 virus but would also be safe for CV application, preserving the inherent 
defense system of the genital tract and causing little or no epithelial damage or inflammation 
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to the genital tract tissues. Based on this, it is important to evaluate the physicochemical 
properties, safety/cytotoxicity, cytokine secretion, epithelial damage, and tissue inflammatory 
reaction for any microbicide formulations (Table 4). 
Table 4: Vaginal/Rectal Microbicide Product Characterization. 
Physicochemical 
properties 
Activity/Efficacy Toxicity/Safety Pharmacokinetics/ 
Biodistribution 
Size, pH, charge, viscosity, 
stiffness, hardness, 
osmolality, spreading, 
retention, stability, 
permeation, compatibility, 
odor, appearance. 
Cell lines Cell lines Cell lines 
Ex vivo Vaginal microbiota Ex vivo 
In vivo  
(animal model) 
Immune response In vivo  
(animal model) In vivo  
(animal model), 
Epithelial 
integrity/damage 
End point End point End point End point 
Optimal physicochemical 
properties of microbicide 
products based on the 
specific requirements 
Anti-HIV activity 
(EC50) 
Cytotoxicity effect 
(CC50) 
Permeability 
Cell uptake Pro-inflammatory 
potential 
Drug distribution in 
tissues/plasma 
Cell-resistance Lactobacillus 
viability, vaginal pH 
changes 
Drug metabolism 
In vivo protection Potential for 
infection 
enhancement 
PK/PD correlation 
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Cytokines play an important role in HIV infection and transmission through CV mucosa 
(68, 69) and must be evaluated for any microbicide formulation. A microbicide formulation 
may elicit a transient change in the mucosal tissues, significant production and secretion of 
proinflammatory cytokines. A microbicide formulation was supposed to be in contact with the 
CV epithelium for a variable time before sexual intercourse and thus, should not cause the onset 
of inflammation or cytokine secretions (31). The role of different cytokines and in HIV 
infection and transmission is given in Table 5. 
Table 5: Cytokine Effects on HIV Disease Progression and Viral Replication. 
Cytokine Producing cells Alteration in 
HIV infection 
Potential effect in 
HIV replication  
IL-1  Macrophage, B cells, endothelial cells and 
fibroblasts in response to infections and 
inflammation 
↑ ↑ Replication 
↑ CD8+ T cell-
mediated HIV 
suppression 
IL-2 CD4 and CD8 T cells ↓ ↑ Replication 
IL-4  Activated CD4 T cells, but also by NK 
cells, mast cells and basophils 
↑ ↑ Replication 
↓TNF-α and IL-1β 
IL-6 T cells, B cells, monocytes, macrophages, 
fibroblasts and endothelial cells, in 
response to viral or bacterial infection 
↑ ↑ Replication 
IL-7  • Prostate in semen. 
• Stromal cells in the bone marrow and 
thymus. 
↑ ↑ Replication 
↑ HIV-1 
transmission and 
dissemination  
19 
 
• Keratinocytes, dendritic cells, 
hepatocytes, neurons, and epithelial 
cells. 
↑ CD8+ T cell 
mediated effect 
IL-8 Macrophages, T cells, neutrophils and 
endothelial cells in acute and chronic 
inflammatory states 
↑ ↑ Replication 
IL-10 Activated T and B cells, monocytes, 
macrophages and keratinocytes 
↑ ↓ Replication 
IL-12 Dendritic cells of macrophage lineage ↑ initially but 
as HIV 
progresses, 
IFN-γ ↓ and 
thus IL-12 
level ↓ 
↑ Replication 
IL-13 Dendritic cells and T cells ↓ ↓ Replication, ↓ RT 
IL-15  Monocytes, macrophages and dendritic 
cells 
↑ ↑ Replication 
↑ CD8+ T cell-
mediated HIV 
suppression 
IL-16 CD4 T cells, mast cells and eosinophils in 
response to stimuli (mitogens, histamine 
and serotonin) 
↓ ↓ Replication 
IL-17 CD4+ T helper (Th) cells, referred to as 
Th17 cells 
↑ ↑ Speed of HIV 
pathogenesis 
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IL-18 Macrophages and other cells ↑ Serum level ↑ HIV Production 
through NF-kB 
pathway 
TFN-α/β Monocytes, macrophages, T cells, B cells, 
NK cells, neutrophils and microglia cells 
↑ ↑ Replication 
IFN-
α/β/γ 
• IFN-α is produced in leukocytes 
infected with virus. 
• IFN-β is from fibroblasts infected with 
virus. 
• IFN-γ is induced by the stimulation of 
sensitized lymphocytes with antigen or 
non-sensitized lymphocytes with 
mitogens. 
↓ Antiviral effect 
 
2.4. DOSAGE FORMS FOR THE VAGINAL DELIVERY OF MICROBICIDES 
 
Microbicides have been extensively investigated in numerous dosage forms such as 
gels, creams, films, nanoformulations, liposomes, quick-dissolving tablets and intravaginal 
rings. The advantages, and limitations of the different types of microbicide dosage forms are 
presented in Table 6. 
Table 6: Vaginal Delivery Systems, Their Advantages and Limitations (3, 8, 9). 
Delivery 
systems 
Advantages Limitations 
Gels   Female controlled. 
 Provide lubrication. 
 Messy and may leak out of 
the vaginal cavity.  
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 Easy to manufacture. 
 Relevant for pericoital or daily use. 
 Non-uniform distribution 
and leakage which lower the 
anti-HIV efficacy. 
 The short bio-retention 
requires the user to apply 
hours before sex, which 
leads to significant patient 
compliance issues. 
Rings   Designed to release microbicides in 
a controlled manner after insertion. 
 Enhanced product stability as a solid 
dosage form. 
 Easy to insert and remove, and no 
side-effects are experienced. 
 Can provide a long-term drug 
release resulting in less frequent 
application and thus, improved 
patient compliance. 
 Expensive to fabricate.  
 The rings needs to be 
carefully compressed and 
placed in the upper third part 
of vagina to avoid 
involuntary expulsion. 
 May not release drug at 
levels equal to what is 
achievable with gels, films. 
Films   Compared to gels, films may be 
easier to apply and less messy. 
 Increased user acceptability. 
 The films rapidly dissolve once in 
contact with the vaginal fluids with 
 Commercial application of 
vaginal films is limited and 
the optimization is still 
under development. 
 Usually, very low drug 
loadings (<1% w/w). 
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no introduction of additional fluids, 
thus reducing the leakage. 
 Their rapid dissolving nature 
ensures quick release once inserted. 
 Increased patient acceptability, 
retention time, and drug stability. 
 The small size of the film and the 
lack of the need for applicators 
results in a less expensive product. 
 Low overall mass may 
preclude delivery of 
sufficient doses of drugs. 
 The physical properties of 
films must be controlled to 
avoid sharp edges that could 
induce abrasion upon 
application and use. 
Tablets   Female controlled and easy to 
formulate.  
 Coitally independent: daily; every 
few days to once a week coitally 
dependent: prior to coitus; before 
and after coitus. 
 No leakage. 
 Cost effective formulation. 
 Applicator may be required. 
 Disintegration of product 
and dissolution of drug 
depend on local hydration.  
 CV distribution is a concern. 
 May leave a grainy residue 
in the vaginal cavity after 
dissolution 
Suppositories   Self-Controlled and no leakage. 
 No applicator required. 
 Low potential for side-effects.  
 Possibility for rapid/sustained 
release of drugs. 
 Stable formulation 
 Absorption in vaginal 
epithelia may be controlled 
by hydration issues. 
 Vaginal epithelium irritation 
may result from contact of 
solids. 
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Nanoparticles 
(NPs)  
 Not only to protect the active agent 
but also facilitate penetration into 
the vaginal mucosa, allowing drug 
to reach HIV target cells. 
 Can provide sustained release of 
drugs, necessary for maintaining 
protective drug concentrations 
between the time of dosing and the 
time of intercourse. 
 More controlled vaginal absorption 
compared to gel, thereby potentially 
requiring reduced amounts of drug. 
 Encapsulation and delivery of 
various drugs on one nanocarrier. 
 Adjustable physicochemical 
properties (size, shape, surface 
functionality). 
 Challenges include the 
biocompatibility, toxicity, 
safety and stability 
 Scale-up of 
nanoformulations 
development. 
 Small size and large surface 
area can leads to particle 
aggregation. 
 Burst release of drug. 
 Non-uniformity of size 
distribution. 
Nanofibers 
(NFs)  
 Typically soft and non-abrasive, 
highly flexible. 
 Variety of possible geometries and 
mechanical properties. 
 No leakage or messiness with 
delivery of fibers into the vaginal 
cavity. 
 Expensive process 
compared to conventional 
fibers due to low production 
rate and high 
instrumentation cost. 
 The vapors emitting from 
the electrospinning solution 
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used may be toxic and raise 
concern over health hazard. 
 Electrospinning process 
depends on several 
variables. 
Liposomes 
and Solid 
Lipid NPs  
 Can provide a sustained and 
controlled release of an incorporated 
drug.  
 An increase in drug stability, the 
ability of incorporating both 
lipophilic and hydrophilic drugs. 
 Higher biocompatibility and non-
immunogenicity. 
 Manufacturing cost, scale 
up. 
 Lipid instability and toxic 
by-products. 
 Low drug loading capacity. 
 Liquid nature of the 
preparation is a problem 
since they cannot offer the 
required effective- 
retention/contact with the 
vaginal epithelium. 
 The commercial production 
of sterile liposomes is 
expensive. 
Dendrimers   Controlled synthesis and different 
drugs could be conjugated to a 
single dendrimer. 
 Can be tailored by manipulating the 
structure/composition or number of 
 Complexity of preparation 
methods. 
 Potential toxicity issues. 
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surface functional groups to obtain 
the desired properties. 
 Thermodynamically stable system. 
 
Nanotechnology-Based Approaches for HIV/AIDS Prevention 
The introduction of nanotechnology in the field of drug delivery opened exciting 
therapeutic options for the treatment of several diseases using macromolecule or small 
molecule drugs (70-72). The development of nanoparticle-based vaginal drug delivery 
formulations has largely been focused on HIV pre-exposure prophylaxis (PrEP) (3, 8, 9). 
Nanocarriers offer various advantages which would be useful to overcome 
challenges/problems associated with current HIV prophylactic modalities (3, 8, 9). The specific 
advantages of nanotechnology in microbicide product development compared to conventional 
vaginal dosage forms are given in Table 7. Although there are benefits, but, there are several 
challenges that must be overcome in the future for successful translation of nano-microbicides 
to clinical settings. These challenges include the biocompatibility, safety, stability, as well as 
the scale-up of nanoformulations development. It is also important that the developed 
nanotechnology should offer significant cost-to-benefit ratio in order to gain wide acceptability 
as the majority of HIV affected individuals are from economically poor and developing 
countries. 
Table 7: Advantages of Nanotechnology over Conventional Vaginal Dosage Forms (3, 8, 9). 
Feature Conventional dosage form Nano-sized delivery systems 
Patient 
compliance  
 Leakage and messiness. 
 Short residence time and 
require repeated dosing. 
 Undesirable adverse effects. 
 Enhanced patient compliance.  
 Potentially no leakage.  
 Reduced adverse effects. 
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Vaginal 
physiological 
conditions  
 Has significant influence on 
drug efficacy. 
 Has less effects on drug efficacy. 
 Vaginal physiological factors can be 
exploited, e.g., pH, temp., enzyme, 
for stimuli-responsive drug release. 
 Can provide improved drug 
distribution to target cells and tissues, 
improving efficacy. 
Physico- 
chemical 
properties of 
microbicides  
 Low encapsulation 
efficiency. 
 Considerable effect on drug 
absorption and efficacy. 
 Low water solubility results 
in decreased drug efficacy. 
 Low drug stability may be 
due to hydrolysis and or 
enzymatic degradation. 
 Ability to encapsulate high drug 
content. 
 Feasibility of carrying both lipophilic 
and hydrophilic drugs. 
 Can facilitate the dissolution of 
hydrophobic drugs, while improving 
drug stability from hydrolysis and 
enzymatic degradation. 
 Increase the aqueous solubility of 
pharmaceuticals. 
 Deliver drugs for slow release to 
maintain the therapeutic dose. 
Specificity 
and 
targeting 
ability  
 Non-specific drug delivery 
and response. 
 Specific drug delivery is possible by 
surface functionalization with 
targeting ligands. 
 Improve the active/passive target 
specificity in drug delivery. 
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 Improve the bioavailability and 
biocompatibility of drugs, non-toxic, 
non-allergenic and non-irritating. 
 
2.5. Stimuli-Sensitive Nanoformulations Delivery System in Vaginal Microbicide 
Research 
The development of stimuli-sensitive delivery systems is an active area of 
pharmaceutical research (73, 74). These novel delivery systems, usually termed ‘smart’ are 
able to respond to their environment to trigger the release of macromolecules/small molecule 
drugs and localize the therapeutic moiety within a particular site. Stimuli responsive materials 
are based on the principle that a specific stimulus can change the structural confirmation of 
formulations which can facilitate the release of drugs encapsulated in the delivery system. 
Although, the concept of stimuli-responsive systems are widely used in cancer therapeutics, it 
is an exciting research area in the nanocarrier development for HIV therapeutics. There are a 
number of signals (pH, temperature, enzymes, oxidative stress, magnetic field, etc.) those can 
be used as a stimulus in anti-HIV drug delivery systems (74, 75).  
 
Normal Vaginal Physiology and Change during the Sexual Intercourse 
 Vaginal flora plays a significant role in maintaining a healthy vaginal environment. The 
pH of the CV mucosa with healthy vaginal microflora is acidic (pH 3.5-4.5) due to the presence 
of lactic acid produced by Lactobacillus bacteria (76). Women with bacterial vaginosis (BV) 
and other genital infections have a higher mean CV pH of 5 to 6 (76, 77). The CV pH is also 
significantly higher (6 to 7) during the menstruation cycle (78). During the sexual intercourse, 
CV fluid is neutralized (pH 7.0-7.4) by the alkaline pH (7.0-8.0) of human semen (with higher 
buffer capacity) within couple of seconds of arrival of seminal fluid (Figure 6) (77, 79). The 
28 
 
neutralization of CV fluid provides a favorable condition to increase male to female HIV virus 
transmission. Moreover, the anatomy and physiology of the mucosal barrier changes 
significantly during the menstrual cycle and in sexually transmitted disease conditions such as 
BV which could further enhance the virus transmission process (77). This change in pH of the 
vaginal flora can be targeted to develop a stimuli-sensitive system for HIV therapeutics. 
 Human seminal fluid contains several enzymes including the Hyaluronidases (HAase) 
(80), which is also abundant in other body fluids and tissues (81). The amount of HAase in 
human semen is entirely dependent on the sperm count. The HAase content of human semen 
containing 100 million sperms/mL is about 0.38 U/mL with the total amount of 1.08 U 
considering the average volume of human ejaculate is 3 mL (82). One could therefore envision 
designing a smart microbicide delivery system which can trigger for burst release of 
microbicides from the delivery system into vagina in the presence of HAase to inactivate the 
potential high viral load present after ejaculation. 
 
Figure 6. Changes in Vaginal Physiology during the Sexual Intercourse. 
 
There are several delivery systems (nanoparticles, hydrogels, nanofibers, 
microparticles, etc.) are elaborated, those are able to release the anti-HIV therapeutic molecules 
29 
 
in response to specific stimuli at the target site (Table 8). However, there is no delivery system 
is developed that has been utilized the seminal fluid HAase enzyme as a triggering element. 
Considering these facts, the present study aimed at developing a microbicide delivery system 
capable of degradation on exposure to seminal fluid HAase enzyme that provides a triggered 
release of microbicide at the vaginal target site. 
Table 8: Stimuli-Sensitive Delivery Systems for anti-HIV Drug Delivery Applications. 
Stimulus Delivery system, (Active moiety) Ref. 
pH Nanoparticle, (Tenofovir) (83) 
 Nanoparticle, (Dapivirine and Etravirine) (84) 
 Lipid nanoparticles, (Atazanavir and Darunavir) (85) 
 Microparticle, (Tenofovir disoproxil fumarate) (43) 
 Osmotic pump tablet, (IQP-0528) (86) 
 Mucin-like polymer constructed with phenylboronic acid 
and salicylhydroxamic acid, (Dapivirine and Etravirine) 
(87) 
 Nanofibers, (Dapivirine and Etravirine) (84) 
 Fibers, (TMC 125, tenofovir disoproxil fumarate) (88) 
Enzyme Nanoparticles, (Tenofovir) (89) 
 Microparticles, (Sodium poly(styrene-4-sulfonate) (pSS)) (90) 
Temperature Thermosensitive gel, (Raltegravir and Efavirenz) (91) 
 Mucoadhesive hydrogels, (MiniCD4 M48U1) (92) 
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Osmotic pressure Rings (93) 
Hydrogen peroxide Drug transmucosal deliver, (Bovine insulin) (94) 
Magneto-electric Nanoparticles, (Zidovudine) (95) 
pH + temperature Liposome gel, (Arctigenin) (96) 
 Hydrogels, (Acid orange dye, FITC-Dextran) (97) 
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CHAPTER 3 
DEVELOPMENT OF HYALURONIDASE SENSITIVE TENOFOVIR LOADED 
HYALURONIC ACID BASED NANOPARTICLES 
 
3.1. Rationale 
 
As explained in Chapters 1 and 2, female-controlled prophylactic methods using 
microbicides are the major focus among HIV prevention strategies (98-100). This study aimed 
at developing a semen-triggered nanoparticles (NP) delivery system that provides a triggered 
release of microbicide on exposure to seminal hyaluronidase (HAase) enzyme. Since, human 
semen is the carrier of HIV virus transmission during male to female intercourse (23), this 
would have the potential to inactivate or kill the HIV virus prior to exposure and penetration 
of the vaginal mucosa. 
In recent years, hyaluronic acid (HA) has been used widely, owing to its biodegradable, 
non-immunogenic and mucoadhesive properties (81, 101). It is a non-sulfated, hydrophilic, 
naturally occurring anionic mucopolysaccharide made of repeating disaccharide units of D-
glucuronic acid and N-acetyl-D-glucosamine, linked through β(1-4) and β(1-3) glycoside 
bonds (101, 102) (Figure 7A). HA is hydrolysable under treatment with the HAase enzyme 
(80), which is abundant in human seminal fluid (82) as well as other body fluids and tissues 
(81). The mechanism of degradation of HA has already been reviewed in detail (103). Due to 
its excellent physicochemical properties, medical and biological functions, HA has been widely 
used for NP designs (101) and other drug delivery applications (104). HA has also been 
reported to possess antioxidant properties, preventing oxidative damages by scavenging free 
radicals or increasing the antioxidant enzymes activities (105). The lubricant properties of HA 
may represent an additional benefit for vaginal delivery of HIV/AIDS microbicides (106). 
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Figure 7A. Chemical Structure of Hyaluronic Acid (HA). 
 
Figure 7B. Chemical Structure of Tenofovir (TFV). 
 
Tenofovir (TFV) (Figure 7B), used as a model microbicide in this study, belongs to the 
category of anti-retroviral drugs under the sub-category of nucleotide reverse transcriptase 
inhibitors (107). The currently available vaginal dosage forms of TFV such as gels and 
suppository cause a somewhat uncomfortable wetness, lack of vaginal retention, and drug 
leakage (100). The NPs delivery systems to the vagina may be beneficial by causing much less 
discomfort and reducing the dosing frequency simultaneously (22). To achieve this aim, in this 
study, the NPs containing TFV were developed using a surfactant-free cross-linking method 
(108). The effects of various formulation factors over physicochemical properties of NPs were 
analyzed using fractional factorial experimental design (FFED) (109). 
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3.2. Materials and Methods 
 
Chemicals 
Tenofovir (99% purity) was purchased from Beijing Zhongshuo Pharmaceutical 
Technology Development Co. Ltd. (Beijing, China). Hyaluronic acid sodium salt of different 
molecular weight was supplied by Zhenjiang DongYuan Biotech Co., Ltd., (Jiangsu, China). 
Hyaluronidase (HAase) from bovine testes with a specified activity of 810 U/mg, bovine serum 
albumin (BSA, Fraction V), N-Hydroxysuccinimide (NHS), adipic acid dihydrazide (ADH), 
sodium D-glucuronate and acetone were purchased from Sigma-Aldrich (St. Louis, MO). 1-
Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) was from Thermo Fisher 
Scientific Inc. (Rockford, IL).  
The human vaginal (VK2/E6E7), endocervical (End1/E6E7) cells and Lactobacillus 
crispatus bacteria were purchased from the American Type Culture Collection (ATCC, 
Manassas, VA). The CellTiter 96® AQueous One Solution Proliferation assay kit with [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium, inner 
salt; MTS] reagent and CytoTox- ONE™, lactate dehydrogenase (LDH) cytotoxicity assay kit 
was from Promega (Madison, WI). Keratinocyte serum-free medium supplements (EGF 
Human recombinant and bovine pituitary extract), nonyl acridine orange (NAO), rhodamine 
123 and the cell-permeant 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) dye were 
obtained from Invitrogen Life Technologies (Grand Island, NY). Fluorescein isothiocyanate 
(FITC) was purchased from Acros Organics (Morris Plains, NJ). Trypsin inhibitor from 
Glycine max (soybean), 0.25% trypsin/EDTA solution, calcium-magnesium-free Dubelco’s 
Phosphate Buffer Saline (DPBS), camptothecin, calcium chloride, H2O2, sodium nitroprusside 
(SNP), neutral red, hoechst 33342, propidium iodide (PI), resazurin, monochlorobimane were 
all obtained from Sigma-Aldrich (St. Louis, MO). CellTiter 96® Aqueous One and Griess 
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reagent system kits were purchased from Promega Corp., (Madison, WI). Deionized water was 
obtained from a Millipore Milli-Q water purification system (Millipore Corp., Danvers, MA). 
All other chemicals were of analytical grades and used as obtained from suppliers. 
 
Design of Experiments Approach in Formulation Development 
The design of experiment is now getting much attention and the US FDA and the 
International Conference on Harmonization (ICH) guidelines (Q8, Q9 and Q10) recommend 
the use of the design of experiment approaches in formulation development (110-113). 
Traditional approaches for formulation development involve the time consuming process of 
varying one factor at a time and examining its effect, which requires a large number of 
experimental runs. Generally, if there are k numbers of independent variables (factors), each at 
two levels (high and low), the full factorial experimental design would require 2k runs (109). 
However, if there are four or more factors, it is generally too complicated and also unnecessary 
to run all the possible combinations of factor levels and experiments(114). In these conditions, 
fractional factorial experimental design (FFED) is useful as it requires only half of the runs (2k-
1) instead of the original 2k runs in a full factorial design (109). The FFED design provides the 
possibility of obtaining maximum information from the minimal number of experiments. Thus, 
in this work the FFED design was employed with k value of four (independent variables) as 
shown in Table 9. 
 
Formulation of HA-NPs, HA-Gel and Drug Encapsulation 
The HA-NPs were prepared by a surfactant-free cross-linking method adopted from a previous 
report (108) with some modifications (Reaction Scheme 1). Chemical structures were drawn 
in a linear format using CS ChemDraw Ultra® version 6.0 (Cambridge Soft Corp., Cambridge, 
MA). Briefly, 1 mg/mL aqueous solution of HA was prepared by dissolving the HA powder in 
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milli Q water with continuous stirring for 1 h at room temperature. A small amount of acetone 
(in a total amount of 40%v/v) was added in the above solution (primary addition) and stirred 
for 1 h to make sure that all the components were well dispersed. Two hundred and fifty 
microliters of aqueous solutions of EDC, NHS, and ADH were added to the above solution and 
stirred for 30 min, respectively, after the addition of each solution. The carbodiimide mediated 
cross-linking was continued with stirring at room temperature for 15 h, leading to the formation 
of amide bonds between the carboxylic acid (-COOH) groups of glucuronic acid units of HA 
and the hydrazide groups of ADH. Finally, a secondary addition of acetone occurred to raise 
the volume 3-6 times with respect to the aqueous phase (X3). After that, the solution was stirred 
continuously for various time points. The color of the solutions turned to light blue after the 
secondary acetone addition due to the Tyndall effects. The organic solvent was evaporated by 
using a rotatory evaporator (BUCHI Labortechnik AG, Flawil, Switzerland). 
The colloidal dispersion was ultra-centrifuged, using a Beckman L8-70M ultra-
centrifuge (Beckman Instruments Inc., Palo Alto, CA) at 20,000 rpm and 10°C for 45 min to 
isolate the NPs. After isolation, the NPs were purified using dialysis method against one liter 
of milli Q water for 24 h with three water changes at every 8 h. After the dialysis, NPs were 
freeze-dried (Labconco Corp., Kansas City, MO) and the process yield of the recovered NPs 
was determined using mass balance calculation. The soaking method (115, 116) was employed 
for encapsulation of TFV in the HA-NPs. Briefly, 10 mg of purified and freeze-dried NPs were 
immersed in an aqueous solution of TFV. The NP: drug ratio in the loading solution was varied 
from 10:1 to 1:1 (w:w). This was left to soak for three days at room temperature. The percent 
encapsulation efficiency (% EE) and drug loading (% DL) was determined indirectly from the 
supernatant (after ultra-centrifugation, washing and appropriate dilution) using a high 
performance liquid chromatography (HPLC) assay (117) applying the Equations 1 and 2, 
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respectively. The formulation of HA-gel was based on hydration and internal cross-linking 
reaction of the native HA at the concentration of 2% w/v in water (118).  
100
mg in used drug of amount Total
mg in nt supernataof content Drug - mg in used drug of amount Total
(%) EE      (1) 
100
mg in used drug and lesnanopartic of Weight
mg in nt supernataof content Drug -mg in used drug of amount Total
(%) LC      (2) 
 
Reaction Scheme 1. Formulation of HA-ADH cross-linked NPs 
 
Briefly, the HPLC system (Waters, Milford, MA) was consisted of a 1575 binary pump 
system, 717 plus auto sampler, 2487 dual wavelength absorbance detector, and a BridgeTM C18 
column (150mm X 4.6mm, 5μm). Results were acquired and processed with Breeze™ software 
(version 3.3). The assay was performed isocratically at ambient temperature at the detection 
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wavelength of 259 nm. The mobile phase composition was water (pH 5.1): acetonitrile (35:65 
v/v) delivered at a flow rate of 1 mL/min. To prepare the aqueous phase (pH 5.1), 0.1% v/v of 
triethylamine was added to water and the final pH was adjusted with orthophosphoric acid 
(85% v/v) to 5.1. The sample volume of 10 µL was injected in each run. The standard solution 
of TFV (100 µg/mL) was prepared by dissolving 1 mg of drug in 10 mL of milli Q water. The 
calibration curve at the concentration range of 0.1-10 µg/mL was prepared using the above 
standard solution. The method was validated according to the ICH Q2:R1 guidelines (117). 
Table 9: Independent and Dependent Variables With Their Corresponding Levels in the FFED 
Design. 
Variables Levels 
 Low Medium High 
Independent variables (factors) 
Coded values of levels of X1, X2, X3 and X4 
Actual values of X1, X2, X3 and X4 
X1; molar concentration of ADH: mM
a 
 
-1 
 
2.49 
 
0 
 
6.23 
 
+1 
 
9.96 
X2; molar concentration of EDC: mM
a 2.49 6.23 9.96 
X3; volume of acetone: mL
b 30  45  60  
X4; reaction time: hour
c 2  4  6  
Dependent variables (responses) 
Y1; particle mean diameter (PMD): nm 
Y2; polydispersity index (PDI) 
Y3; zeta (ζ) potential: mV 
a Molar concentration with respect to the molar concentration of HA (constant at 2.49 mM).  
b Volume of acetone with respect to the volume of aqueous phase (kept constant at 10 mL)  
c Reaction time after secondary acetone addition. 
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Physicochemical Characterization of HA-NPs 
Spectral Analysis by Fourier Transform Infra-Red (FT-IR) Spectroscopy 
The cross-linking between HA and ADH (Reaction Scheme-1) was assessed by FT-IR 
analysis using Nicolet iS10 Spectrometer (Thermo Scientific, West Palm Beach, FL). The 
instrument was equipped with a deuterated triglycine sulfate (DTGS) detector and was 
controlled by OMNIC™ Spectra™ software version 7.0. A transmission mode was selected to 
make observations with the sampling area of about 1 mm. Analysis was systematically 
performed at 650 to 4000 cm-1 (wavenumbers). The background data was collected at ambient 
conditions before analyzing freeze dried samples of the HA-NPs. Spectra were automatically 
corrected with a linear baseline. No specific sample preparation method was used before FT-
IR analyses. 
Spectral Analysis by 13C-CP/MAS NMR Spectroscopy 
The cross-linking between HA and ADH (Reaction Scheme-1) was further assessed by 
using solid state high resolution 13C cross-polarization magic angle spinning (CP/MAS) nuclear 
magnetic resonance (NMR) analysis. The NMR spectra were acquired on a Tecmag Apollo 
console (Houston, TX) with a homebuilt, 2-channel, wide-bore NMR probe at 1H and 13C 
Larmor frequencies of 357.2 MHz and 89.827 MHz, respectively. The MAS spinning 
frequency, proton RF field decoupling strength, cross polarization contact time and 900 pulse 
length is, 13 kHz, 110 kHz, 2 ms and 5 µs, respectively. All MAS experiments were performed 
at ambient temperature without any corrections for sample heating. About 30 mg of NP sample 
was taken for each analysis. The NMR signals were represented as chemical shift (δ) values in 
ppm. 
Size Distribution and Zeta (ζ) Potential Analyses using Dynamic Light Scattering  
The NPs were analyzed for their particle mean diameter (PMD); nm, polydispersity 
index (PDI), and size distribution by dynamic light scattering (DLS) method using Zetasizer 
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Nano ZS (Malvern Instruments Ltd., Worcestershire, UK). The ζ potential was analyzed by 
Laser Doppler Velocimetry and Phase Analysis Light Scattering methods using the same Nano 
ZS instrument. After suspending 100 µL of NP dispersion in 1 mL of water, the measurement 
was undertaken at 25°C. The PMD of the NPs was represented as Z-average diameter following 
the cumulant model (119). It is noteworthy that estimation of the PMD and PDI was based on 
the intensity of the light signal processed according to the cumulant method. Cumulants were 
defined as the coefficients of an expansion of a MacLaurin series (120). The PDI value was 
given by Eq. (3): 
12 KKDIP           (3) 
The cumulant K1 is an effective mean diffusion coefficient; whereas, K2 describes the 
relative width of the size distribution if normalized by K1 (120). The instrument was calibrated 
by using nanosphere™ of PMD (59.0 ± 2.5 nm) and ζ potential standards (-68.0 ± 6.8 mV) 
prior to the analysis. According to the National Institute Standard, a sample with a PDI value 
< 0.05 was considered mono-dispersed (121). 
Size Distribution Analyses using Nanoparticle Tracking Analysis 
The NPs were analyzed for their particle mean diameter (PMD); nm, using Nanoparticle 
Tracking Analysis (NTA) measurements. NTA analysis was performed using a NanoSight 
LM20 instrument (NanoSight, Amesbury, UK). The instrument was equipped with a sample 
chamber with a 640-nm laser and a Viton fluoro-elastomer O-ring. NTA version 2.3 Build 0017 
software was used for the capture and data processing. The samples were injected in the sample 
chamber with syringe and measurements were performed at room temperature. The samples 
were measured for 90 sec with manual shutter and gain adjustments. 
Surface Morphology Analysis of HA-NPs 
The surface morphology of HA-NPs was analyzed by transmission electron microscopy 
(TEM) using a Philips TEM CM12 instrument (FEI, Hillsboro, OR). The instrument was 
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equipped with the large format (II Megapixel), retractable and fiber-optical coupled SC100 
ORIUS© CCD camera (Gatan, Inc., Pleasanton, CA) for digital image acquisition. The TEM 
analysis was performed by placing a drop (10 µL) of colloid dispersion of the HA-NPs over a 
carbon-coated copper grid. The excess fluid was removed before samples were completely 
dried at room temperature and examined for TEM imaging without any further modifications. 
The TEM observations were performed at an accelerating voltage of 80 kV. 
 
Enzymatic Degradation Analysis of HA-NPs 
An Uronic acid-carbazole assay (122) was used to analyze the degradation of the HA-
NPs under the influence of HAase enzyme. The degradation analysis was performed with the 
amount of HAase that is normally present in human ejaculate (82). The amount of HAase in 
human semen is entirely dependent on the sperm count. The HAase content of human semen 
containing 100 million sperms/mL is about 0.38 U/mL with the total amount of 1.08 U 
considering the average volume of human ejaculate is 3 mL (82). The degradation study was 
performed at pH 7.1, which was equivalent to the pH condition of vaginal fluid during sexual 
intercourse (23). The optimum pH for maximum hydrolytic activity of HAase is 4 to 5 (123, 
124). However, HAase exerts its activity also at weakly acidic (pH 5 to 6) (124) and alkaline 
conditions (pH 7 to 8) (123, 125). The bovine testicular HAase was used as a model enzyme, 
since it was commercially available and, like human HAase, it catalyzes the hydrolysis of the 
β (1-4) glycosidic bonds in HA (126).  
Briefly, the HA-NPs (10 mg) were dispersed in 3 mL of the simulant mixture (pH 7.1) 
of vaginal fluid simulant (VFS, pH 4.2) and seminal fluid simulant (SFS, pH 7.8), prepared 
according to the previous reports (127, 128). The 1:4 volume ratios of the VFS and SFS, 
respectively, were used for preparing the simulant mixture, considering that the volumes of 
normal human vaginal fluid and male ejaculate (127, 128). The pH of VFS and SFS buffers 
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was adjusted using hydrochloric acid (HCl) or sodium hydroxide (NaOH) solutions, prepared 
accordingly. The NP dispersion was transferred to a dialysis bag (Spectra/Por Float-A-Lyzer 
G2, MWCO, 3.5-5 kDa), supplied from Spectrum Lab., Inc. (Rancho Dominguez, CA), and 
placed inside a dialysis tube containing 20 mL of the simulant buffer mixture. The whole 
system was then placed in a thermostatic shaking water bath (BS-06, Lab Companion, Seoul, 
Korea) with 60 rpm at 37°C. Aliquots of 100 µL solutions were taken from the medium at 
different time intervals (0, 1, 3, 6, 24, 48, 72, 96, 120 h), boiled for 10 min to inactivate the 
enzyme and analyzed for the amount of glucuronic acid released. The fresh simulant mixture 
was added at the same rate to maintain the sink condition. 
The Genesys 10 Bio UV-Vis Spectrophotometer (Thermo Electron Sci. Inst., LLC, 
Madison, WI) was used for the degradation analysis of HA-NPs at the wavelength of 530 nm. 
The amount of glucuronic acid released at each time point was determined by using the 
standard curve of sodium D-glucuronate. The curve was found linear in the concentration range 
of 0-200 µg/mL (Correlation coefficient: r = 0.998). The measured amount of D-glucuronic 
acid was represented as percent cumulative degradation (%w/w) of HA-NPs compared to the 
degradation of native HA incubated either in the presence or absence of HAase. The reaction 
mechanism of the Uronic acid-Carbazole assay was given in Reaction scheme 2. 
 
Reaction Scheme 2. Reaction Mechanism of the Uronic acid-Carbazole Assay. 
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In Vitro Drug Release Analysis of HA-NPs 
The release study was performed with the 10 mg of drug loaded HA-NPs or HA-gel 
using the dialysis method as explained above for the enzymatic degradation analysis. The blank 
HA-NPs, HA-gel and TFV powder were taken as control samples. Aliquots of samples (1 mL) 
were taken at, 0, 1, 3, 6, 9, 12, 24, 48, and 72 h from the release medium. Simultaneously, an 
equivalent volume of fresh simulant mixture was added at the same rate to the release medium 
to maintain the sink condition. The amount of TFV was quantified by using HPLC assay (117). 
 
Enzymatic Degradation and In Vitro Drug Release Kinetics 
The drug release kinetics of HA-NPs was analyzed by using zero order, first order, 
Higuchi, and Korsmeyer-Peppas models as given by Equations (4), (5), (6), and (7), 
respectively, (129).  
tK+MM 00t           (4) 
t/2.303K+MlogMlog 1t 0        (5) 
50.
Ht tKM            (6) 
n
t kt/MM           (7) 
In these Equations, Mt is the amount of drug released at time t, M0 is initial amount of 
drug in solution, K0 is zero order release constant, K1 is first order release constant, KH is 
Higuchi dissolution constant, Mt/M∞ is the fraction of drug released at time t, M∞ is the total 
amount of drug released, k is a kinetic constant and n is the exponent explaining the drug release 
mechanisms (129). The exponent n is classified as Fickian diffusion (n ≤ 0.5), case-II transport 
(n = 1), anomalous transport (0.5 < n < 1) and super case-II transport (n > 1) (129). 
The Eq. (7) in Peppas model was further depicted in a log-transformed Eq. (8): 
k log+tlogn/MMlog t                  (8) 
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The model independent approach was then applied to compare the enzymatic 
degradation and drug release kinetics of the HA-NPs (test compounds) with HA-gel (reference 
compound) as per US FDA guidance to industry (129). In the case of HA degradation study, 
the difference (f1) and similarity factors (f2) were calculated, using Equations (9), and (10), 
respectively. 
      (9) 
    (10) 
  Where, n is the number of time points, Rt and Tt are the cumulative degradation and 
drug release (% w/w) at time t for reference (HA-gel) and test compounds (HA-NPs) in the 
presence or absence of enzymes, respectively. Here, f1 measured the percent errors while f2 
measured the sum-squared error between the test and reference compounds over all time points. 
The curves for the samples with f1 and f2 values close to 0 and 100, respectively, were 
considered similar. Generally, f1 ˂ 15 (0-15) and f2 > 50 (50-100) ensured equivalence of the 
two curves (129). Here, the difference and similarity factors were represented as f1 and f2 and 
f1’ and f2’, for drug release kinetics and enzymatic degradation of HA-NPs, respectively. 
 
Computational Modelling: Interaction of TFV with HA and HA-NPs and its Effect over 
Encapsulation and Drug Release Properties of NPs 
Computational modelling (CM) and dynamics that could predict and quantify drug-NP 
interactions would greatly reduce the costs and time associated with formulation development 
(130). A better understanding of these interactions could help in explaining drug encapsulation 
and release process from nanocarriers (131). In this study CM was investigated to understand 
the effect of cross-linking of HA for the drug loading efficiency and drug release properties of 
HA-NPs. The chemical structure of TFV was docked into native HA (tetramer unit) and cross-
     100
111
   tt
n
ttt
n RTRf
    





 

 1001150
50
2
12
.
ttt
n TRn/logf
44 
 
linked HA-NPs using Glide (Grid-Based Ligand Docking with Energetic) software version 5.5 
from Schrodinger (LLC, New York, NY).  
Glide is a docking program to predict the binding modes through a scoring function 
(132, 133). Grids were prepared with the size of the bounding box enclosing the whole 
molecule. Glide XP Mode was employed using default options in Glide for all docking 
calculations and 100 poses were kept per molecule of ligand. Generally, Glide utilizes standard-
precision (SP) and extra-precision (XP) Glide Scoring functions to rank-order compounds. 
Glide Score was the sum of van der Waals (VWs), hydrogen bonds (H-bonds), electrostatic, 
lipophilic, and some additional interaction energy (IE) terms as given in Eq. (11) below (133, 
134). The IE was considered as the difference between the total energy of the drug loaded NPs 
and the sum of the energies of the drug and the native polymer. 
Glide Score = 0.065 VWs + 0.130 Electrostatic + Lipophilic + H-bonds + K (11) 
Here, K is the sum of the metal-binding term, penalty for buried polar groups, penalty 
for freezing rotatable bonds, polar interactions in the active site, hydrophobic enclosure reward, 
reward for low molecular weight, electrostatic reward, chemscore lipophilic pair term and 
fraction of the total VW energy. Glide's Scoring functions were used to evaluate binding 
energies of the docking output comprising low energy docked poses. The docking output was 
clustered into conformational families and analysed in terms of lowest energy conformation 
and the most populated clusters. 
 
Degradation Kinetics and Stability Evaluation of Tenofovir  
The stability evaluation of TFV under various stress conditions was analyzed using a 
liquid chromatography (LC) and mass spectrometric (MS) assay since the drug was exposed to 
acidic and alkaline pH conditions of the medium to perform the release and degradation 
analyses of the HA-NPs. Briefly, LC analysis was carried out on a UFLC Shimadzu 
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prominence system (Shimadzu USA manufacturing Inc., Torrance, CA) consisting of a LC-20 
AD low pressure gradient pump, SPD-M20A photodiode array (PDA) detector, SIL-20AST 
auto sampler, and DGU-20As degasser. A reversed phase Waters Symmetry® C18 column (150 
mm × 4.6 mm, 5 µm) was used as a stationary phase. The LC elution conditions were as follows 
(all solvent percentages were volume fractions): mobile phase-A, 0.1% v/v formic acid in 
water; mobile phase-B, 0.1% v/v formic acid in acetonitrile; mobile phase-C, 30% A + 70% B. 
The time program was: 0.01 min, 100% A; 10 min, 100% C; 13 min, 100% B; 14 min, 100% 
A; and 18 min, 100% A. The flow rate was 0.6 mL/min and the detection was carried out at 
259 nm under ambient temperature conditions using a sample injection volume of 10 μL in 
each analysis. 
MS studies were performed on a 3200 QTrap mass spectrometer (Applied Biosystems 
Sciex, Framingham, MA). Spectra were recorded using Enhanced mass spectrum (EMS) scan 
in positive mode. Analyst® software version 1.4.2 (Applied Biosystems Sciex, Framingham, 
MA) was used for data acquisition. MS operational parameters were as follows: Collision 
activated dissociation (CAD):  high; Ion source Gas1 (GS1): 50 psi; Gas2 (GS2): 50 psi; Turbo 
ion spray voltage (IS):  5500 V; Source temperature (TEM): 350 °C; Collision energy (CE); 5 
V; Declustering potential (DP): 2 V, and Entrance potential (EP): 2 V. Nitrogen gas was used 
as the nebulizer, and the scan rate was 4000 amu/sec. The spectra were obtained by scanning 
between 100-700 amu. The validation of the LC-MS assay was performed according to the 
ICH, Q2:R1 guidelines. 
LC-MS Sample Preparation and Forced Degradation Analysis  
The drug at the concentration of 1 mg/mL was subjected to stress degradation under 
various stress conditions (Table 10). A stock solution of TFV (10 mM) in Milli Q water was 
diluted with mobile phase-A (0.1% v/v formic acid in water) to yield the solutions in the 
concentration range of 7.81-500 µM for the calibration curve. The stressed samples were 
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collected after each time period and diluted with the same mobile phase to the concentration of 
250 µM and to make them suitable for LC analysis (135). For comparison, a freshly prepared 
TFV (250 µM) and the blank samples (without TFV, processed in the similar way as of stressed 
samples) were also analyzed. In all the assays, the drug was considered stable if there was < 
10% degradation of the initial amount was observed (136, 137).  
Table 10: Stress Conditions Employed For the Forced Degradation Analysis of TFV. 
Stress conditions Solvent Analysis time Experimental conditions 
Hydrolysis  
Acidic 0.1 N HCl, pH 1 Up to 5 days Reflux  
Acidic 0.1 N HCl, pH 4.5 Up to 5 days Reflux  
Basic 0.1 N NaOH Up to 5 days Reflux 
Neutral Water Up to 5 days Reflux 
Oxidation 3% and 30% H2O2 Up to 7 days Room temperature (RT) 
Long term (accelerated) 
Solid samples 
 
- 
 
Up to 12 months -20°C 
5°C 
25°C/60% RH  
40°C/75% RH 
Thermal stress 
Solid samples 
 
- Up to  12 months 40°C, 50°C, 60°C 
Up to 30 days 80°C 
Liquid samples 0.1 N HCl Up to 10 days 25°C, 40°C 
 HCl, pH 4.5 Up to 10 days 25°C, 40°C 
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Powder X-ray Diffraction Analysis 
Powder X-ray diffraction (PXRD) analysis is a well-established and the most versatile 
techniques for the determination of crystalline forms of bio-active molecules. The effects of 
temperature and % relative humidity (RH) conditions on the crystal structure of TFV 
(unstressed sample and samples stored at -20°C, 5°C, 25°C/60% RH, 40°C/75% RH, 50°C, and 
80°C) was determined using solid state powder X-ray diffraction (PXRD) analysis. The PXRD 
patterns were obtained using a Rigaku MiniFlex automated X-ray diffractometer (Rigaku, The 
Woodland, TX). The samples were mounted on single-crystal Si zero-background plates for 
analysis. The analyses were performed at room temperature using Cu Kα radiation produced 
at 35 kV and 15 mA, with a Ni filter. The scan angle (2θ) was from 5° to 40° with a step size of 
0.05° 2θ and 3 sec per step. The diffraction patterns were processed using Jade 8+ software 
(Materials Data, Inc., Livermore, CA). 
Stability Analysis Using Arrhenius Plot 
The influence of temperature on the degradation kinetics of TFV was further 
determined using accelerated stability testing and Arrhenius equation (138-140) (Eq. 12).  
RT
E
)Aln()kln( a          (12) 
Where, k is the degradation rate constant, A is the frequency factor, Ea is the activation 
energy, R is the gas constant and T is the absolute temperature in degrees Kelvin. The k value 
depends on the Ea and is characteristic of a specific compound (141).   
 Based on the first order reaction kinetics (138), Eq. (13) was generated into its 
logarithmic form.  
303.2
kt
C
C
log
0
          (13) 
In this Eq. (13), k, C0, C and C/C0 are the first order rate constant, initial concentration 
and concentration of drug remaining after time t, and fraction of drug remaining after time t, 
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respectively. The values of k at each temperature was determined using Eq. (13), from the slope 
of the regression equation of the plot between log % drug remaining and time (t) in months. 
 To construct the Arrhenius plot, the value of 1000/T (in Kelvin) was calculated for each 
temperature and the Arrhenius plot between ln (k) vs. 1000/T was constructed. The slope and 
intercept values of this plot were equal to -Ea/R and ln (A), respectively, according to Eq. (12). 
The Ea was calculated by multiplying the slope value by R (8.314 J.mol
-1.Kelvin-1). The 
significance of the Ea value was to determine the temperature dependency of a chemical 
reaction. The higher the value of Ea for a chemical reaction the greater the acceleration with 
increase in temperature and the more the stability of a drug is temperature dependent (141, 142) 
Generally, drugs with lower Ea values have significantly lower reduction and longer shelf-lives 
(141). The rate constant (k25) that corresponds to room temperature (25
°C) was calculated from 
the regression equation. The shelf-life (t90: time required for the drug to decrease its amount by 
10% of its initial amount) was calculated as explained below. 
The k25 value was used for the calculation of shelf-life (t90), half-life (t50), and the time 
required for the drug to decrease its initial amount by 90 % (t10). The determination of the t90, 
t50, and t10 values was based on Eq. (13). The t50 is the time required for 50% degradation. This 
was calculated by replacing C and t with C0/2 and t50, respectively, in Eq. (13). This gives the 
Eq. (14) after logarithmic calculations. The t90 was calculated by replacing C and t with 0.9 C0 
and t90; whereas, t10 was calculated by replacing C and t with 0.1C0 and t10 in Eq. (13), which 
were given by Equations, 15, and 16, respectively. 
k
693.0
 t50            (14) 
k
105.0
 t90            (15) 
k
303.2
 t10            (16) 
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Cytotoxicity Assays: Effects of the HA-NPs on the Vaginal Epithelial Cells 
The safety of vaginal microbicides is an important concern in anti-HIV formulation 
development and is critical to understand the effect of interaction of the nanocarriers with the 
vaginal epithelial cells. Considering that, this study was designed to test the hypothesis that the 
developed HA-NPs are non-cytotoxic to the cervicovaginal (CV) keratinocyte cells. The 
VK2/E6E7, and End1/E6E7 cells were selected as in vitro models as they were the primary 
exposure route for HIV transmission and NPs exposure to vaginal mucosa (143). A series of 
cell-based assays were performed to investigate several endpoints which may upon disruption 
lead to cell death. These end points were; plasma membrane integrity, mitochondrial functions 
(metabolism/respiration, membrane potential and mass), cellular redox state (reactive oxygen 
species and intracellular glutathione). Moreover, the inflammatory response was studied via 
the release of the pro-inflammatory mediator nitric oxide (NO). As the safety of 1% TFV gel 
has already been determined (17, 144), in this study blank HA-NPs (without drug) at the 
concentration of 1-1000 µg/mL were tested for their effects on the viability and membrane 
integrity of VK2/E6E7, and End1/E6E7 cells.  
Cells were grown and routinely maintained in monolayer culture, in 75 cm2 culture 
flasks (TPP, Switzerland), at 37°C in a humidified atmosphere of 5% carbon dioxide (CO2), 
95% air. The cells were cultured in an antibiotic-free keratinocyte medium supplemented with 
EGF human recombinant (0.1 ng/mL), bovine pituitary extract (0.05 mg/mL), and calcium 
chloride CaCl2 (0.4 mM). The culture medium was replaced every 2-3 days. Before confluence, 
cultures were washed with DPBS, and cells were subsequently detached by enzymatic 
treatment by using 0.25% trypsin/EDTA solution for 3-5 min at 37°C (which was inhibited by 
soybean trypsin inhibitor at a molar ratio of 1:1), washed, and seeded in new flasks or treatment 
wells. The HA-NPs were dispersed in the culture medium at the concentration range of 1-1000 
µg/mL and sterilized for 30 min under UV light (145). The cells were then exposed up to 24 h 
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to 100 µL of HA-NPs at the concentration of 1, 10, 100 and 1000 µg/mL, corresponding to 
0.3125, 3.125, 31.25 and 312.5 μg of NPs/cm2, respectively, considering the growth surface of 
each well is 0.32 cm2. Wells containing cells without HA-NPs were used as the negative 
controls whereas, 1% Triton-X-100, H2O2 (100 mM), camptothecin (100 µM) and 1 mg/mL of 
sodium nitroprusside (SNP) were used as positive controls in their respective assays. 
Assessment of Cell Viability Using MTS and Resazurin Assays 
Briefly, cells were seeded to 96-well plates in a keratinocyte-serum free medium and 
were allowed to grow until 80% confluence was reached. The medium was replaced with 100 
µL of HA-NPs at different concentrations and kept in contact with the cell lines for 24 h. The 
amount of formazan product formed was determined by adding 20 µL of MTS reagent to 
culture wells. The wells were further incubated for 4 h at 37°C in a humidified, 5% CO2 
atmosphere and the absorbance was measured at 490 nm using a DTX 800 multimode 
microplate reader (Beckman Coulter, Brea, CA). The medium and 1% Triton-X-100 were used 
as negative and positive controls, respectively. The %cell viability was determined by Eq. (17): 
100
(control) ABS
(test) ABS
%)Viability(         (17) 
Where, ABS (test) and ABS (control) represented the absorbance of the amount of 
formazan product formed in viable cells. 
Assessment of Cell Membrane Integrity  
The effects of HA-NPs on the cell membrane integrity was measured using the specific 
accumulation of the vital dye neutral red (NR) in the lysosomes (146). The neutral red uptake 
assay provided a quantitative estimation of the number of viable cells in a culture. After the 
NPs exposure to the cells for 24 h, cells were washed twice with DPBS and replaced with fresh 
medium (100 μL) containing 50 µg/mL of NR dye followed by incubation for 3 h to allow the 
viable cells to accumulate NR dye in the lysosomes. After the incubation time, cells were 
washed twice with DPBS followed by disruption with a solution of 1% acetic acid/50% ethanol 
51 
 
(100 µL/well). The plate was shaken for 15 min in the dark to solubilize the NR dye crystals, 
prior to the fluorescence intensity was measured (530-560 nm excitation, 590 nm emission) 
using the above microplate reader. The % cytotoxicity was determined using Eq. (18): 
100
Background -ntrolPositiveco
Background -alExperiment
ty(%)Cytotoxici      (18) 
Here, experimental, background and positive control represented the fluorescence of 
the wells with NP treatment, without NP treatment and with 1% Triton-X-100 treatment, 
respectively. 
Assessment of Apoptosis through Chromatin Condensation 
The detection of apoptosis was performed using Hoechst 33342 (HO) assay (147). After 
exposure to the HA-NPs for 24 h, the cells were washed twice with DPBS and replaced with 
100 μL of DPBS containing HO and propidium iodide (PI) at the final concentrations of 10 
µg/mL and 2 µg/mL, respectively. The PI was added to the HO solution to control necrotic 
cells, as PI allowed HO to stain the viable and apoptotic cells only. The assay plate was 
incubated in the dark for 30 min at room temperature to allow the HO dye to stain viable and 
apoptotic cells. The fluorescence intensity was monitored using the above microplate reader 
(350 nm excitation, 450 nm emission). Camptothecin (100 µM), a well-known apoptosis 
inducer was used as positive control. Results were displayed by calculating the index ratio 
(HO/NR) and compared with the untreated cells (148). This index allowed differentiating 
apoptosis and necrosis process by evaluating the importance of chromatin condensation in 
comparison with the number of cells with intact membrane: apoptosis (HO/NR > 1), 
proliferating cell (HO/NR=1) and necrosis (HO/NR < 1). 
Assessment of Mitochondrial Functions 
In an effort to identify specific cellular events that may contribute to NPs-induced 
cytotoxicity, the mitochondrial functions were analyzed as given below.   
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Mitochondrial Respiratory Function  
Mitochondrial respiratory function (MRF) was examined using Resazurin assay. After 
exposure to HA-NPs for 24 h, the cells were washed twice with DPBS and replaced with fresh 
medium (100 μL). Then, 10 μL of resazurin (0.1 mg/mL in DPBS) was added to each well. 
The assay plate was shaken briefly for 30-60 s to ensure uniform distribution of resazurin and 
incubated for 3 h. The plate was further shaken for 30-60 s and fluorescence intensity (530-560 
nm excitation, 590 nm emission) was determined using the above microplate reader.   
Mitochondrial Membrane Potential 
The mitochondrial membrane potential (ΔΨm) was analysed by assessing the 
accumulation of Rhodamine-123 dye inside the mitochondria (149). After the exposure to HA-
NPs for 24 h, the cells were washed with DPBS and replaced with fresh medium containing 
Rhodamine-123 (10 µg/mL). The plate was incubated for 30 min to allow Rhodamine-123 
uptake. The cells were washed twice with DPBS, replaced with fresh medium and incubated at 
37°C for 1 h to allow cells to efflux Rhodamine-123 dye. The cells were washed again with 
DPBS followed by disruption with a solution of 1% acetic acid/50% ethanol (100 µL/well). 
The plate was shaken for 15 min in the dark at room temperature and fluorescence intensity 
was measured (490 nm excitation, 535 nm emission) using the above microplate reader. 
Mitochondrial Mass 
The mitochondrial mass was assessed by using the fluorescent dye nonyl acridine 
orange (NAO), which specifically binds to cardiolipin in mitochondria independently of their 
ΔΨm (150). After exposure to HA-NPs for 24 h, the cells were washed twice with DPBS and 
replaced with fresh medium containing NAO (10 µM). The assay plate was incubated for 30 
min to allow NAO to bind to cardiolipin. NAO loaded cells were washed twice with DPBS and 
replaced with fresh medium and incubated at 37°C for 1 h to allow cells to efflux NAO dye. 
The cells were washed twice with DPBS followed by disruption with a solution of 1% acetic 
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acid/50% ethanol (100 µL/well). The plate was shaken for 15 min in the dark at room 
temperature prior to the fluorescence intensity was measurement (490 nm excitation, 535 nm 
emission) using the above microplate reader. 
Assessment of Intracellular Reactive Oxygen and Nitrogen Species Production  
Reactive Oxygen Species Production 
Reactive oxygen species (ROS) are produced by a variety of nanomaterials (151-154).  
Mitochondria are a major source of ROS production as by-products of cellular energy 
metabolism (155), and an over-production of ROS may lead to the cell death. ROS induce the 
cell toxicity by damaging macromolecules (DNA, lipids, proteins) and depleting intracellular 
glutathione (GSH), an antioxidant that helps to prevent damage to cellular components caused 
by ROS. A potential effect of HA-NPs in inducing ROS production was investigated using the 
2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) dye (156). Cells were pre-incubated for 
30 min with a 20 µM H2DCFDA solution before any treatment. After that, the cells were 
washed twice with DPBS followed by the exposure with the HA-NPs for 3 and 24 h. The 
fluorescence intensity was measured at the excitation and emission wavelengths of 490 nm and 
535 nm, respectively, using the above microplate reader. 
Nitric Oxide Production 
Nitric oxide (NO) production in the culture supernatant is a measure of iNOS activity. 
Inducible NO Synthase (iNOS)-mediated NO production is widely used as a marker of 
inflammation (157). Thus, the potential of HA-NPs in inducing NO secretion within the genital 
keratinocyte cells was examined by measuring the nitrite accumulation (158). After exposure 
to HA-NPs for 24 h, supernatant was collected centrifugation at 1000 g for 10 min to remove 
cellular debris and particulate materials. Then, 50 µL of the supernatant was placed into a new 
plate and mixed with Griess reagent (Promega Corp., Madison, WI) according to the 
manufacturer instructions. Absorbance was measured at 540 nm and nitrite concentration was 
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calculated using the standard curve of sodium nitrite. Sodium nitroprusside (SNP), an external 
donor of NO was used as the positive control at the concentration of 1 mg/mL (159). 
Cellular Antioxidant Glutathione Assessment 
Intracellular antioxidant glutathione (GSH) is a key natural non-enzymatic antioxidant 
within the eukaryotic cells and a sensitive biomarker to determine the oxidative stress. GSH 
content was quantified using monochlorobimane dye (MCB) (156). After exposure to HA-NPs 
for 24 h, the cells were washed twice with DPBS and replaced with 100 µL of fresh solution 
of MCB (110 µM). Then, the assay plate was left at room temperature in the dark to incubate 
for 45 min to allow MCB dye to react with cellular GSH. The fluorescence intensity was 
measured at the excitation and emission wavelengths of 360 nm and 480 nm, respectively, 
using the above microplate reader. 
 
Lactobacillus Viability Assay of HA-NPs 
The acidic environment of vagina is maintained by Lactobacilli, which lowers the risk 
of HIV infection by its natural defense mechanism (76). Hence, any microbicide formulation 
will need to preserve the vagina’s natural defense mechanism by not disturbing the Lactobacilli 
layer. This was assessed by using Lactobacillus viability assay (62). The L. crispatus was used 
as model bacteria was grown in ATCC medium 416 Lactobacilli MRS broth (BD, Franklin 
Lakes, NJ) at 37°C and the viability assay was performed using an established method (160). 
Briefly, the bacteria density was adjusted to an OD670 of 0.06, which corresponds to 0.5 
McFarland Standard or 108 CFU/mL (161). L. crispatus was seeded in a 96-well plate at a 
volume of 100 µL and incubated with 100 µL of the NP suspension for 48 h at 37°C. The 
bacterial wells treated with 10 µg/mL of commercially available penicillin-streptomycin 
solution (positive control) from Invitrogen (Carlsbad, CA). After the incubation, 20 µL MTS 
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reagent was added to each well and viability was expressed using Eq. (17) and determined by 
measuring the absorbance at 490 nm using the above microplate reader. 
 
Cell Uptake Assay of Fluorescently Labelled HA-NPs 
Fluorescently labelled HA-NPs were prepared via a stable covalent bond between 
Fluorescein isothiocyanate (FITC) and HA-NPs (162). The FITC-labelled NPs were purified 
in the dark using dialysis method and lyophilized. After treatment with FITC labelled HA-NPs 
at the concentrations ranging from 1 to 1000 μg/mL for 24 h, VK2/E6E7 and End1/E6E7 cells 
were washed twice with DPBS and stained for DNA with Hoechst 33342 dye. The assessment 
and visualization of cellular uptake of HA-NPs was carried out by a laser scanning confocal 
microscopy (Leica TCS SP5) using a Leica TSC SP5 inverted confocal microscope with a 100x 
oil immersion objective (N.A. 1.44).  FITC was excited using a 488 nm line of an argon ion 
laser, and the detection window was set from 505-575 nm. For detection of Hoechst 33342 in 
a separate scan, excitation was performed using a 405 nm diode laser with a detection window 
set from 412-497 nm. Detector gain and laser power for all channels were set to result in no 
detector saturation with the highest concentration of HA-NPs used. Images were processed 
using ImageJ software (National Institutes of Health, http://rsbweb.nih.gov/ij/). 
 
Data Analyses 
JMP® - Release 9.0.2 (SAS Institute Inc. Cary, NC) was used for the statistical analysis 
and experimental design. Values were expressed as mean ± standard deviation (SD) and the 
differences in measured variables between treated groups and corresponding control were 
determined by one-way analysis of variance (ANOVA) followed by Dunnett post hoc test using 
JMP 9.0.2 software. Difference among means was considered significant at p < 0.05. 
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3.3. Results and Discussion 
 
Mechanism of Formation of Cross-linked HA-NPs 
In the surfactant-free cross-linking method, the HA-NP formation was based on cross-
linking efficiency of HA, water-HA, water-acetone and acetone-HA interactions. The rationale 
for the selection of four factors (independent variables) in FFED design (Table  9) was based 
on the fact that the molar concentrations of ADH (X1) and EDC (X2) were significant for 
efficient cross-linking between HA and ADH while the interactions among aqueous phase, 
organic solvent and HA were critical for NP formation (108, 163). In the aqueous phase, the 
HA polymer was swollen and took an expanded coil conformation due to the inter- and intra-
molecular hydrogen bonding among its functional groups and water molecules (164). The 
repulsive force exerted by the negatively charged carboxylate (-COOH) groups of HA also 
contributed in its expanded coil confirmation. Moreover, the organic solvent (acetone) induced 
the breakage of the hydrogen bonds of HA. After this, the -COOH groups of HA became 
available to be cross-linked with ADH through amide bond coupling.  
The adequate ratio (X3) between the volume of acetone and the aqueous phase initiated 
the cross-linking reaction and NP formation. After the secondary addition of acetone, water 
was diffused into acetone and caused the precipitation of HA with a coil-to-globule transition. 
Since, HA was cross-linked with ADH, it underwent molecular transition to form the HA-NPs 
(165). The reaction time (X4) after the secondary acetone addition, when the color of the 
solution changed from clear to light blue (Figure 8) due to the Tyndall effects and the  
transformation of HA from extended coil confirmation to a compact globular structure 
confirmed the NP formation. 
There are few methods have been described for the preparation of HA-NPs; such as 
reversed-phase micro-emulsion (115) and surfactant-free (108) methods. The surfactant-free 
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method adopted in this study was advantageous in terms of avoiding the use of surfactants, 
which might be deleterious and difficult to remove from the final formulation and could cause 
significant loss of NPs in the washing steps. Moreover, the modified surfactant-free cross-
linking method described in this work required lesser time (˂ 24 h) compared to the surfactant-
free method (> 44 h) (108) previously reported to produce the NPs. The shorter time was 
achieved by effective screening of the factors responsible for NPs formation using the FFED 
design as given in Table 9. 
 
Figure 8. HA-NPs Solution Turned To Light Blue After the Secondary Acetone Addition 
Due To the Tyndall Effects. 
 
Experimental Data Analysis in HA-NP Formulations Development 
The measured values for responses Y1 (PMD), Y2 (PDI) and Y3 (ζ) for runs F1 to F12 
were summarized in Table 11. The polynomial Equations (19), (20), and (21) for the responses 
Y1, Y2, and Y3, respectively, were developed after the data analysis in order to evaluate the best 
predictive model for each responses in relation to each factors.  
Y1 = 122.75-1.81X1+0.47X2-4.14X3-12.52X4+9.61X1X2+21.57X1X3+17.14X1X4 (19) 
Y2 = 0.179-0.007X1-0.067X2-0.016X3-0.013X4-0.0004X1X2+0.033X1X3-0.028X1X4 (20) 
Y3 = -38.18-0.091X1+0.84X2-0.99X3-1.09X4+0.88X1X2+1.21X1X3+0.086X1X4 (21) 
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Table 11: FFED Design Showing Factors With Their Corresponding Measured Responses. 
Run Factorsa Measured responses 
 X1 X2 X3 X4 Y1; PMD: nm Y2; PDI Y3; ζ: mV 
F1 - 1 - 1 +1 +1   78.7 0.22 -42.4 
F2 +1 - 1 +1 - 1 124.0  0.30 -41.4 
F3 - 1 +1 - 1 +1 111.8 0.18 -38.1 
F4 - 1 +1 +1 - 1 119.7 0.06 -38.6 
F5 +1 +1 - 1 - 1 109.3 0.13 -38.4 
F6 +1 - 1 - 1 +1   98.4 0.18 -42.3 
F7 +1 +1 +1 +1 153.4 0.08 -38.4 
F8 - 1 - 1 - 1 - 1 189.4 0.29 -34.1 
F9   0   0   0   0 115.4 0.22 -36.9 
F10   0   0   0   0 128.7 0.19  -34.1 
F11   0   0   0   0 121.1 0.15 -36.3 
F12   0   0   0   0 123.2 0.16 -37.1 
a Coded values of factors, X1; molar concentration of ADH in mM, X2; molar concentration of 
EDC in mM, X3; volume of acetone in mL, X4; reaction time in hour. 
 
In the above Equations, the positive coefficients before the terms demonstrated an 
increasing effect; whereas, the negative coefficients showed a decreasing effect on the selected 
responses. The interaction terms displayed how the responses changed when the two factors 
were varied simultaneously. To confirm the acceptability of the model, analysis of variance 
(ANOVA) was performed (Table 12). The acceptability criterion for a good model is a p value 
in ANOVA analysis ˂ 0.01 and RSquare (R2, ratio of the difference to the reduced negative 
log-likelihood values) should be in the range of 0.70 ≤ R2 ≤ 0.90 (59). According to the 
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acceptability criteria, the polynomial Equations for Y1 and Y2 fitted very well with the data 
modelling. However, the polynomial Eq. (21) for response Y3 (ζ potential) did not fit well 
according to the acceptability criteria and was not considered for subsequent modeling and 
prediction efforts. This might be due to the fact that NPs were made of HA as a main matrix, 
which did not lead to a significant changes in the ζ potential (Y3) values. 
Table 12: ANOVA Analysis. 
Responses ANOVA analysis 
 Source dfa SSb MSc R2 F ratio  p value 
Y1; PMD model 7 8231.16 1175.88 0.99 50.46 0.001 
 error 4 93.21 23.30    
 total 11 8324.37     
Y2; PDI model 7 0.055 0.01 0.94 9.65 0.022 
 error 4 0.033 0.001    
 total 11 0.058     
Y3; ζ model 7 53.55 7.65 0.99 0.97 0.545 
 error 4 31.51 7.88    
 total 11 85.06     
a Degree of freedom. b Sum of squares. c Mean sum of square. 
 
To understand the factors effects and significance, Pareto charts were generated as 
shown in Figure 9A and 9B, for the responses Y1, and Y2, respectively. The values on the x-axis 
of the Pareto charts represented the standardize effects; the ratio of estimate and the standard 
error of the factor effect (tratio values). These t values were obtained on the basis of the estimate 
of factor effects, which were the coefficients in Equations (19), (20), and (21) and the standard 
error of an effect (166). The obtained t value was compared with a tabulated critical t value 
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(tcritical = 2.78) as shown in the vertical lines in the Pareto charts. This tcritical value was 
determined at α = 0.05 for residual degrees of freedom (residual df = number of runs-number 
of terms-1) (166). In Figure 9A and 9B, the absolute t value of the factors whose length of the 
chart passed the vertical line (tcritical at p < 0.05 and df = 4) had significant effects on responses. 
 
Figure 9. Pareto Charts Showing the Standardized Effect of Factors, X1; molar concentration 
of ADH: mM, X2; molar concentration of EDC: mM, X3; volume of organic phase: mL, X4; 
reaction time: h, and their interactions for responses. (A) Y1; particle mean diameter: PMD, 
nm. (B) Y2; polydispersity index: PDI. Bars extended past the vertical lines indicated the values 
reaching statistical significance (α = 0.05). Asterisk (*) indicated the significant effect (p ˂ 
0.05) of factors over the responses. (C) Prediction profiler and desirability plot showing the 
effect of factors, X1, X2, X3, and X4, on the responses, Y1 and Y2. The desirability value of 0.91 
corresponded to the optimized HA-NPs formulation (F13) with the coded values of, X1 = -1; 
X2 = +1; X3 = +1; and X4 = +1. The coded values listed above corresponded with the actual 
values of, X1 = 2.49 mM; X2 = 9.96 mM; X3 = 60 mL; and X4 = 6 h. 
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According to Figure 9A, Y1 was significantly affected by interactions of X1X2, X1X3, 
X1X4 (all positively) and X4 (negatively). The response Y2 was significantly affected by X1X3 
(positively) and X2 (negatively) (Figure 9B). By considering only the significant effects, it 
appeared that X1 interacted with the factors X2, X3 and X4 that increased the PMD and PDI 
values of the NPs. The physical significance of this is explained later in the dissertation. The 
relationship among factors and responses was further investigated by constructing a prediction 
and desirability plot (Figure 9C). 
According to the desirability value of 0.91, one that was very close to the ideal value (d 
= 1) (Figure 9C), the run F13 (coded values: X1 = -1; X2 = +1; X3 = +1; X4 = +1; Actual 
values of, X1 = 2.49 mM, X2 = 9.96 mM, X3 = 60 mL; and X4 = 6 h) was selected as the 
optimized NP formulation which showed the Y1 and Y2 values of 70.6 ± 4.1 nm and 0.07 ± 
0.02, respectively, (n = 3). Meanwhile, to evaluate the effect of molar concentrations of ADH 
(X1) and EDC (X2) over the enzymatic degradation, drug release, and % DL of the NPs, the 
runs F1 (Coded values: X1 = -1; X2 = -1; X3 = +1; X4 = +1; Actual values: X1 = 2.49 mM; X2 
= 2.49 mM; X3 = 60 mL; and X4 = 6 h), and F7 (Coded values: X1 = +1; X2 = +1; X3 = +1; 
X4 = +1; Actual values: X1 = 9.96 mM; X2 = 9.96 mM; X3 = 60 mL; and X4 = 6 h) were selected 
as control formulations. These control formulations F1 and F7 had the lowest and highest molar 
concentrations of ADH and EDC, respectively. The rationale for this selection was based on 
the fact that the free -COOH groups on HA were the recognition sites to initiate its degradation 
by HAase enzyme (167). Increasing the molar concentrations of ADH and EDC could affect 
the cross-linking between HA and ADH. Theoretically, this affected the degradation kinetics 
of the HA-NPs due to the higher cross-linking density of the -COOH groups and was not 
favorable for the attack of HAase on its recognition site. 
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Checkpoint Analysis 
The resultant model was analyzed for its acceptability and validity with the theoretical 
optimum run, F13, which shows the maximum desirability value (Figure 9C), while 
minimizing both Y1 and Y2 values as given in Table 13. Two randomly selected runs, F14 
(coded values; X1 = -0.5; X2 = -0.5; X3 = +1; X4 = +1) and F15 (coded values; X1 = 0; X2 = 0; 
X3 = +1; X4 = +1) were also analyzed to perform the checkpoint analysis (n = 3) to ensure 
reproducibility of the model. The difference between the predicted and measured values was 
statistically insignificant (p > 0.05). 
Table 13: Checkpoint Analysis (n = 3). 
Responses Run Measured value Predicted value % Error p value 
Y1; PMD: nm F13   70.6 ± 4.1   60.1 ± 13.1 -17.6 0.25 
 F14   96.3 ± 5.3   89.8 ± 9.2          -7.22 0.35 
 F15 108.4 ± 3.9 106.1 ± 7.7          -2.13 0.68 
Y2; PDI F13   0.07 ± 0.02   0.09 ± 0.08       17.7 0.70 
 F14   0.17 ± 0.01   0.18 ± 0.05        7.61 0.60 
 F15   0.16 ± 0.02   0.15 ± 0.05         -7.38 0.79 
 
Physicochemical Characterization of HA-NPs Formulations 
PMD, Size Distribution, and % DL 
The size distribution, PMD and PDI values for the NPs were analyzed by DLS 
measurements and shown in Figure 10A and Table 14. The % DL and % yield of HA-NPs 
calculated after purification and freeze-drying process was given in Table 14. The size 
distribution of NPs (F13) was also measured using NTA method and results were shown in 
Figure 10B. Both the analyses (DLS and NTA) confirmed the NPs formation in the nanoscale 
size range.  
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Table 14: Physicochemical Characterization of HA-NPs. 
HA-NPs Y1; PMD: nm* Y2; PDI* DL (% w/w)* Yield (% w/w)* 
F13   70.6 ± 4.1 0.07 ± 0.02 26.1  1.2 93.3 ± 0.7 
F1   81.5  2.6 0.21  0.01     22.0  0.7 90.9 ± 0.8 
F7 157.7  4.0 0.08  0.02     10.6 ± 1.8 84.2 ± 1.1 
* Values were given as mean ± SD, n = 3. 
 
Figure 10A. Surface Morphology and Size Distribution of HA-NPs (F13) by TEM and DLS 
Analyses. 
 
Figure 10B. Size Distribution Analysis of HA-NPs (F13) by NTA Measurements. 
 
The NPs were found stable as the ζ potential value was -38.2 ± 2.8 mV (n = 3), which 
was above (absolute value) the ζ potential limits ( ± 30 mV) for a colloidal dispersion to be 
64 
 
stable (168). The % DL of the NPs was increased with increasing the drug concentration in the 
loading solution. The % DL was increased from about 16 to 26% for F13, 13 to 22% for F1 
and 5.5 to 11% w/w for F7, when the ratio of drug to NPs was changed from 1:10 to 1:1 (w/w), 
respectively, in the loading solution. This was probably due to the presence of a higher 
concentration of drug in the loading solution as also observed by other researchers (169, 170). 
In addition, increasing the NP amount and thus the concentration of HA polymer in the loading 
solution might have exhibited greater molecular tortuosity which have interfered with the 
diffusion of drug into the NPs and lowered the drug loading as previously explained (170, 171).  
There are other factors such as pH and temperature that could have also affected the 
drug loading of HA-NPs. In this study, the drug loading experiment was performed at neutral 
pH (greater than the pKa value of HA; 2.9) (172). It was anticipated that at this pH, due to the 
presence of ionized -COOH groups in the HA-NP matrix (belonging to HA), there was an 
electrostatic repulsion among the HA chains (115). This might have increased the inter-chain 
distances and degree of swelling leading to higher drug loading inside the NPs (115). 
The higher % DL associated with F13, compared to F1 and F7 formulations can be 
explained by the effect of the lower cross-linking density of -COOH groups of HA in F13. 
Thus, there would be higher electrostatic interaction of the positively charged amino group of 
TFV and the negatively charged -COOH of HA. Also, the introduction of cross-linking into 
native HA produced porous surfaces, while native HA has a fibrous and irregular structure 
(173). This might have also promoted the diffusion of TFV inside the HA matrix and increased 
the % EE and DL of the HA-NPs. The porosity was further affected by high molar 
concentration of EDC compared to the ADH in the F13 NP formulation (174).  
Spectral Analysis by FT-IR spectroscopy 
To assess the cross-linking between HA and ADH (prepared according to the Reaction 
Scheme 1), FT-IR analysis was performed. The peaks observed in the FT-IR spectra were 
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summarized in Table 15 together with their peak assignments. In the FT-IR spectra of NPs 
(Figure 11E, F and G), instead of a single band at 1620 cm-1 as present in the spectrum of HA 
(Figure 11C) there were two intense bands at about 1650 cm-1 (associated with the amide bond 
formed between HA and ADH) and at 1550 cm-1 (due to the presence of secondary amide 
groups of ADH). The reduced intensity of the small band at 1405 cm-1 in the NPs spectrum 
compared to that of native HA was attributed to the reduction in the numbers of -COOH groups 
of HA due to the amide coupling. 
 
Figure 11. FT-IR Spectrum: (A) EDC. (B) ADH. (C) Native HA. (D) HA-PM. (E) HA-NP; 
F1. (F) HA-NP; F7. (G) HA-NP; F13. 
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Past studies showed similar FT-IR spectrum of native HA (175), ADH (173), and HA 
cross-linked with dihydrazide (175), which strongly supported the hypothesis of this work that 
HA and ADH were indeed cross-linked, using carbodiimide chemistry. The NP formation 
reaction was also performed excluding the cross-linking agents (ADH, EDC and NHS) to 
further assess the eventual effects of external factors on the formation of NPs. The product of 
this reaction (HA-PM: Figure 11D) generated the similar spectrum as of native HA (Figure 
11C). This clearly indicated that the ADH and EDC were critical to formulate the cross-linked 
HA-NPs. 
Table 15: Peaks Observed in the FT-IR Spectra with Their Peak Assignments. 
Sample Wavenumbers (cm-1) Peak assignments  
(peak designation in the spectrum) 
ADH 3200-3400 
2800-2950 
1640 
1530 
Stretching vibrations of -NH and -NH2 groups (1) 
C-H stretching (2) 
C=O stretching vibration (3) 
Secondary amide group (4) 
Native HA 3290 
2850-2950 
1620 
1550 
1405 
1160 
950-1150 
OH and -NH stretching vibrations (5) 
CH2 asymmetric and symmetric stretching (6) 
Asymmetric stretching of C=O of COO− group (7) 
Amidic -NH bending of acetamide group (8) 
COO− symmetric stretching (9) 
C-O-C glycoside bond in saccharidic units (10) 
C-O stretching vibrations in alcoholic groups (11) 
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NPs (F1, F7 
and F13) 
3100-3500 
 
 
1650 
 
1550 
1200-1400 
Stretching vibrations of -NH and -NH2 groups of 
ADH also associated with the -OH and -NH 
stretching vibrations of HA (12) 
Amide-I, due to the cross-linked HA and ADH 
(13) 
Amide-II, amide group of ADH (14) 
C-N, C-O and CH2 stretch, indicating the presence 
of pendant hydrazide groups of ADH (15) 
 
Solid State 13C-CP/MAS NMR Spectroscopy for Spectral Analysis 
The NMR spectra were given in Figure 12 and the results were summarized in Table 
16, together with their peak assignments as shown in reaction scheme 1. The NMR. The intense 
signal at 175 ppm was attributed to the amide group associated carbonyl carbon in the spectrum 
of ADH (Figure 12B); whereas, it was associated with -COOH and carbonyl acetamido carbons 
in the spectrum of HA (Figure 12C). In the spectrum of HA-NPs the characteristic signal at 
about 175 ppm was associated with the carbonyl carbons of amide groups formed due to the 
cross-linking between native HA and ADH. One remarkable difference among the spectrum of 
the NPs, native HA and ADH was that the signals in the NPs spectrum were considerably 
broader and extended over a larger region possibly due to the ionic interactions between the 
randomly cross-linked HA.  
The similar spectrum of native HA and dihydrazide cross-linked HA (176) have been 
observed in previous studies, which also confirmed that HA and ADH were indeed cross-linked 
in this study. The signal at about 156 ppm was more intense in F13 (Figure 12F). This could 
be due to the presence of higher molar concentration of EDC in F13 compared to F1 and F7. 
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Thus the intermediate product of HA and EDC was formed efficiently and showed an intense 
signal (80, 176).  
Overall, the results indicated by FT-IR (Figure 11, Table 15) and NMR (Figure 12, 
Table 16) analyses confirmed the cross-linking between HA and ADH. 
Table 16: Chemical Shift (δ: ppm) Values Observed with Their Peak Assignments. 
Sample Chemical shift (δ: ppm) Peak assignments 
ADH 175 
36 and 26 
Amide group associated carbonyl carbons 
α  and β carbons, respectively, corresponded with 
the aliphatic region 
HA 175 
100 
 
65-80 
45-65 
25 
Carboxylate and acetamido carbonyl carbon 
Two anomeric carbons of D-glucuronic acid moiety 
of HA associated with C-O-C glycoside bonds 
Ring carbons 
Methylene carbons 
Methyl carbon of acetamido group 
NPs (F1,  
F7 & 
F13) 
175 
 
36 and 26 
Amide group associated carbonyl carbons of HA 
and ADH 
α  and β carbons of ADH, respectively 
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Figure 12. Solid State 13C-CP/MAS NMR Spectrum: (A) EDC. (B) ADH. (C) Native HA. (D) 
HA-NP; F1. (E) HA-NP; F7. (F) HA-NP; F13. Asterisked (*) Signals Indicated the Formation 
of EDC-HA Adduct. 
 
Enzymatic Degradation Analysis of HA-NPs 
The percent cumulative degradation either in the presence or absence of HAase enzyme 
was analyzed using Uronic acid-Carbazole assay and represented in Figure 13A, B, C and D 
for native HA, F13, F1, and F7 NPs formulations, respectively. It was observed that in the 
presence of HAase, the degradation of native HA was higher in comparison to formulation F13, 
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F1 and F7. The variance in the degradation of these samples was due to the different 
interactions of HAase with its recognition site of HA as explained below. 
 
Figure 13. Percent Cumulative HA degradation (% w/w) either in Presence or Absence of 
HAase enzyme at pH 7.1. (A) HA-gel. (B) HA-NP; F13. (C) HA-NP; F1 and (D) HA-NP; F7. 
Results are given as mean ± SD, n = 3. 
 
It is well known that HAase begins its action by effecting the free -COOH groups of 
HA (167). Thus, the molar concentrations of ADH (cross-linking agent) was considered as the 
major formulation variable in the formulation design that could have significantly affected the 
cross-linking density, enzymatic degradation and release kinetics of the HA-NPs. It was 
observed that the degradation was highest for native HA as compared to the HA-NPs since, in 
the native HA all the -COOH groups were free to interact with HAase enzyme. The slower 
degradation rate for formulation F7 can be explained by the fact that, in this, the molar 
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concentrations of ADH and EDC were highest in F7 with the maximum -COOH groups of HA 
being blocked by forming the amide bonds with ADH. The degradation of native HA and HA-
NPs in the absence of HAase might be due to the hydrolytic degradation of HA as previously 
explained (80, 103). Overall, the degradation rate for HA-gel and HA-NPs was faster in the 
presence of HAase compared to its absence. 
 
In Vitro Drug Release Analysis of HA-NPs 
The in vitro drug release profile was depicted in Figure 14A, B, C and D for TVF 
containing HA-gel and native TFV control, F13, F1, and F7 NPs, respectively. A significantly 
triggered release of drug (~90% w/w) was observed from NPs (F13) in the presence of HAase 
enzyme; whereas, in its absence the value was ~39% w/w as analyzed after 24 h. It was 
observed that HA-gel exhibit a burst release at ~78% and ~73% w/w of the drug was released 
in first 6 h in the presence and absence of HAase, respectively. However, ~97% w/w of drug 
was released from HA-gel either in the presence of absence of HAase after 24 h (Figure 14A). 
These results indicated that the drug release rate was much faster from the HA gel; whereas, 
comparatively slow release of TFV was observed in the case of HA-NPs. This might be due to 
the difference in cross-linking density of the HA-NPs and HA-gel that has been significantly 
affected their enzymatic degradation behavior as explained before (Figure 13). In addition, the 
van der Waal and electrostatic interactions of TFV with HA polymeric chains inside the NPs 
could also be one of the reasons for the slow release of drug from NPs as explained below.  
TFV has two pKa values at 2.0 and 6.7 (56), whereas HA has a pKa value at 2.9 (172). 
Hence, both TFV and HA were negatively charged at pH 7.1 (above their pKa values). 
Therefore, there was a minimal possibility of interaction between them. Due to these minimal 
interactions of HA with TFV a higher drug release rate was observed in case of the native HA-
gel. However, after the cross-linking of native HA polymeric chains inside NPs, the cross-
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linker (ADH) increased the interactions of HA with TFV through its nonpolar carbon atoms 
and its amino groups (positively charged at the working pH of 7.1). These interactions might 
have caused a slower drug release rate from the NPs. 
 
Figure 14. Percent Cumulative Drug Release (% w/w) profile either in Presence or Absence 
of HAase at pH 7.1. (A) HA-gel and TFV control. (B) HA-NPs; F13. (C) HA-NPs; F1. (D) 
HA-NPs; F7. Results are given as mean ± SD, n = 3. 
The effective molar concentration (EC50) of TFV required for in vitro anti-HIV activity 
varies between 5-7.4 µM (177). The HIV virus can cross the CV mucosa barrier in 2 to 6 h and 
interacts with the macrophages, and dendritic cells (178). Ideally, the effective concentration 
(EC50) of TFV required to exhibit its activity should be released from the NPs before the HIV 
virus crosses the vaginal mucosa between 2-6 h. Based on the drug loading of HA-NPs (~26 
%w/w), the actual amount of TFV was ~91 μM per 100 mg of NPs. Considering the 20 mg of 
HA-NPs will be used in each treatment dose, this would be equivalent to ~18 μM of TFV drug 
dose. It is noteworthy that although, only 32% w/w of the drug was released in 3-6 h from the 
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optimized formulation (F13), the EC50 value of TFV was achieved in that critical timeframe in 
the presence of HAase; whereas, more than 9 h was required in the absence of HAase based on 
the release data (Figure 13). 
 
Kinetics of Enzymatic Degradation and In Vitro Drug Release Profile of HA-NPs 
The drug release was analyzed using various in vitro kinetic models as given by 
Equations (4), (5), (6), and (8), respectively. The parameters obtained were given in Table 17. 
It was observed that in the absence of HAase the drug release from F13 and F1 followed the 
Peppas model. However, in the presence of HAase enzyme, F13 and F1 followed first order 
and Peppas models, respectively. The drug release kinetics from HA-gel followed first order 
model (r2: 0.97), whereas drug release from F7 was governed by the combination of zero and 
first order kinetic models (Table 17), either in the presence or absence of HAase.  
To further determine the drug release mechanism from NPs and gel formulation the 
Korsmeyer-Peppas model was applied. The decision to use the Korsmeyer-Peppas model was 
based on its simplicity and efficiency in analyzing the drug release mechanism when more than 
one form of mechanisms were involved. It was observed that the drug release from F13 and F1 
occurred by Fickian diffusion (n ˂ 0.5), whereas F7 followed anomalous transport (diffusion 
and erosion controlled release) mechanism since 0.5 < n < 1. The drug release from the HA-
gel followed Super Case-II transport (erosion of and degradation of HA) since n > 1.  
The f1 and f2 values were calculated using Equations (9), and (10), respectively (129), 
and shown in Table 17. Results indicated that there was a significant difference between the 
HA degradation and drug release kinetics from HA-gel and HA-NPs either in the presence and 
absence of HAase enzyme.  
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Table 17: Estimated Parameters: In Vitro Drug Release and Degradation Kinetics Models. 
HA-
NPs 
Zero 
order  
First order  Higuchi 
model 
Korsmeyer-
Peppas model 
Model independent analysis 
 r2 a  r2 a  r2 a r2 a,  
(exponent n) 
Enzymatic 
degradation 
In Vitro drug 
release 
f1, (f2) f1', (f2') 
F13b* 0.785 0.969 0.926 0.928, (0.29) 32.0, (12.9) 26.4, (13.3) 
F13c* 0.626 0.718 0.855 0.982, (0.25) 35.4, (28.6) 57.3, (-3.1) 
F1b** 0.754 0.882 0.938 0.952, (0.34) 29.7, (14.5) 40.9, (3.8) 
F1c** 0.716 0.798 0.916 0.971, (0.32) 36.8, (28.2) 62.3, (-4.9) 
F7b*** 0.993 0.995 0.946 0.973, (0.78) 64.3, (-2.3) 61.4, (-1.5) 
F7c*** 0.996 0.988 0.926 0.950, (0.68) 74.5, (12.5) 83.4, (-7.6) 
a Correlation coefficient. b Presence of HAase enzyme. c Absence of HAase enzyme.  
 
Surface Morphology and Size Distribution Analysis of HA-NPs during the Enzymatic 
Degradation Process 
The HA-NPs demonstrated a spherical shape and small PMD, as analyzed by TEM and 
DLS analyses (Figure 15A). The surface morphology of the NPs during the enzymatic 
degradation process was analyzed for up to 3 days (Figure 15B) showed that the surface 
morphology in the absence of HAase was not changed significantly; whereas, in its presence 
there was a significant change (Figure 15C) compared to that of native HA-NPs (Figure 15A). 
This was potentially due to the degradation of HA at the surface of the NPs, which generated 
the fragments of HA and caused its transition from globular to coil confirmation (164).  
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Figure 15. (A) Surface morphology: scale bar, 500 nm, and size distribution analysis of native 
HA-NPs (F13) by TEM and DLS analyses. Surface morphology of formulation F13: (B) in the 
absence of HAase, after day one: scale bar, 500 nm, and day three: scale bar, 200 nm. (C) in 
the presence of HAase, after day one: scale bar, 500 nm and day three: scale bar, 200 nm.  
 
The PMD of the degradation medium (taken as control) at day zero was 7.03 ± 0.49 nm 
(n = 3), (Figure 16A). The PMD observed was mainly due to the presence of bovine serum 
albumin (BSA;~7 nm) (179) at high concentration (~40 mg/mL) (127) in the degradation 
medium. A slight increase (~2 fold) observed in the NPs diameter when incubated in medium 
in the absence of enzyme (Figure 16A) could be due to the interaction of BSA with HA (180) 
and self-aggregation (179, 181) of BSA. This was further confirmed by UV-Vis spectroscopy 
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and ζ potential measurements as explained below. The PDI value of all the samples was very 
high (> 0.5) which could be due to the presence of particles of variable diameters. 
Self-aggregation of BSA and its Interaction with HA: Effect over PMD and Enzymatic 
Degradation of HA-NPs 
BSA is a globular protein that has been stabilized by electrostatic repulsions in its native 
form (179). The diameter of the BSA has been affected greatly by various factors such as time, 
temperature, concentration, and its self-aggregation (179). The interaction between BSA and 
HA is a pH dependent process and maximum at pH 4 to 5 (172). In this study the enzymatic 
degradation analysis was conducted at pH 7.1, which was substantially higher than the 
isoelectric points of BSA (5.2) and HA (2.9) (172). But, due to the heterogeneity of the charge 
of the BSA molecule, the binding sites can be localized even at pH 7.1 (182). Thus, the 
existence of positive charge patches at the BSA surface, allowed the electrostatic interaction of 
HA at this pH. This was confirmed by an increase in the UV absorbance value of the solution 
containing BSA and HA at 400 nm (Figure 16B). The interaction between BSA and HA was 
further analyzed by ζ potential measurements as shown in Figure 16C. The self-aggregation 
and size distribution analysis of native HA-NPs (F13) in the presence of BSA (release medium) 
was analyzed by DLS analysis (Figure 17). 
The slow enzymatic degradation rates of the HA-NPs could also be explained on the 
basis of interaction between BSA and HA, since BSA compete with HAase to form electrostatic 
complex with HA (172, 183). Also, at high concentration, BSA formed a dense complex with 
HA and covered it completely (adsorption layer), hindering the hydrolysable sites on HA (172, 
183). This ultimately inhibited or slowed down the degradation of HA by HAase. Indeed, the 
study of complex formation between BSA and HA and several other components (enzymes, 
amine bases) present in the vaginal and seminal fluids was complicated and needs further 
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analysis techniques such as, X-ray photoelectron spectroscopy (XPS) and Auger electron 
spectroscopy in the future work.  
 
Figure 16. (A) Particle mean diameter; PMD; nm. (B) Absorbance of complex mixture of BSA 
and HA at 400 nm. (C) Zeta potential analysis. Results are analyzed up to three days of 
incubation at 37°C and given as mean ± SD, n = 3. 
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 Figure 17. Self-aggregation of BSA and its Interaction with HA-NPs. 
 
Modelling the Interaction of TFV with HA and HA-NPs and its Effect over Drug Loading 
and Drug Release Profile of NPs 
The lowest energy conformation of TFV within core assembly of native HA and HA-
NPs after the docking calculations was shown by Figure 18A and 18D, respectively. In this 
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case, the lowest energy conformation also belongs to the most populated cluster and was 
selected for the analysis. Amide cross-linking of HA placed its units at a distance that facilitated 
the formation of H-bonds of each unit to an appropriately positioned heteroatom’s (N and O) 
of TFV at an appropriate distance by forming three H-bonds with hydroxyl groups of HA. This 
facilitated the encapsulation of drug inside NPs. This phenomenon was further analysed by 
interaction energy (IE) calculation. 
 
Figure 18. Structural Representation of Computational Modelling Interaction of TFV with: 
(A) Native HA. (D) HA-NPs. Surface representation with hydrophilicity/hydrophobicity 
projected onto a molecular surface of TFV with: (B) Native HA. (E) HA-NPs. Surface 
representation with hydrophilicity/hydrophobicity projected onto a molecular surface of TFV 
for better visualization with: (C) Native HA. (F) HA-NPs, showing cavity formation which is 
beneficial for drug entrapment. The colour code was based on the atom type: in Grey were the 
carbons, in Blue were the nitrogen’s, in Red were the oxygen’s, and in purple was the 
phosphorus atom. Hydrophilic surface (turquoise) and hydrophobic surface (blue). 
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The VW interaction appeared to be a predominant determinant of the IE between drug 
and HA-NPs affecting the encapsulation and release properties of NPs (Table 18). The 
increased VW interactions energy between TFV and the HA-NPs components compared to that 
of TFV and native HA resulted in the higher drug encapsulation by the NPs. This was expected 
because the cross-linking of HA introduces more nonpolar carbon atoms, which interacted with 
the polar parts of TFV, and increased the polar VW (induced dipole-dipole) interactions. There 
was also a polar-polar interaction between the polar parts of the HA-NPs and TFV (N and 
O atoms), contributed to the total VW interactions. The lipophilic component of the VW 
interactions was very small (not many nonpolar VW interactions e.g. carbon-carbon 
interactions resulted from temporarily polarization). The surface representation of the 
interaction between TFV with native HA (Figure 18B and 18C) and with HA-NPs (Figure 18E 
and 18F), respectively, clearly showed the cavity formation in the NPs structure which was 
beneficial for the encapsulation of TFV inside NPs. The surfaces were found to be highly 
hydrophilic (hydrophilic: 448.57A0; hydrophobic: 6.93A0). The purine moiety of the TFV was 
partially buried with its phosphonic acid group and extended out of the cavity to interact with 
hydrophilic solvents through the formation of H-bonds.  
Table 18: Molecular Docking Simulation for Interaction Energy (IE) Calculations. 
Types of interactions IE (kcal/mol) 
(between TFV and native HA) 
IE (kcal/mol) 
(between TFV and NPs) 
Hydrogen bond (H-bond) -1.63 -1.52 
Van der Waal (VW)      -6.03 -16.3 
Lipophilic -0.56 -0.94 
Electrostatic -10.9 -9.72 
Glide Score* -4.71 -5.28 
*Glide Score is the predicted binding energy, calculated by using Eq. (11) in the text. 
81 
 
The theoretical observation from CM was correlated with the experimentally 
determined in vitro drug release profile of HA-NPs. As most of the drug was solvent exposed, 
which resulted in relatively faster release rate of TFV when a hydrophilic solvent (ex. water) 
replaced the H-bonds between drug and HA-NPs, which was also seen in this study as NPs 
showed a burst release in first couple of hours (Figure 14). However, due to the higher VW 
interaction of TFV with NPs (Table 18), a slow release was observed later. Overall, the 
modelling prediction was informative and explanatory in terms of getting theoretical 
information’s about drug encapsulation and release from HA-NPs in the rational design of 
delivery systems in the future work. 
 
Stability Evaluation of Tenofovir 
Solid State PXRD Analyses  
PXRD analyses confirmed that the drug was stable and maintained its original crystalline 
pattern under the variable stress conditions of temperature and % RH. The characteristic peaks 
of native TFV were observed at the diffraction angle of 2θ = 7.44°, 14.89°, 18.11°, 18.59°, 
22.41°, 23.45°, 24.75°, 28.90°, and 29.80° (Figure 19). The PXRD pattern of the unstressed 
sample of TFV were similar to that observed in a previous study (43). 
Degradation Kinetics of TFV under Hydrolytic Conditions 
The degradation mechanism of TFV under hydrolytic, oxidation, thermal and accelerated 
stress conditions was analyzed using a validated LC-MS assay. The drug showed degradation 
in acidic (0.1 M HCl) and alkaline (0.1 M NaOH) hydrolytic conditions, and followed first 
order degradation kinetics behavior (Figure 20A). The drug was found stable at pH 4.5 (< 10% 
degradation) (vaginal pH environment) under refluxing conditions for 5 days. No significant 
degradation (< 5%) and degradation products were observed at pH 4.5 whether the temperature 
was 25°C or 40°C as analyzed for up to 10 days. TFV was also found stable under oxidative 
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stress conditions in 3% and 30% v/v H2O2 solutions as incubated up to 7 days at room 
temperature. On exposure to acidic (0.1 and 0.01 M HCl) and alkaline (0.1 and 0.01 M NaOH) 
conditions at 25°C and 40°C, the drug was found stable (< 5% degradation). The drug was also 
found stable in thermal, and accelerated stress conditions (data not shown). 
 
Figure 19. Solid State PXRD Pattern of TFV (unstressed) and TFV Stressed Samples. From 
bottom to top, (A) TFV-unstressed sample, (B) TFV at -20°C, (C) TFV at 5°C (D) TFV at 
25°C/60% RH, (E) TFV at 40°C/75% RH, (F) TFV at 50°C and, (G) TFV at 80°C. Each sample 
was analyzed after 12 months of stressed conditions applied except the sample at 80°C which 
was analyzed after one month of exposure. 
 
Arrhenius Equation Plot 
The degradation kinetic plot of TFV between ln (% drug remaining) and time (t) in 
months at 40, 50, and 60°C was shown by Figure 20B. The k values determined from the slope 
of the regression equation were observed as 0.60 (± 0.04), 0.70 (± 0.06), and 0.84 (± 0.06) × 
10-2 months-1 at 40, 50, and 60°C, respectively, after triplicate analysis (n = 3). A linear 
relationship between ln (k) in months-1 and 1000/T (in Kelvin) at 40°C (313.15 Kelvin), 50°C 
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(323.15 Kelvin), and 60°C (333.15 Kelvin) was observed in the Arrhenius plot (Figure 20B). 
The slope and r2 values were found to be -1.75 ± 0.29 and 0.974 ± 0.032, respectively, (n = 3). 
The k25 value was 0.45 × 10
-2 (± 0.03) months-1 (n = 3).  
 
Figure 20. (A) First order Degradation Kinetic Plots of TFV between log (% drug remaining) 
and Time in Hours under Acidic (0.1 M HCl; ) and Alkaline (0.1 M NaOH; ) Hydrolytic 
Conditions. (B) Arrhenius Plot of TFV between ln (k) in Month-1 and 1000/T-1 (in Kelvin-1) at 
40°C, 50°C, and 60°C. 
 
The Ea value derived from the slope of Arrhenius plot (Figure 20B) was calculated as 
14.54 ± 2.45 kJ/mol (n = 3). The lower Ea value obtained here reflected that the stability of 
TFV under an accelerated condition was temperature independent. The shelf-life (t90) of TFV 
calculated using the obtained k25 value and Eq. (15) was found to be 23.40 ± 1.56 months (1.95 
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± 0.13 years), (n = 3). This was close to the shelf-life of TFV (24 months: two years) found in 
the literature under the recommended storage conditions (184). Overall, stability analyses 
revealed that formulation strategies should be implemented to protect the TFV from strong 
acidic and alkaline conditions. However, stability of TFV at pH 4.5 (normal vaginal pH), 
oxidative, accelerated, and thermal stress conditions makes TFV a suitable topical microbicide 
candidate for long-term storage and controlled vaginal delivery applications. 
 
Cytotoxicity Evaluations of HA-NPs 
Nanoparticles Characterization in Cell Culture (Keratinocyte) Medium 
The size distribution of HA-NPs (optimized formulation F13) was characterized in the 
supplemented keratinocyte medium after 24 h incubation at 37°C before the in vitro 
cytotoxicity evaluations. The ζ potential of blank medium after 24 h of incubation at 37°C was 
~ -12 mV, the PMD was 929.23 ± 549.86 nm with a high PDI values (0.734 ± 0.247), (n = 3) 
indicated a broad size distribution (Figure 21B). The TEM image of blank (no NPs) 
keratinocyte medium was shown in Figure 21B. The higher PDI values of size distribution of 
keratinocyte medium could be due to the presence of various proteins, nutrients and electrolytes 
(185, 186).  These proteins tend to form electrostatic interaction and agglomeration with other 
components in the culture medium during the incubation process. This led to an increased PMD 
of HA-NPs in keratinocyte medium (PMD: 238.87 ± 4.21 nm; PDI: 0.322 ± 0.002; -12.33 ± 
0.68 mV, n = 3) (Figure 21C) compared to the PMD of HA-NPs dispersion in water (PMD: 
100.20 ± 20.00 nm; PDI: 0.07 ± 0.01; ζ potential: -42.30 ± 1.70 mV, n = 3) (Figure 21A). An 
increase in the ζ potential of HA-NPs in keratinocyte medium was due to the presence of 
various positively charges proteins adsorbed on NPs surface. The TEM image showed that the 
proteins in the culture medium were adsorbed onto the HA-NPs surface to form a protein-NPs 
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corona (Figure 21D). The presence of the corona corroborated well with the decrease in ζ 
potential of HA-NPs in the culture medium.  
 
Figure 21. Size Distribution Analysis of HA-NPs in Keratinocyte Medium and Water by 
DLS and TEM Measurements. 
 
The discrepancy between DLS and TEM results regarding the size of HA-NPs in cell 
culture medium could be explained as following (187, 188) (189). The DLS analysis provided 
the hydrodynamic diameter of the NPs. When NPs were dispersed in a liquid medium, a thin 
hydration layer of the solvent attached to their surface, which influenced their Brownian motion 
in the medium. Thus, the hydrodynamic diameter provided the information about the NPs core 
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size in addition to the coating layer and the solvent layer interacted with the NPs. Whereas, 
TEM analysis estimated the projected area diameter of the NPs. In this case, only the 
information about the core size of the NPs was provided. This led to a greater hydrodynamic 
diameter of the NPs in DLS compared to the size estimated by TEM. Although, the TEM 
measurements gave accurate core size of the NPs, the size assessment of the coating layer can 
sometimes be underestimated or missed in the event of a poor contrast of TEM. Contrary to 
TEM measurements, the hydrodynamic diameter of the NPs provided a better understanding 
of the NPs migration in the liquid media.  
Cell Viability Assay of HA-NPs 
Resazurin and MTS assays demonstrated that HA-NPs did not have any significant 
effects (p > 0.05) on the viability of VK2/E6E7 and End1/E6E7 cells, compared to the cell 
culture medium (negative control) (Figure 22).  
 
Figure 22. Effects of HA-NPs on Cell Viability in VK2/E6E7 and End1/E6E7 Cells. The 
results are represented as mean ± SD of three independent experiments carried out in five 
replicates. Statistically significant differences relative to control were indicated at p < 0.05. 
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Assessment of Cell Membrane Integrity 
The HA-NPs were investigated for their effect on plasma membrane integrity. As 
suggested in Figure 23, HA-NPs did not significantly compromise the cell membrane integrity 
in vaginal epithelial cells. However, on exposure to the positive control (1% Triton-X-100), 
the epithelial cells showed a significant loss of cell membrane integrity to < 10% (p<0.01) 
compared to the negative control (medium). 
 
Figure 23. Effects of HA-NPs on Cell Membrane Integrity in VK2/E6E7 and End1/E6E7 
Cells. The results are represented as mean ± SD of three independent experiments carried out 
in five replicates. Statistically significant differences relative to control were indicated at p < 
0.05. 
Assessment of Apoptosis through Chromatin Condensation 
Apoptotic cells can be erroneously classified as viable cells since the plasma membrane 
integrity of cells undergoing apoptosis is preserved (190). Cells were examined for evidence 
of chromatin condensation, one of the characteristic features of apoptosis. The ratio of 
fluorescence intensity from HO/NR ratio was determined as previously described (148). As 
shown in Figure 24, no significant variation of HO/NR ratio was noted in the presence of HA-
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NP compared to untreated cells, indicated the absence of apoptosis in both the cell lines. For 
comparison, camptothecin (100 µM), a well-known inducer of apoptosis (191), markedly 
increased the HO/NR ratio to 1.8-3.4 (p<0.01), reflected the presence of apoptosis. 
 
Figure 24. Effects of HA-NPs on Chromatin Condensation in VK2/E6E7 and End1/E6E7 
Cells. The results are represented as mean ± SD of three independent experiments carried out 
in five replicates. Statistically significant differences relative to control were indicated at p < 
0.05. 
 
Assessment of Mitochondrial Function 
Assessment of Mitochondrial Respiratory Function 
Resazurin assay was used to evaluate the activity of mitochondrial respiratory enzymes. 
The genital epithelial cells showed a high tolerance to HA-NPs exposure at the time point 
examined however, MRF was significantly decreased (p<0.01) in both cell lines in the presence 
of positive control (p<0.01) (Figure 25). 
Assessment of Mitochondrial Membrane Potential (ΔΨm) 
Results (Figure 26) showed that the ΔΨm was maintained by proton and pH gradients 
across mitochondrial inner membrane after the NPs treatment. Contrary to End1/E6E7 cells, 
HA-NPs significantly decreased the ΔΨm in VK2/E6E7 cells (p<0.05) at higher concentration 
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(1000 µg/mL). However, the lower concentrations (1-100 µg/mL) of NPs did not show any 
significant (p>0.05) effect. The positive control (100 mM H2O2) significantly decreased the 
ΔΨm (p<0.01) compared to the negative control. 
 
Figure 25. Effects of HA-NPs on Mitochondrial Respiratory Function in VK2/E6E7 and 
End1/E6E7 Cells. The results are represented as mean ± SD of three independent experiments 
carried out in five replicates. Statistically significant differences relative to control were 
indicated at p < 0.05. 
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Figure 26. Effects of HA-NPs on Mitochondrial Membrane Potential (ΔΨm) in VK2/E6E7 and 
End1/E6E7 Cells. The results are represented as mean ± SD of three independent experiments 
carried out in five replicates. Statistically significant differences relative to control were 
indicated at p < 0.05. 
Assessment of Mitochondria Mass 
Results indicated that up to 100 μg/mL of HA-NPs, there was no significant (p>0.05) 
variation in NAO fluorescence intensity in both the genital epithelial cell lines (Figure 27). 
However, exposure of cells to the positive control (100 mM H2O2) caused a significant decrease 
of NAO fluorescence intensity (P<0.01). 
 
Figure 27. Effects of HA-NPs on Mitochondrial Mass in VK2/E6E7 and End1/E6E7 Cells. 
The results are represented as mean ± SD of three independent experiments carried out in five 
replicates. Statistically significant differences relative to control were indicated at p < 0.05. 
 
Intracellular ROS Production  
HA-NPs did not increase the ROS level at all concentrations tested compared with the 
positive control (100 mM H2O2) (Figure 28). Instead, a significant decrease in the endogenous 
ROS production (p<0.05) below the basal level was observed at the concentrations of 10-1000 
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μg/mL. Results suggested an important role for HA-NPs in ROS scavenging, which was 
consistent with the antioxidant properties of the HA (105). 
 
Figure 28. Generation of Reactive Oxygen (ROS) Species Induced by HA-NPs in VK2/E6E7 
and End1/E6E7 Cells. The results are represented as mean ± SD of three independent 
experiments carried out in five replicates. Statistically significant differences relative to control 
were indicated at p < 0.05. 
 
Intracellular NO Production 
In the presence of positive control (SNP), a significant higher amount of nitrites (> 30 
µM) was released in the culture medium (Figure 29). However, in the presence of HA-NPs, the 
NO profile was not altered and all determinations were similar to those of the endogenous NO 
(5-10 µM) regardless the concentrations of NPs tested. These data indicated that HA-NPs did 
not induce the iNOS-mediated inflammation. 
Intracellular Antioxidant GSH Assay 
The intracellular GSH has been examined to evaluate the cellular redox state that 
consists in equilibrium between the pro-oxidant and antioxidant systems. It was observed that 
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upon HA-NPs exposure, the intracellular GSH content was not significantly affected (p>0.05) 
(Figure 30). Whereas, positive control significantly reduced the intracellular GSH level in both 
the cell lines (p<0.01) compared to the negative control.  
 
Figure 29. Generation of NO Induced by HA-NPs in VK2/E6E7 and End1/E6E7 Cells. The 
results are represented as mean ± SD of three independent experiments carried out in five 
replicates. Statistically significant differences relative to control were indicated at p < 0.05. 
 
Figure 30. Effects of HA-NPs on Antioxidant Glutathione (GSH) Content in VK2/E6E7 and 
End1/E6E7 Cells. The results are represented as mean ± SD of three independent experiments 
carried out in five replicates. Statistically significant differences relative to control were 
indicated at p < 0.05. 
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Effects of HA-NPs on the Viability of Lactobacillus Crispatus Bacteria  
A microbicide formulation should not disturb the normal Lactobacillus vaginal 
microflora since it is a key component of the innate immune environment which can reduce the 
risk of HIV transmission through vaginal mucosa. As shown in Figure 31, the HA-NPs had no 
statistically significant effect (p > 0.05) over the viability of L. crispatus bacteria compared to 
the cell culture medium.  
 
Figure 31. Effect of HA-NPs over the viability of L. crispatus Bacteria. Results are given after 
48 h of incubation as mean ± SD, n = 3. Statistically significant differences relative to control 
were indicated at p < 0.05. 
 
Intracellular Uptake Assay of HA-NPs 
Fluorescence and confocal microscopy were employed to study the uptake and 
localization of HA-NPs in the VK2/E6E7 (Figure 32) and End1/E6E7 (Figure 33) epithelial 
cells at the concentration of 1-1000 μg/mL. Results showed that the uptake of NPs was 
concentration dependent as almost a negligible cellular uptake was observed below the 
concentration of 100 μg/mL. The data proved the internalization and distribution of HA-NPs 
across the treated cells which were localized mostly in the cytoplasm and around the nucleus. 
The uptake in VK2/E6E7 (Figure 32) and End1/E6E7 (Figure 33) cell lines appeared to be 
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comparable, which could be indicative of a similar cellular uptake mechanism. At the NPs 
concentration of 1000 μg/mL, a higher uptake was observed which was due to the presence of 
clusters or agglomerates of NPs at the cell membrane. At lower concentrations, the uptake was 
almost negligible, suggesting that the uptake might be governed by an endocytic mechanism 
rather than a direct translocation or penetration. A very few bright spots were visible inside the 
cells even at the NPs concentration of 100 μg/mL. Thus, for a very small size NPs, a critical 
threshold density on the cell membrane has to be exceeded to trigger the internalization process. 
 
Figure 32. Cellular Uptake in VK2/E6E7 Cells Exposed for 24 h to FITC-labelled HA-NPs (1 
- 1000 μg/mL). FITC and Hoechst 33342 (for nuclei) appeared as green and blue fluorescence, 
respectively. The merged image represented overlay of green and blue fluorescence channels. 
Scale bar: 10 μm. 
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Further studies were needed to fully clarify the time and concentration-dependent 
uptake mechanisms of HA-NPs. It is noteworthy that the HA-NPs surface chemistry was 
changed when suspended in culture medium, as shown by the TEM analysis which revealed 
the presence of a protein layer on the HA-NPs surface (Figure 21). At this time, it was unclear 
how this corona might have modulated the actual biological response of the epithelial cells to 
HA-NPs exposure, since NPs were expected to interact with cell membrane (101). However, it 
was suspected that, the protein corona around NPs may act as a protective layer, shielding the 
NP surface from direct interactions with receptors on the cell membrane that remain to be 
elucidated further. 
 
Figure 33. Cellular Uptake in End1/E6E7 Cells Exposed for 24 h to FITC-labelled HA-NPs (1 
- 1000 μg/mL). FITC and Hoechst 33342 (for nuclei) appeared as green and blue fluorescence, 
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respectively. The merged image represented overlay of green and blue fluorescence channels. 
Scale bar: 10 μm. 
 
3.4. Conclusion 
 
The HAase sensitive HA-NPs loaded with TFV were formulated using surfactant free cross-
linking method. The modified surfactant-free method used in this study required less time (˂ 
24 h) compared to native surfactant-free method (> 44 h) to produce the NPs. The shorter time 
was achieved by effective screening of the factors responsible for NPs formation using 
experimental design applications. The NPs were found stable, small PMD (~75 nm) and 
exhibited a spherical shape as confirmed by TEM analysis. It was observed that HAase enzyme 
significantly triggered the degradation and drug release of the HA-NPs. The cytotoxicity data 
demonstrated that the HA-NPs were well tolerated by both cervical (End1/E6E7) and vaginal 
(VK2/E6E7) epithelial cells and had no effect on Lactobacillus bacteria viability. Collectively, 
these results suggested that TFV loaded HAase sensitive HA-NP templates developed in this 
study have the potential of topical vaginal delivery of microbicides for the prevention of HIV 
transmission after successful completion of safety and efficacy studies.  
Although, several positive results have been observed, there were certain limitations in 
the current NPs design. One of the major concern was that the HAase triggered drug release 
from the NPs took about 24 h to reach ~90% w/w. The limitations, their possible reasons and 
prospective solutions were summarized below in Scheme 1. These limitations led to the 
development of stimuli-sensitive tenofovir loaded mucoadhesive nanofibers as explained in the 
following Chapter 4. 
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Scheme 1. Limitations of the HA-NPs Systems and Possible Solutions. 
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CHAPTER 4 
FABRICATION OF HYALURONIDASE SENSITIVE TENOFOVIR LOADED 
HYALURONIC ACID BASED MUCOADHESIVE NANOFIBERS 
 
4.1. Rationale 
 
The success of vaginal delivery systems depends on the locally prolonged residence 
time of drug-containing formulations (192). Mucoadhesive polymers are widely used in 
vaginal delivery due to their prolonged contact with the adsorption site (193). These polymers 
interact with mucus by Vander Waals, hydrophobic, electrostatic, and hydrogen bond 
interactions. Consequently, through the mucoadhesion process the therapeutic efficacy of drug 
can be efficiently improved (193). As explained in Chapter 3, hyaluronic acid (HA) has been 
widely used in drug delivery applications (81, 101, 102). The hyaluronic acid based 
nanoparticle (HA-NPs) delivery system has been successfully developed and explained in 
chapter 3. Although, HA is characterized by its weak mucoadhesive properties due to the 
presence of carboxylate (-COOH) groups on its glucuronic acid units which promotes the weak 
hydrogen bonding with mucin (194). In contrast, functionalized polymers bearing sulfhydryl 
(-SH) groups on their backbone are capable of forming strong interactions with cysteine 
subunits of mucin (195).  
Nowadays, electrospun nanofibers (NFs) are extensively studied in drug delivery 
applications (112, 196). The NFs formulations may offer various potential advantages in 
vaginal delivery such as flexibility to be formulated in various shapes, higer bio-retention, and 
no leakage or messiness (110, 111, 197). The added advantages of electrospun fibers include 
high surface-to-volume ratio and high porosity. These benefits make the NFs a particularly 
attractive candidate for vaginal formulations of therapeutic molecules. Furthermore, the 
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encapsulation of labile molecules in polymeric delivery systems such as NFs can enhance their 
stability against a harsh acidic vaginal environment and presence of enzymes such as proteases, 
hydrolases, and phosphatases.  
 Considering these facts, in this study, a stimuli-sensitive and mucoadhesive delivery 
system that is capable of degradation on exposure to seminal HAase enzyme to provide a 
triggered release of microbicide (TFV) was designed, as illustrated in Reaction scheme 3. To 
test this hypothesis, sulfhydryl (-SH) group modified thiolated HA (HA-SH) derivatives were 
synthesized. Thiolated HA-SH derivatives were then used to fabricate the NFs (having different 
geometry compared to the HA-NPs) and physicochemically characterized as described below. 
 
Reaction Scheme 3. Mechanism of Microbicide Loaded Stimuli-sensitive Nanofibers. 
 
4.2. MATERIALS AND METHODS 
 
Chemicals 
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Tenofovir was purchased from Beijing Zhongshuo Pharmaceutical Technology 
Development Co. Ltd. (Beijing, China). Hyaluronic acid sodium salt was kindly provided by 
Mr. Jack Liu (Zhenjiang DongYuan Biotech Co., Ltd., Jiangsu, China). Hyaluronidase (HAase) 
from bovine testes with a specified activity of 810 U/mg, purified type II mucin from porcine 
stomach, 5, 5’-Dithio-bis-(2-nitrobenzoic acid) (DTNB), poly (ethylene oxide) (PEO: MW of 
400 kDa), cysteine hydrochloride, ethylene sulfide (ES), Dithiothreitol (DTT), and deuterium 
oxide (D2O) were from Sigma-Aldrich (St. Louis, MO).  
The human vaginal epithelial cell lines (VK2/E6E7), endocervical epithelial cell lines 
(End1/E6E7) and Lactobacillus crispatus bacteria were from the American Type Culture 
Collection (ATCC, Manassas, VA). The CellTiter 96® AQueous One Solution Proliferation 
assay kit with [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2Htetrazolium, inner salt; MTS] reagent and CytoTox- ONE™, lactate dehydrogenase (LDH) 
cytotoxicity assay kit were from Promega (Madison, WI). Deionized water for all the 
experiments was obtained through a Millipore Milli Q water purification system (Millipore 
Corp., Danvers, MA). All other chemicals were of analytical grades and used as obtained from 
the suppliers. The pH adjustment of all the solutions was measured using a SevenEasy pH 
meter (Mettler Toledo, Schwerzenbach, Switzerland) under ambient temperature (22-24°C). 
 
Synthesis of Thiolated Hyaluronic Acid (HA-SH) Derivatives 
The sulfhydryl (-SH) group modified thiolated HA derivatives (HA-SH) were 
synthesized using the nucleophilic opening reaction of ethylene sulfide (198) as shown by the 
Reaction scheme 4. Briefly, aqueous solution of HA (0.5% w/v) was prepared in the Milli Q 
water and stirred for 2 h to make a homogeneous solution. The pH of the solution was raised 
to 9.5 using NaOH solution. A five-fold molar excess of the ethylene sulfide was added drop-
wise to the above solution and the reaction mixture was stirred for 24 h at room temperature. 
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To separate the precipitate observed due to the oligomerization of ethylene sulfide (ES), the 
solution was vacuum filtered. To the clear filtrate, a five-fold molar excess of DTT was added 
to reduce the disulfide (S-S) bonds. The pH of the solution was raised to 8.5 using NaOH 
solution and mixture was further stirred for 24 h at room temperature. The pH of the reaction 
mixture was then lowered to 3.5 using the HCl solution. To purify the final HA-SH product , 
the acidified solution was dialyzed against diluted HCl solution (pH 3.5) for 24 h using the 
dialysis membrane (Spectra/Por Float-A-Lyzer G2, MWCO: 8-10 kDa) supplied from 
Spectrum Laboratories Inc. (Rancho Dominguez, CA) with three media changes at every 8 h. 
The final product was then lyophilized (Labconco Corp., Kansas City, MO) and stored at 4°C 
until further analyses. 
 
Reaction Scheme 4. Synthesis of Thiolated Derivatives (HA-SH) of Hyaluronic Acid. 
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Characterization of the Synthesized HA-SH Derivative 
Spectral Analyses Using Proton Nuclear Magnetic Resonance (1H-NMR) Spectroscopy 
The 1H-NMR spectra of HA-SH derivatives were acquired on a 400 MHz NMR 
instrument (Varian Inc., Palo Alto, CA). The data were analyzed by Mnova Lite software and 
spectra were acquired with a 90° pulse length of 14.2 µs and recorded with 64 scans with a 
recycle time of 1 sec at 25°C. Tetramethylsilane (TMS) was used as internal reference 
compound. Chemical shifts were reported as δ in parts per million (ppm). The NMR samples 
were prepared by dissolving each sample in 500 μL of D2O as solvent in a 5-mm outer diameter 
NMR tubes (Wilmad-LabGlass, Vineland, NJ). 
Spectral Analyses Using Fourier Transform Infrared (FT-IR) Spectroscopy 
The FT-IR analysis of HA-SH derivatives was performed using Nicolet iS10 
Spectrometer (Thermo Scientific, West Palm Beach, FL). The instrument was equipped with a 
deuterated triglycine sulfate (DTGS) detector and was controlled by OMNIC™ Spectra™ 
software. A transmission mode was selected to make observations with the sampling area of 
about 1 mm. The analysis was performed at 500 to 4000 cm-1 wavenumbers. The background 
data was collected at ambient temperature conditions before analyzing the samples. The spectra 
was automatically corrected with a linear baseline. No specific sample preparation method was 
used before the FT-IR analyses. 
Sulfhydryl Group Quantitation using Ellman’s Method 
The amount of SH groups on HA-SH derivatives was determined using Ellman’s 
method (199). Cysteine hydrochloride (MW: 157.62 Da) in the concentration range of 0.19-
1.50 mM was used as the standard for making the calibration curve. Briefly, 50 μL of Ellman’s 
reagent solution (4 mg/mL of DTNB in reaction buffer (pH 8.0) contacting 0.1 M sodium 
phosphate and 1 mM EDTA was added to a test tube contacting 2.5 mL of the same reaction 
buffer. Two hundred and fifty microliters of cysteine standard was added, mixed and incubate 
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at room temperature for 15 min. The absorbance of the yellow color developed was measured 
at 412 nm using Genesys 10 Bio UV-Vis Spectrophotometer (Thermo Electron Sci. Inst., LLC, 
Madison, WI).  
Size Exclusion Chromatography (SEC) 
The molecular weight (MW) and eventual degradation of HA during the -SH group 
modification was determined using size exclusion chromatography (SEC). Briefly, the SEC 
system (Waters, Milford, MA) consisted of a 1575 binary pump, 717 plus auto sampler, 410-
differential refractive index (RI) detector, and Ultrahydrogel 500 and 250 columns (7.8 X 300 
mm) connected in series. The mobile phase was composed of 0.1 M sodium nitrate (NaNO3) 
at the flow rate of 1 mL/min. The mobile phase solvent was filtered with 0.2 μm cellulose 
acetate membrane filter (Sterlitech™, Kent, WA) and degassed using Ultrasonic bath sonicator 
(Model 150 D; VWR International., West Chester, PA) for 10 min before its use. The internal 
and external temperatures of the SEC column was maintained at 35°C using Waters column 
heater module controlled by 410 RI detector. The data were acquired and processed with 
Waters Millenium32 software (version 3.2). A calibration curve was prepared by using Dextran 
SEC standards (Polymer Standards Service-USA, Amherst, MA) in the MW range of 5.2 to 
410 kDa. A volume of 200 µL was injected into the SEC system in each analysis. 
Powder X-ray Diffraction (PXRD) Analysis 
To determine any changes in the amorphous nature of the native HA during the –SH 
group modification reaction process, the PXRD patterns were analyzed using Rigaku MiniFlex 
automated X-ray diffractometer (Rigaku, The Woodland, TX). The samples were mounted on 
single-crystal Si zero-background plates and the analysis were performed at room temperature 
using Cu Kα radiation produced at 35 kV and 15 mA, with a Ni filter. The scan angle (2θ) was 
from 5° to 40° with a step size of 0.05° 2θ and 3 sec per step. The diffraction patterns were 
processed using Jade 8+ software (Materials Data, Inc., Livermore, CA). 
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Fabrication of HA-SH Based Nanofibers using Electrospinning Method 
Native HA or HA-SH solutions alone were difficult to processed by electrospinning 
into NFs due to their high viscosity and enormous water affinity (200). To improve the 
electrospinnability of HA, poly (ethylene oxide) (PEO: MW 400 kDa), a well-known fiber 
forming polymer (201, 202) was used as a core material. The potential use of PEO as a fiber 
forming polymer and for other biomedical applications has attracted a great attention due to its 
water-soluble, biodegradable, and biocompatible characteristics (203). Preliminary 
experiments were performed to get the optimal conditions for the electrospinning process. The 
electrospinning process parameters such as feeding rate, applied voltage, and needle tip-to-
collector distance were optimized. However, the formulation variables were the concentration, 
MW, and solubility of the polymers (110, 111). 
During the electrospinning process, a polymer solution was injected through a needle 
by electrostatic repulsive forces on a grounded collector (Figure 34) (204). The charged fluid 
jet underwent a highly stretching and whipping process through the air and the solvent 
evaporated quickly, and as a result, NFs were formulated and deposited on the collector. To 
prepare the HA-SH-NFs, the aqueous solutions of HA-SH (20 mg/mL) and PEO (30 mg/mL) 
were prepared at room temperature by stirring for 2 h, and 24 h, respectively. An electrospun 
system with a coaxial nozzle (NaBond Technologies Co., Ltd., Hong Kong, China) was used 
for HA-SH-NFs production. The inner core (PEO) and outer shell (HA-SH) solutions were 
placed separately in two glass syringes (Becton, Dickinson and Company, NJ). To prepare the 
drug (TFV) loaded HA-SH-NFs, free TFV (10 mg/mL) was mixed with the PEO solution and 
used as core material. Two syringe pumps (Cole-Parmer Instrument Company, IL) were used 
to provide a constant feeding rate (0.02 mL/h) of each solutions. A voltage of 15 kV was 
applied in the electrospinning process using a high voltage power supply (Gamma High 
Voltage Research, Inc., FL). The distance from electrospinning syringe needle tip-to-collector 
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was kept constant at 10 cm. The NFs were collected onto an aluminum foil connected to the 
ground. The HA-SH-NFs were vacuum dried at room temperature for 48 h and stored in a 
vacuum desiccator until further uses. 
 
Figure 34. Nanofibers Fabrication using Electrospinning Method. 
 
Physicochemical Characterization of HA-SH-NFs 
The developed HA-SH-NFs were characterized for their physicochemical properties 
such as surface morphology, size distribution, mucoadhesive property and in vitro drug release 
profile. 
Surface Morphology, Size Distribution Analyses and Drug Loading Determination 
The surface morphology of NFs was analyzed by scanning electron microscopy (SEM) 
method. A small amount of the NFs was put onto a grid. The membrane was mounted on a 
1/200 SEM stubs with double-sticky carbon tape. The NFs samples were then sputter coated 
with 20 nm thickness of gold and visualized under a Philips SEM 515 microscope (Eindhoven, 
The Netherlands) and observations were performed at an accelerating voltage of 5 kV. The 
diameter of individual NFs was analyzed using Image Pro® Plus software (Image-Pro®Plus 6.0, 
Media Cybernetics, Silver Spring, MD). At least 100 NFs were counted per group. The 
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histogram and distribution curve were generated by IBM® SPSS® Statistics software Version 
23 (IBM Corp., Armonk, NY).  
To determine the drug loading, NFs at the concentration of 1 mg/mL were kept in water 
under constant shaking at 100 rpm for 48 h to allow complete dissolution of the PEO core and 
vortexed for 5 min. The sample was centrifuged at 19,500 g for 30 min and the supernatant was 
analyzed by liquid chromatography-mass spectroscopy (LC-MS) assay of TFV (205) explained 
later in this chapter. The drug loading was calculated using Eq. (22). 
100
mg in NFs of amount Total
mg in TFV of amount Total
(%) Loading Drug      (22) 
In Vitro Mucoadhesion Analyses 
The in vitro mucoadhesion analysis of HA-SH-NFs was performed using mucin 
interaction (206, 207) and ellipsometer measurements (208-210). Mucin interaction method 
was used to study the mucin-NFs interactions in solution form and ellipsometer was used to 
study the interactions between the HA-SH-NFs and mucin-coated silica surfaces.  
Mucoadhesion Assessment by Mucin Interaction Method 
The mucin interaction analysis was performed using native HA, and HA-SH-NFs at the 
concentration of 10 mg/mL in PBS (pH 7.4), VFS (pH 4.2), and in water (with 10 mM NaCl), 
prepared accordingly (127, 128). The mucin at the concentration of 1.5% w/v (207) was used 
in the analysis. The polymer samples were incubated for 0, 3, 6, and 24 h at 37°C and 60 rpm 
with or without mucin. The size and zeta (ζ) potential values were analyzed by Laser Doppler 
Velocimetry and Phase Analysis Light Scattering methods using Zetasizer Nano ZS (Malvern 
Instruments Ltd., Worcestershire, UK) at 25°C. The instrument was calibrated by using 
nanosphere™ of PMD (59.0 ± 2.5 nm) and ζ potential standards (−68.0 ± 6.8 mV). 
Mucoadhesion Assessment by Ellipsometer Measurements 
Ellipsometer is the study of adsorbed mass on a polymer surface (210). The adsorption of 
mucin and polymers on methylated silicon wafer surface was studied using an alpha-SE® 
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ellipsometer (J.A. Woollam Co. Inc., Lincoln, NE) at a single angle of incidence. The 
acquisition and analysis of ellipsometer data were performed using CompleteEASE® software 
version 5.03 (J.A. Woollam Co. Inc., Lincoln, NE). The 2-inch-diameter silicon wafers (WRS 
Materials, San Jose, CA) were hydrophobized (methylated) to enhance the interaction with 
proteins (211, 212) as previously described (213). Briefly, silicon wafers with thermal oxide 
layer of 30 ± 3 nm (n = 3) were dipped into a solution of trimethylchlorosilane (TMCS) in 
ethanol (1:5 v/v ratios) for 2 h. Afterwards, the wafers were rinsed with water followed by 
ethanol (3 times each) and stored in ethanol prior to use.  Immediately before use, wafers were 
rinsed with water, blown dry using nitrogen gas, dipped in a mucin solution (1 mg/mL) and 
incubated for 15 h at 37°C followed by washing with ethanol and water. The native HA and 
HA-SH-NFs solutions at the concentration of 10 mg/mL in PBS (pH 7.4) were added on 
methylated wafers and analyzed by ellipsometer after 30, 60, and 120 min.  
A change in polarization was measured after light was reflected from the wafer 
surfaces. The data were represented as two values: Psi (Ψ, amplitude ratio) and Delta (Δ, phase 
difference) (214). Interference occurs as light recombined after traveling different paths 
through the thin film. The thickness (d) measured was used to calculate the adsorbed mass (m 
in µg/cm2) using Eq. (23).  
𝐴𝑑𝑠𝑜𝑟𝑏𝑒𝑑 𝑚𝑎𝑠𝑠 (𝑚) =
𝑑 (𝑛−𝑛0)
𝑑𝑛/𝑑𝑐
       (23) 
Where, n and n0 are the refractive index of the sample and the ambient environment, 
respectively, dn/dc is the refractive index increment as a function of bulk concentration (0.165 
mL/g) of mucin (215). 
 
In Vitro Drug Release Analysis  
The in vitro drug release analysis of HA-SH-NFs in the presence or absence of HAase 
enzyme was performed using the dialysis method. An amount of HAase (~1.08 U) similar to 
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that is normally present in human ejaculate containing 100 million sperms/mL was used in the 
drug release analysis considering the average volume of human ejaculate of 3 mL (82). Briefly, 
the drug loaded HA-SH-NFs were transferred to a dialysis bag (MWCO, 3.5-5 kDa) containing 
the simulant mixture (pH 7.2) of the VFS (pH 4.2) and seminal fluid simulant (SFS, pH 7.8) in 
1:4 volume ratio, respectively, and placed inside a dialysis tube containing the release medium 
(PBS, pH 7.2). These VFS and SFS buffers were prepared according to the previous reports 
(127, 128). The whole system was then placed in a thermostatic shaking water bath (BS-06, 
Lab Companion, Seoul, Korea) at 37°C with constant agitation at 60 rpm. Aliquots of samples 
(100 µL) were taken at, 0, 1, 3, 6, 12, 24 h from the release medium. Simultaneously, an 
equivalent volume of the fresh release medium was added at the same rate to maintain the sink 
conditions. The amount of drug released from NFs was quantified using a LC-MS assay (205). 
Briefly, LC analysis is carried out on a UFLC Shimadzu prominence system (Shimadzu 
USA manufacturing Inc., Torrance, CA). A reversed phase Waters Symmetry® C18 column 
(150 mm × 4.6 mm, 5 µm) is used as a stationary phase under ambient temperature conditions. 
The detection is carried out at 259 nm using the flow rate of 0.6 mL/min and a sample injection 
volume of 10 μL in each analysis. The LC elution conditions of (all solvent percentages were 
volume fractions): mobile phase-A, 0.1% v/v formic acid in water; mobile phase-B, 0.1% v/v 
formic acid in acetonitrile; mobile phase-C, 30% A /70% B is applied. The time program was: 
0.01 min, 100% A; 10 min, 100% C; 13 min, 100% B; 14 min, 100% A; and 18 min, 100% A. 
The samples are injected in to the LC system after appropriate dilution with mobile phase-A. 
MS study is performed on a 3200 QTrap mass spectrometer (Applied Biosystems Sciex, 
Framingham, MA). Spectra are recorded by scanning between 100-700 amu using Enhanced 
mass spectrum (EMS) scan in positive mode. Analyst® software version 1.4.2 (Applied 
Biosystems Sciex, Framingham, MA) is used for data acquisition. MS operational parameters 
were as follows: Collision activated dissociation (CAD):  high; Ion source Gas1 (GS1): 50 psi; 
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Gas2 (GS2): 50 psi; Turbo ion spray voltage (IS):  5500 V; Source temperature (TEM): 350 °C; 
Collision energy (CE); 5 V; Declustering potential (DP): 2 V, and Entrance potential (EP): 2 V. 
Nitrogen gas is used as the nebulizer, and the scan rate was 4000 amu/sec.  
 
In vitro Drug Release Kinetics  
The drug release kinetics of TFV loaded HA-SH-NFs was analyzed by using various 
kinetic models (89, 129) using the previously described add-in DDSolver program (216). The 
kinetic models used were zero-order (Eq. 24), first-order (Eq. 25), Higuchi (Eq. 26), 
Korsmeyer-Peppas (Eq. 27), Hixson-Crowell (Eq. 28), and Weibull (Eq. 29) and, Quadratic 
(Eq. 30) models (216). The criteria for selecting the most appropriate model were based on the 
correlation coefficient (R), the coefficient of determination (R2), and the Akaike information 
criterion (AIC) (216). The AIC criteria has its wide applicability and simplicity. The model 
with a higher R or R2 values and lower AIC value was considered to be the better model. 
tK+MM 00t           (24) 
t/2.303K+MlogMlog 1t 0         (25) 
50.
Ht tKM            (26) 
n
t kt/MM            (27) 
tK M-M HC
1/3
t
1/3
0           (28) 
𝑀 =  𝑀0 [1 − 𝑒
(𝑡−𝑇)𝑏
𝑎 ]         (29) 
𝑀𝑡 =  100 (𝐾1 𝑡
2 + 𝐾2 𝑡
 )        (30) 
In these Equations, Mt is the amount of drug released at time t, M0 is initial amount of 
drug in solution, K0 is zero order release constant, K1 is first order release constant, KH is 
Higuchi dissolution constant, KHC is Hixson-Crowell release constant, Mt/M∞ is the fraction of 
drug released at time t, T is the lag time measured as a result of the dissolution process, M∞ is 
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the total amount of drug released, k is a kinetic constant, K1 and K2 are release constants, and 
n is the exponent explaining the drug release mechanisms (129). Parameter a, denotes a scale 
parameter that describes the time dependence, while b describes the shape of the dissolution 
curve progression. The exponent n is classified as Fickian diffusion (n ≤0.5), case-II transport 
(n = 1), anomalous transport (0.5<n<1) and super case-II transport (n >1) (129).  
The Eq. (27) in Peppas model was further depicted in a log-transformed Eq. (31): 
k log+tlogn/MMlog t                 (31) 
One important area in release data analysis is assessment of the similarity between 
dissolution profiles of drug formulations. To perform this, the model independent approach 
was applied to compare the drug release kinetics of the HA-SH-NFs as per US FDA guidance 
to industry (129). The release profiles of NFs in the absence of HAase enzyme was taken as 
reference whereas, the release of NFs in the presence of HAase enzyme was considered as the 
test compound. The difference (f1) and similarity factors (f2) were calculated using the Eq. (32), 
and (33), respectively. 
      (32) 
   (33) 
  Here, n is the number of time points, Rt and Tt are the cumulative drug release (% w/w) 
at time t for the reference and test samples, respectively. Generally,  f1 ˂ 15 and f2 > 50 ensure 
sameness or equivalence of the two curves (129). 
 
In Vitro Cytotoxicity Assays of HA-SH-NFs 
The cytotoxic effects of HA-SH-NFs in the concentration range of 1-1000 µg/mL were 
tested on the viability (MTS assay) and membrane integrity (LDH assay) of VK2/E6E7 and 
End1/E6E7 cells using published protocols (89).  
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Cell Viability Assays 
To perform the cell viability (MTS) assay, cells were seeded to 96-well plates in a 
keratinocyte-serum free medium and were allowed to grow until 80% confluence was reached. 
The medium was replaced with 100 µL of native HA or HA-SH-NF samples in the 
concentration range of 1-1000 µg/mL. The samples were kept in contact with the cells for 48 
h. The amount of formazan product formed was determined by adding 20 µL of MTS reagent 
to the culture wells. The wells were incubated for 4 h at 37°C in a humidified, 5% CO2 
atmosphere and the absorbance was measured at 490 nm using a DTX 800 multimode 
microplate reader (Beckman Coulter, Brea, CA). The medium and 1% Triton-X-100 was used 
as negative and positive controls, respectively. The percent (%) cell viability was determined 
using Eq. (34). 
100
(control) ABS
(test) ABS
(%)Viability         (34) 
Where, ABS (test) and ABS (control) represented the absorbance of the amount of formazan 
product generated in viable cells. 
Cell Cytotoxicity (Membrane Integrity) Assays 
To perform the cell cytotoxicity (LDH) assay, the cells were incubated with 100 µL 
medium containing the samples of native HA and HA-SH-NFs in the concentration range of 1-
1000 µg/mL. The plates were incubated at 37°C for 48 h and equilibrated to room temperature 
for 30 min. One hundred microliters of CytoTox-One™ reagent was added in each well and 
vortexed for 30 sec. The plates were incubated at room temperature for 10 min. Fifty microliters 
of stop solution from Promega (Madison, WI) was added in each well and the plates were 
shaken for 10 sec. The fluorescence intensity was measured at the excitation/emission 
wavelengths of 560 nm/590 nm, respectively, using the above microplate reader. The percent 
(%) cytotoxicity was determined using Eq. (35): 
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100
Background -control Positive
Background -alExperiment
ty(%)Cytotoxici      (35) 
Where, experimental, background and positive control represented the fluorescence 
intensity of the wells with and without sample, and with 1% Triton-X treatment, respectively. 
 
Lactobacillus Crispatus Viability Assay 
A microbicide formulation should not disturb the normal Lactobacillus vaginal 
microflora since this can enhance the risk of HIV transmission through CV mucosa (217). In 
this study, L. crispatus bacteria was used as representative species since it was one of the most 
common vaginal Lactobacillus (218). The L. crispatus was grown in ATCC medium 416 
Lactobacilli MRS broths (BD, Franklin Lakes, NJ) at 37°C. The viability assay was performed 
using Lactobacillus viability assay (61). Briefly, the bacteria density was adjusted to an OD670 
of 0.06, which corresponded to 0.5 McFarland Standard or 108 CFU/mL. The L. crispatus 
bacteria was seeded in a 96-well plate at a volume of 100 µL and incubated with 100 µL of the 
sample suspension for 48 h at 37°C. The wells were treated with 10 µg/mL of commercially 
available penicillin-streptomycin solution (positive control) from Invitrogen (Carlsbad, CA). 
After the incubation, 20 µL MTS reagent was added to each well and the absorbance was 
measured at 490 nm to express the viability using Eq. (34). 
 
Statistical Data Analysis 
The experimental values were generally presented as mean ± standard deviation (SD) 
of triplicate determinations (n = 3). Statistical data analysis was evaluated using Students t-test 
with 95% confidence interval (CI). A p value ˂ 0.05 was considered statistically significant. 
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4.3. Results and Discussion 
 
Characterization of Thiolated HA-SH Derivative 
Thiol group’s derivatives were generated at the primary hydroxyl group of the GlcNAc 
units of HA using the nucleophilic opening reaction of ethylene sulfide (Reaction scheme 4). 
The HA-SH derivatives exhibited to have 0.763 ± 0.016 mM (n = 3) of -SH groups determined 
by Ellman’s method (199). 
1H-NMR and FT-IR Analyses 
Compared to the HA spectrum, a peak corresponding to the methylene group attached 
to the former hydroxyl oxygen (-CH2-CH2-SH), appeared at 3.8 ppm in the spectrum of HA-
SH. The second methylene group, closer to the -SH functionality was overlapped with GlcA 
and GlcNAc protons of HA at 3.0-3.8 ppm and appears at about 3.65 ppm (219) (Figure 35A).  
In the FT-IR spectrum of HA-SH (Figure 35B), a small -SH group peak was observed at 
about 2550 cm-1. The HA-SH1 and HA-SH2 were the HA-SH samples prepared on two 
different days. The –SH group signal was very weak and broad due to its hydrogen bonding as 
also observed by others (220, 221). Overall, the FT-IR and NMR analyses confirmed the 
effective thiol modification of HA polymer. 
SEC and PXRD Analyses 
The SEC analysis showed that the average MW of HA-SH was ~58 kDa which was 
close to the average MW of native HA (~60 kDa) (Figure 35C). This means that the native HA 
was quiet stable under the basic and acidic conditions used in the reaction process.  
The PXRD results revealed that the amorphous nature of native HA has been 
maintained during the reaction process (Figure 35D). The PXRD spectrum of HA-SH showed 
one additional peak at 2θ of 32° which was the typical PXRD peak of sodium chloride (NaCl) 
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(222). This could be due to the crystallization of the NaCl resulting from the sodium ions (Na+) 
of HA and the chloride ions (Cl−) of HCl used in the pH adjustment media. 
 
Figure 35. HA and Thiolated HA-SH Derivatives: (A) 1H-NMR Spectrum. (B) FT-IR 
Spectrum. (C) SEC Chromatogram. (D) PXRD Pattern. 
 
Physicochemical Characterization of HA-SH-NFs  
Surface Morphology and Size Distribution 
Initially, the HA-SH solution was electrospun alone and no fibers were formed (Figure 
36A) due to the higher viscosity and enormous water affinity of the polymer (200). Scanning 
electron microscopy (SEM) images revealed that the blended HA-SH and poly (ethylene oxide) 
(PEO) solutions produced the HA-SH-NFs (Figure 36A) since PEO facilitated the fiber 
formation process during the electrospinning. Some beaded fibers were also observed (Figure 
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36B) which could be due to the presence of ionizable groups and concentrations of the HA-SH 
polymer, and feed rate of electrospinning solutions (204). During the electrospinning process, 
the repulsive force between the ionizable groups within the polymer backbone limit its 
electrospinnability and inhibits the formation of continuous fiber under the high electric field 
(223). To reduce the beads formation, feed ratio was optimized and positive results were 
obtained (Figure 36C). However, some beads were still observed (Inset Figure D) The mean 
diameter of HA-SH-NFs was found to be 74.96 ± 46.31 nm (n = 100) (Figure 36D). 
 
Figure 36. Surface Morphology of Nanofibers: (A) HS-SH alone; scale bar, 2 µm. (B) Beaded 
HA-SH-NFs; scale bar, 2 µm. (C) Optimized HA-SH-NFs; scale bar, 1 µm. (D) Size 
Distribution of HA-SH-NFs, averaged Using at least 100 Measurements/Group. (D) Inset 
figure: still some beads were observed in optimized NFs. 
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In Vitro Mucoadhesion Analysis  
Mucin Interaction Assay 
Figure 37. In vitro Mucoadhesion Analysis of Nanofibers using: Mucin Interaction Method; 
(A) PBS (pH 7.4). (B) VFS (pH 4.2). (C) Water (with 10 mM NaCl). Ellipsometer 
Measurements: (D) Thickness (d) in nm. (E) Amount adsorbed (m) in µg/cm2. 
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In this study, the relationship between the size of mucin and polymer aggregate was 
correlated to the mucoadhesive property of HA-SH-NFs to native HA. The mucin interaction 
analysis showed that the size of HA-SH-NFs was significantly increased to ~4-7 µm compared 
to the native HA (~1-3 µm) in the presence of mucin as analyzed after 3h incubation in PBS 
(Figure 37A), VFS (pH 4.2) (Figure 37B), and water (Figure 37C). This was due to the higher 
thiol-thiol (S-S) group interactions between mucin and thiolated HA-SH-NFs in addition to the 
hydrophobic and electrostatic interactions. However, the study of mucin-HA interaction was 
limited due to the very large and broad size distribution of these two molecules. The interaction 
between mucin and HA-SH-NFs needs to be further analyzed using more sophisticated 
microscopy methods such as atomic force microscopy in the future. 
Ellipsometer Measurements 
In the ellipsometer measurements, an increased mucoadhesion of HA-SH-NFs was 
confirmed by an increase in thickness (~3 fold) (Figure 37D) and adsorbed mucin amount (~2 
fold) (Figure 37E) of HA-SH-NFs (~321 nm, ~34 µg/cm2, respectively) compared to the native 
HA (~105 nm, ~19 µg/cm2, respectively) as calculated by Eq. (23). Overall, the mucin 
interaction and ellipsometer measurements confirmed the higher mucoadhesion of thiolated 
HA-SH-NFs compared to native HA polymer. 
 
In Vitro Drug Release Analysis of HA-SH-NFs 
The in vitro drug release profile for TFV loaded HA-SH-NFs (loading ~16-17 % w/w) 
in the presence and absence of HAase enzyme was depicted in Figure 38. A significantly 
triggered drug release (~87 %w/w) was observed from the HA-SH-NFs in the presence of 
HAase enzyme, whereas, in its absence the value was about ~54 %w/w after 1 h. However, the 
drug release was almost ~99% and ~62% w/w after a 6 h analysis in the presence and absence 
of HAase enzyme, respectively.  
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The observed drug release from HA-SH-NFs in the absence and presence of HAase 
enzyme might be due to two facts; firstly, it was anticipated that the interaction between -
COOH groups of the HA and amino groups of TFV could have affected the drug release profile 
of the HA-SH-NFs. Since, TFV has two pKa values (2.0 and 6.7) (56), whereas HA has a pKa 
value at 2.9 (172), both (native TFV and HA) will have a negative charge at the working pH 
(7.2) of the release medium. Therefore, there would be a minimal possibility of interaction 
between TFV and HA. Due to these minimal interactions of HA with TFV, a higher % 
cumulative drug release was also observed from the HA-SH-NFs in the absence of HAase in 
the first couple of hours however, this drug release was significantly lower than that observed 
in the presence of HAase. Secondly, the large surface areas to volume ratios of HA-SH-NFs 
provided a larger area for drug interaction with the surrounding medium. This facilitated the 
mass transfer and thus, a fast release of therapeutic molecules. 
 
Figure 38. Percent Cumulative Drug Release (% w/w) Profile of TFV Loaded HA-SH-NFs 
either in the Presence or Absence of HAase. Results are given as mean ± SD, n = 3. 
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Ideally, the effective molar concentration (EC50) of TFV (5-7.6 µM) (177) required to 
exhibit its anti-HIV activity should be locally released from the HA-SH-NFs before HIV virus 
crosses the vaginal mucosa in the time frame of 2-6 h and interacts with the macrophages, and 
dendritic cells (178). Based on the drug loading of HA-SH-NFs (~16-17 %w/w), the actual 
amount of TFV was ~59 μM per 100 mg of NFs. Considering the 10 mg of HA-SH-NFs will 
be used in each treatment dose, this would be equivalent to ~6 μM of TFV drug dose. It can be 
reasonably speculated that a microbicide released from the enzyme-sensitive HA-SH-NFs 
would potentially exhibit an anti-HIV effect in less than 6 h as most of the drug from HA-SH-
NFs was released out (~99% w/w) in this time frame. It is noteworthy that the EC50 value of 
TFV from the HA-SH-NFs was achieved within that critical timeframe of 2-6 h in the presence 
of HAase. However, the in vivo drug release profile of these HA-SH-NFs in the presence and 
absence of enzyme remain to be confirmed in the future studies. 
 
In Vitro Drug Release Kinetics of HA-SH-NFs 
The drug release from the HA-SH-NFs was analyzed using various in vitro kinetic 
models (129, 216). The model with a higher R or R2 values and lower AIC value was considered 
to be the better model. It was observed that in the absence of HAase the drug release from NFs 
followed the Peppas model (R: 0.995; R2: 0.990; AIC: 25.030) however, in the presence of 
HAase, NFs followed the Weibull model (R: 0.999; R2: 0.999; AIC: 9.396) (Table 19).  
The model independent approach was then applied to compare the drug release kinetics 
of the HA-SH-NFs in the absence and presence of HAase enzyme. The f1 (35.00) and f2 (12.51) 
values(129) were calculated using Eq. (32), and (33), respectively. The results indicated that 
there was a significant difference between the drug release profiles from HA-SH-NFs in the 
presence and absence of HAase since the f1 and f2 values were >15 and ˂50, respectively.  
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Table 19: Estimated Parameters: In Vitro Drug Release Kinetics Models. 
Kinetic model Absence of HAase enzyme Presence of HAase enzyme 
 R* R2** AIC*** R* R2** AIC*** 
Zero-order 0.604 -1.042 55.187 0.489 -1.448 61.088 
First-order 0.805 0.109 50.207 0.999 0.996 21.993 
Korsmeyer-Peppas 0.995 0.990 25.030 0.999 0.997 21.921 
Higuchi 0.784 0.232 49.319 0.702 -0.015 55.803 
Hixon-Crowell 0.750 -0.106 51.509 0.717 0.016 55.622 
Weibull 0.995 0.990 27.497 0.999 0.999 9.396 
Quadratic 0.718 0.026 52.747 0.694 -0.060 45.259 
* Correlation coefficient. ** Coefficient of determination. *** Akaike Information Criterion. 
 
In Vitro Cytotoxicity Analysis of HA-SH-NFs 
According to ISO standard, if the cell viability of control samples is 100%, viability 
>80% is attributed to absence of cytotoxicity, 60-80% to mild cytotoxicity, 40-60% to moderate 
cytotoxicity and if the viability is <40%, the cytotoxicity is severe (224). Based on the results 
obtained, the HA-SH-NFs did not show any significant effect (p > 0.05) on the viability of 
VK2/E6E7 and End1/E6E7 cells, compared to medium (negative control) (Figure 39A). A 
statistically insignificant (p > 0.05) A lower LDH release and percent cytotoxicity was 
observed from the cells incubated with the HA-SH-NFs for 48 h in comparison to the negative 
control (medium) (Figure 39B). 
 
Effects on the Viability of L. Crispatus Bacteria 
A microbicide formulation should not disturb the normal Lactobacillus vaginal 
microflora since it is a key component of the innate immune environment which can reduce the 
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risk of HIV transmission through vaginal mucosa (217). It was observed that the HA-SH-NFs 
have no significant (p > 0.05) deleterious effect over the viability of L. crispatus bacteria 
compared to the medium as shown in Figure 39C. 
 
Figure 39. Cytotoxicity Assays of TFV loaded HA-SH-NFs and Native HA on VK2/E6E7 and 
End1/E6E7 cells. (A) Effects on the viability (MTS assay). (B) Effects on lactate 
dehydrogenase release (LDH assay). (C) Effects on L. crispatus bacteria viability. Results are 
given as mean ± SD, n = 3 after 48 h incubation. Asterisk (*) indicated the significant difference 
(p ˂ 0.05), compared with the control (media). 
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4.4. Conclusion 
 
In this study, a novel stimuli-sensitive and mucoadhesive thiolated HA based NF loaded 
with a vaginal anti-HIV microbicide tenofovir was developed using the electrospinning 
method. It was observed that HAase enzyme triggered a significant drug release (~87 %w/w) 
from the HA-SH-NFs within an hour of the enzyme incubation. The HA-SH-NFs were found 
to have a much better response in the presence of HAase enzyme in terms of triggered drug 
release compared to the NPs in the presence of HAase enzyme. In addition, NFs have a higher 
mucoadhesion property due to the presence of thiol groups on their surface compared to the 
native HA polymer thus to the HA-NPs. The triggered drug release might be due to the porous 
surface, large surface areas to volume ratios, and absence of any cross-linking chemistry at the 
HAase enzyme target size (carboxylic acid groups) of HA in HA-NFs compared to the HA-
NPs. The large surface areas to volume ratios of HA-SH-NFs provided a larger area for drug 
interaction with the surrounding medium. This facilitated the mass transfer and thus, a fast 
release of therapeutic molecules was observed. The HA-SH-NFs were non-cytotoxic to human 
vaginal VK2/E6E7, and End1/E6E7 cells and had no deleterious effect on the viability of 
Lactobacillus bacteria. Collectively, the results suggested that TFV loaded HAase sensitive 
HA-SH-NFs templates developed in this study have the potential of topical vaginal delivery of 
microbicides for the prevention of HIV virus transmission. 
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CHAPTER 5 
PRECLINICAL SAFETY AND IN VITRO HIV EFFICACY EVALUATIONS OF 
HYALURONIDASE SENSITIVE TENOFOVIR LOADED HYALURONIC ACID BASED 
NANOFORMULATIONS 
 
5.1. Rationale 
 
The safety of vaginal microbicides is an important concern in anti-HIV formulation 
development as they must preserve the integrity of the genital mucosa and demonstrate no 
localized toxicity, irritation and inflammation (225). Such adverse effects create a direct portal 
of entry for HIV virus and mucosal inflammation may activate and recruit a high level of HIV 
target cells (macrophages and T lymphocytes) at the port of viral entry (Figure 40) (160). This 
increases the susceptibility to sexually transmitted infections. Thus, it is essential that a 
microbicide product undergoes a rigorous safety evaluation using in vitro cell culture and 
preclinical animal models before evaluating their effects in humans.  
 
Figure 40. Assessment of Vaginal Epithelial Damage Following the Application of a Topical 
Microbicide Formulation. 
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The in vitro cytotoxicity assays of HA-NPs and HA-SH-NFs in cervicovaginal cell 
culture models (ex. VK2/E6E7, and End1/E6E7 cells) has already been explained in Chapters 
3 and 4, respectively. However, they do not allow a prolonged or repeated exposure to a 
microbicide candidate and do not assess inflammatory responses that can only be seen in intact 
mucosal tissues. Hence, this study is designed to evaluate the preclinical safety, cytokine 
secretion, epithelial damage and tissue inflammatory responses of HA-NPs and HA-SH-NFs 
in an animal (mice) model. The optimized formulations of HA-NPs and HA-SH-NFs developed 
in Chapters 3 and 4, respectively, were used in this study. The in vitro anti-HIV activity of the 
developed HA-NPs and HA-SH-NFs was also evaluated on the pseudotyped HIV virus 
particles generated using a lipofectamine plasmid transfection method. 
 
5.2. Materials and Methods 
 
Chemicals 
Tenofovir was purchased from Beijing Zhongshuo Pharmaceutical Technology 
Development Co. Ltd. (Beijing, China). Hyaluronic acid sodium salt was kindly provided by 
Mr. Jack Liu (Zhenjiang DongYuan Biotech Co., Ltd., Jiangsu, China). Medroxyprogesterone 
acetate (Depo-Provera®) was from Greenstone, Peapack, NJ). Nonoxynol-9 (Conceptrol®) was 
from Revive Personal, (Madison, NJ). Benzalkonium chloride (BZK, 2 %v/v) was from Sigma-
Aldrich (St. Louis, MO).  The following reagents are obtained through the NIH AIDS Research 
and Reference Reagent Program, Division of AIDS, NIAID, NIH: MT-4 cells from Dr. 
Douglas Richman; the plasmid pNL4-3.Luc.R–.E– from Dr. Nathaniel Landau and; pHEF-
VSVG from Dr. Lung-Ji Chang. All other chemicals were of analytical grades and used as 
obtained from the suppliers. 
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In Vivo Evaluation of Hyaluronic Acid Based Nanoformulations in Animal (Mice) Model 
Female C57BL/6 mice with an average body weight of 20 g at 8-12 weeks old from 
Jackson Laboratories (Harbor, ME) were used for the in vivo evaluations due to their easy 
breeding, and robustness. All mice were housed (no more than 5 per cage) under a 12 h light: 
dark regime in the UMKC Laboratory Animal Resource Center (LARC) facility which is a 
fully AAALAC (the Association for Assessment and Accreditation of Laboratory Animal 
Care) accredited with HEPA-filtered, temperature, humidity, and lighting control systems. 
Vaginal Cytology: Mice Estrus Cycle Stages Identification 
In humans, the reproductive cycle, called the menstrual cycle, lasts approximately for 
28 days however, in mice, this cycle, called the estrous cycle, and lasts approximately for 4-5 
days (226). Several changes occurred in the mouse estrous cycle can be detected by using a 
variety of methods including the vaginal cytology, measuring electrical impedance, 
biochemical analysis of urine, and visual observation of the external genitalia to determine the 
estrous cycle stages (226, 227). Out of these methods, vaginal cytology is most accurate for 
identifying all the stages of the estrous cycle. 
The full estrus cycle in mice can be divided into four stages (227) (Figure 41):  
(a) Proestrus: in this stage, there is a predominance of nucleated epithelial cells appear in 
clusters or individually. Occasionally, some cornified cells may also appear. 
(b) Estrus: this stage is distinctively characterized by clusters of cornified squamous epithelial 
cells. There is no visible nucleus. 
(c) Metestrus: in this stage, there is a mix of cell types with a predominance of leucocytes and 
a few nucleated epithelial and/or cornified squamous epithelial cells. 
(d) Diestrus: this stage consists predominantly of leukocytes. 
In this study, to determine the estrous stages, mice were treated with 2 mg of 
subcutaneous medroxyprogesterone acetate (Depo-Provera®) diluted in Lactated Ringer’s 
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solution at 4-5 days prior to the in vivo experiments. This treatment induced a diestrus-like state 
that is characterized by thinning of the vaginal epithelial layer and reduced inter-individual 
variability of vaginal histology (228). Vaginal cytology analysis was then performed to identify 
the mice estrous cycle stages by visualizing the nucleated and cornified squamous epithelial 
cells and polymorph nuclear leukocytes (227).  
 
Figure 41. Vaginal Cytology: Mouse Estrus Cycle Stage Identification. 
 
Preclinical Safety and Toxicity Evaluation 
In vivo safety of HA-NPs and HA-SH-NFs at the dose of 25 mg/kg (equivalent to the 
drug dose of ~6.5 mg/kg), and 275 mg/kg (equivalent to the drug dose of ~46 mg/kg), 
respectively, upon once-daily vaginal administration up to 7 days was assessed by histological 
analysis of mice genital tract (vagina, cervix, uterus, and ovary), and other organs (rectum, 
spleen, lung, liver, kidney, heart, brain). The vagina was washed 2 times by flushing repeatedly 
with 50 μL of PBS with a micropipette before any treatment. To instill the samples, mice were 
held upwards by the base of the tail and samples were administered intra-vaginally using a 
micropipette with a soft tip. Care was taken in order to minimize tissue injury or disturbance 
of vaginal mucus. Animals were maintained in an upward position for 1 min in order to reduce 
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any immediate vaginal leakage. Mice treated with nonoxynol-9 (Conceptrol®, N-9, and 4% 
w/v) and benzalkonium chloride (BZK, 2% v/v) were used as positive control groups due to 
their well-recognized toxic effects on genital tract (229, 230). The mice treated with PBS were 
used as negative control groups. The animal experimental set-up was shown in Figure 42. 
 
Figure 42. Animal (Mice) Experimental Set-Up. 
 
At predetermined time points, mice were euthanized by CO2 asphyxiation at 70% (v/v) 
CO2 (30% v/v oxygen). The collected tissues were formalin fixed and embedded in paraffin 
following standard tissue processing procedure. Histopathologic review was performed on 
tissues stained with hematoxylin and eosin (H&E). Images were viewed and captured using a 
Nikon Labophot-2 microscope (Nikon Instruments, Inc., Melville, NY) equipped with a 
PAXCam digital microscope camera and analyzed using PAX-it image management and 
analysis software (Midwest Information Systems, Inc., Villa Park, IL). 
Osmolality Determination of the Tested Samples 
Ideally, the osmolality of a microbicide formulation should not exceed 400 mOsm/Kg 
to minimize any risk of vaginal epithelial damage (231, 232). Thus, before any treatment, the 
osmolality of each sample was analyzed (n = 3) using a Vapor Pressure 5520 Osmometer 
(Wescor, Inc., Logan, UT) calibrated with Opti-mole 100, 290 and 1000 mOsm/kg osmolality 
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standards. To analyze the osmolality, metal forceps were used to place a single 1/8'' solute-free 
Whatman No.1 filter paper disc (Wescor, Inc., Logan, UT) in the central depression of the 
holder. Ten microliters of each sample was expelled onto the disc so that the area of the disc 
was fully covered by the sample. The sample holder was then inserted into the instrument and 
osmolality measurement was performed. The osmolality of the each samples was recorded in 
mOsm/kg. 
Immunoassay of Cytokines Secretion in Mice Cervicovaginal Lavage (CVL) and 
Cervicovaginal Tissue Samples 
Cytokines play an important role in HIV infection and transmission through CV mucosa 
and must be evaluated for any microbicide formulation (Table 5 in Chapter 2) (69). A 
microbicide formulation was supposed to be in contact with the CV epithelium for a variable 
time before sexual intercourse and thus, should not cause the onset of inflammation or cytokine 
secretions (31). At predetermined time points after the sample treatments, the mouse vagina 
was washed 2-times by flushing repeatedly with 50 μL of PBS and CVL was collected. The 
CVL sample was centrifuged (1000 g, 10 min, 4°C) and supernatant was collected. Mice were 
then euthanized by CO2 asphyxiation and the CV tissues were collected. The CVL supernatant 
and the CV tissue samples were kept frozen at -20°C until further processing. The levels 
(pg/mL) of several cytokines including interleukins (ILs) IL-1α, IL-1β, IL-6, Interferon 
gamma-induced protein 10 (IP-10), IL-7, tumor necrosis factor-alpha (TNF-α), and mice 
keratinocyte-derived chemokine (MKC) were measured according to the manufacturer's 
protocol (Milliplex MAP Mouse Cytokine/Chemokine Magnetic Bead Panel, EMD Millipore 
Corp., Billerica, MA) as explained below. 
To process the above samples for the cytokines assay, the homogenization buffer was 
freshly prepared by mixing the protease inhibitors cocktail (Sigma, St. Louis, MO) to the Tissue 
Extraction Reagent I (Invitrogen, Carlsbad, CA) following the manufacturer’s protocol. The 
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tissue samples were prepared in the homogenization buffer (Invitrogen, Carlsbad, CA) at the 
concentration of 100 mg/mL. The tissue samples were homogenized using the Omni 
Homogenizer (Omni International, Kennesaw, GA) at full speed, each cycle of 30 sec and a 
30 sec dwell time. The tissue homogenates were kept on ice for 60 min to allow the maximum 
protein extraction from the samples. The tissue debris and other particulate matter from the 
homogenate were removed by centrifugation at 14,000 g for 15 min at 4°C. The supernatant 
was then removed and placed on ice. The protocol provided with the cytokine assay kit 
(Millipore Corp., Billerica, MA) was then followed using the Luminex MAGPIX instrument 
with xPONENT® version 4.2 software (Luminex Corp., Austin, TX). The extraction medium 
was used as the matrix solution in the blank, standards and control samples. 
Briefly, premixed magnetic beads conjugated to antibodies for all 7 cytokines were 
mixed with equal volumes of supernatants (25 μL) in 96-well plates. Plates were protected 
from light and incubated on a microplate shaker overnight at 4°C. Then, magnetic beads were 
washed twice with 200 μL of wash buffer, and detection antibodies were added to each well. 
The mixtures were incubated at room temperature for 1 h. Streptavidin-phycoerythrin 
conjugate was added to each well, and the mixtures were incubated for 30 min at room 
temperature. The magnetic beads were washed twice and re-suspended in wash buffer for 5 
min, the plates were assayed on the MAGPIX system. The median fluorescence intensity was 
analyzed using a 5-parameter logistic method from a standard curve of each respective cytokine 
to determine their concentration in supernatants in duplicate (n = 2). Basically, the red 
classification laser (635 nm) probed the internal dyes to identify bead regions. The green 
reporter laser (532 nm) interrogated the fluorescent reporter to measure analyte concentrations. 
Immunohistochemical Analysis to Identify the Inflammatory Cells in CV Tissues 
An increased lymphocytes infiltration within the vagina epithelium is indicative of 
vaginal inflammation (228). Thus, to identify the inflammatory cells (CD45) infiltration in 
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mice genital tract, the immunohistochemistry assay was performed. The CD45-associated 
protein is a lymphocyte-specific membrane protein. To visualize the lymphocytes, CV tissues 
were harvested from the treated mice following the immunohistochemistry protocol 
(ImmunoCruzTM mouse ABC Staining System, Santa Cruz Biotechnology, Dallas, TX) as 
explained below.  
Paraffin-embedded tissue sections were deparaffinized and rehydrated using xylene, 
ethanol gradient, and deionized water. Antigen retrieval was performed using steam heat 
method in citrate buffer/0.05%Tween-20 for 20 min. Following this incubation, tissue sections 
were rinsed with Tris-buffered saline/0.05%Tween-20 for 5 min each (three times). The tissue 
sections were then treated with 3% v/v H2O2 in PBS for 10 min and blocked with 10% normal 
goat serum for 2 h (Vector Laboratories, Burlingame, CA). Anti-CD45 from Santa Cruz 
Biotechnology, Inc. (Dallas, TX) was diluted in 1.5% normal goat serum to 5 µg/mL (1:50) 
and applied to the tissue sections overnight at 4°C in a humidified chamber. Following the 
incubation with primary antibody, tissue sections were rinsed three times. The appropriate 
biotinylated secondary antibody (Santa Cruz Biotechnology, Inc., Dallas, TX) was then diluted 
to 5 µg/mL (1:50) and applied to tissue sections at room temperature for 1 h. After the 
incubation with the secondary antibody, visualization of the cells was performed using the 
DAB: Peroxidase Substrate Kit (Sigma, Saint Louis, MO) under the above microscope. The 
tissue was then counter-stained using hematoxylin (Sigma, Saint Louis, MO) and processed 
through an alcohol gradient and xylene before application of a coverslip mounted using 
cytoseal 60 mounting media (Richard Allan Scientific, Kalamazoo, MI). 
 
In Vitro Anti-HIV Activity of HA Nanoformulations (HA-NPs and HA-SH-NFs) 
Generation and Characterization of Pseudotyped HIV Virus Particles 
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The pseudotyped virus particles were generated from two plasmids, one coding for the 
envelope, and the other for the backbone. The glycoprotein G from Vesicular Stomatitis Virus 
G Protein (VSV-G) was selected as the envelope protein because it allowed the infection for a 
very wide range of cell types from a variety of organisms and known to provide high titers 
(233). The proviral vector pNL4.3.Luc.R-E-, with envelop deleted and with the firefly 
luciferase gene was selected as the reporter plasmid (233). 
The virus particles were produced by co-transfection of HEK293T producer cells using 
lipofectamine 2000 (Invitrogen) assay (Figure 43) (234, 235). The plasmids encoding VSV-G 
were co-transfected with luciferase expressing pNL4.3.Luc.R-E- plasmid to generate VSV-G 
pseudotyped virus (234, 235). The viral supernatant was then harvested at 72 h post-
transfection, centrifuged for 15 min at low speed (500 g) to remove the cellular debris. The 
supernatant was filtered through a 0.45 µm pore size filter and stored in aliquots at -80°C until 
used for the single-cycle infection assay.  
 
Figure 43. Generation of Pseudotyped HIV Virus Particles using Plasmid Transfection 
Method. 
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To determine the titer (number of particles/mL) and size distribution of virus particles, 
nanoparticle-tracking analysis (NTA) was performed using a Nanosight LM10 instrument 
(Nanosight, Salisbury, UK) outfitted with a LM14C laser. The samples were diluted first in 
PBS to meet the optimal concentration between 105-108 particles/mL. At least 300 μL of diluted 
sample was needed for each analysis and was mixed by vortexing before injection into the 
chamber. Each video of moving particles was 60 s in duration, with a shutter speed of 30 ms 
and camera gain of 680. Software settings for analysis were: Detection threshold: 6, Blur: auto, 
Minimum expected particle size: 50 nm. A minimum of 200 completed particle tracks were 
completed for each video and the data was analyzed using the NTA 2.3 analytical software 
(Malvern Inc.). Briefly, the NTA analysis determines the particle diffusion coefficient (Dt) by 
measuring the movement of the particle (Brownian motion) and then this employs the Stokes-
Einstein equation (Eq. 36) to determine the size distribution and virus titer in each sample (236, 
237). 
d3
TK
D Bt

           (36) 
Here, T = sample temperature, KB = Boltzmann's constant, and η = solvent viscosity. 
Using Dt, the sphere-equivalent hydrodynamic diameter (d) of the virus particles was 
determined. 
In Vitro Anti-HIV Activity 
The anti-HIV activity assay of HA-NPs and HA-SH-NFs was performed using MT-4 
cells since, they are highly permissive to viruses (238). Briefly, MT-4 cells at the density of 
5x103 cells/ mL were incubated with 25 μL of free TFV or TFV loaded HA-NPs or HA-SH-
NFs suspended in cell culture medium. The nanoformulations were used in a concentration that 
is equivalent to the TFV dose of 0.035-35 µM for 24 h prior to the virus treatment (Figure 44). 
The cells were then exposed to 25 μL of the pseudotyped virus particles at the multiplicity of 
infection (MOI) of 10,000, 5000 and 1,000 and incubated for 48 h. Here, MOI was the ratio of 
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the number of pseudotyped virus particles to the number of cells being exposed. The inhibition 
of the pseudotyped HIV virus replication was analyzed using luciferase assay (Figure 44) due 
to its high sensitivity, and robustness toward a variety of drugs and complex biological samples 
(239). Briefly, after the 48 h of virus particles treatment, an equal volume of luciferase buffer 
and substrate (Promega, Madison, WI) was added and the plates were incubated for 10 min at 
37°C under 5% CO2. The bioluminescence was then immediately measured using a 
Luminometer (Promega, Madison, WI), according to the manufacturer’s directions. The wells 
with no cells were used as positive control whereas, cells suspended in medium without free 
TFV and HA-NPs or HA-SH-NFs were used as negative control samples, respectively. The 
inhibition of pseudotyped HIV virus replication was presented in terms of percentage (%) of 
viral load. 
 
Figure 44. Luciferase Assay Protocol. 
 
In Vitro Cytotoxicity Assay of HA-NPs on MT-4 Cells  
The in vitro cytotoxicity assay was performed up to 48 h incubation using the MTS cell 
viability assay. Briefly, MT-4 cells were seeded to 96-well plates in RPMI 1640 medium 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) and were 
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allowed to grow until 80% confluence was reached. The medium was replaced with 100 µL of 
samples suspended in culture medium at different concentrations of HA-NPs or HA-SH-NFs 
(equivalent to the TFV dose of 0.035-35 µM) and pseudotyped virus particles with MOIs of 
10,000, 5,000, and 1,000. The samples were kept in contact with the cells for 24 h at 37°C. 
After the incubation, 20 μL of CellTiter 96® Aqueous One Solution Reagent (Promega, 
Madison, WI) was added to each well and the absorbance was measured at 490 nm after 3 h 
incubation at 37°C. The absorbance was directly proportional to the number of viable cells as 
analyzed by using Eq. (37). Cells with no treatment and those treated with 1% Triton-X-100 
were considered as negative and positive controls, respectively. 
100
(control) ABS
(test) ABS
%)Viability(         (37) 
Where, ABS (test) and ABS (control) represented the absorbance of the amount of 
formazan product formed in viable cells. 
 
Statistical data analysis 
The experimental values were generally presented as mean ± standard deviation (SD) 
of triplicate determinations (n = 3). All animal experimental conditions (treatments and time 
points) were tested in a group of at least four mice unless otherwise mentioned. Statistical data 
analysis was evaluated using Students t-test with 95% confidence interval (CI). A p value ˂ 
0.05 was considered statistically significant. 
 
5.3. Results and Discussion 
 
Preclinical Safety and Toxicity Analysis in Mice Model  
The osmolality of a vaginal microbicide formulation could have profound effects on 
the vaginal environment and epithelium which could enhance HIV vaginal transmission and 
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infection (240, 241). The normal osmolality of female vaginal secretions and human seminal 
fluid was reported in the range of 260-290 mOsm/kg and 250-380 mOsm/kg, respectively, 
(128, 242). In this study, the osmolality values determined for each tested samples were well 
below the recommended osmolality for intra-vaginal application (<400 mOsm/kg) (231, 232) 
except for the N-9 (>1200 mOsm/kg). During the samples treatments, mice were inspected 
daily and no alterations in behavior, body weight, or temperature was noted between the 
treatment and control mice groups (data not shown). It was observed that Depo-Provera 
treatment maintained the diestrus conditions in the mice vagina as analyzed up to 9 days 
whereas, control mice (no Depo-Provera treatment) showed changes in the estrous cycle stages 
(appearance of the different types of cells) at different days (Figure 45). 
 
Figure 45. Cytological Assessment of Mouse CVL to Identify the Estrous Cycle Stages. Three 
Main Cell Types Detected in Mice CVL were: Nucleated Epithelial Cells (White Arrow); 
Cornified Squamous Epithelial Cells (Red Arrow); and Leukocytes (Blue Arrow). 
 
The histological analysis of the mice genital tract (vagina, cervix, uterus, and ovary), 
rectum, and other organs (spleen, lung, liver, kidney, heart, brain) did not show any signs of 
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toxicity and damage upon once-daily administration of TFV loaded HA-NPs or HA-SH-NFs 
up to 24 h (Figure 46A & 46B), and 7 days (Figure 47A & 47B), respectively.  
 
Figure 46A. Preclinical Safety Evaluation of HA-NPs and HA-SH-NFs Analyzed After 24 h 
Exposure to Mice Genital Tract Tissues (Vagina, Cervix, Uterus, Ovary) and Rectum. 
 
In case of the vagina, no changes to the typical histological architecture were observed 
in mice treated with nanoformulations and PBS (negative control groups). However, a clear 
thinning of the vaginal epithelium and stripping (damage) of the epithelium was observed 
(indicated by red arrows) following 24 h treatment in the N-9 and BZK treated mice (positive 
control groups) (Figure 46A) and a layer of dead cells was shown after 7 days treatment (Figure 
47A).  
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Figure 46B. Preclinical Safety Evaluation of HA-NPs and HA-SH-NFs Analyzed After 24 h 
Exposure to Mice Body Tissues (Kidney, Spleen, Lung, Liver, Heart). 
 
Figure 47A. Preclinical Safety Evaluation of HA-NPs and HA-SH-NFs Analyzed After 7 
Days Exposure to Mice Genital Tract Tissues (Vagina, Cervix, Uterus, Ovary) and Rectum. 
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Figure 47B. Preclinical Safety Evaluation of HA-NPs and HA-SH-NFs Analyzed After 7 
Days Exposure to Mice Tissues (Kidney, Spleen, Lung, Liver, Heart, Brain). 
 
These observations further supported the toxicity of N-9 and BZK to the vaginal 
mucosa. For the uterus and ovary, no signs of alterations were observed in the presence of any 
of the tested samples including the positive controls. This suggested that N-9 and BZK were 
not able to reach the upper genital tract in sufficient quantities to produce any toxicity or 
damage. Overall, the preclinical safety data showed that the developed HA-NPs and HA-SH-
NFs were safe in vivo at the concentrations tested. 
Immunoassay of Cytokines Secretion in CVL 
The levels (pg/mL) of 7 different cytokines including IL-1α, IL-1β, IL-6, IP-10, IL-7, 
MKC, and TNF-α, in mice CVL and CV tissues were analyzed after 24 h exposure with PBS 
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(negative control), N-9 and BZK (positive controls), and HA-NPs/HA-SH-NFs (treatments). 
The role of these cytokines in HIV virus vaginal transmission and infection is summarized 
below.  
 
Figure 48. Cytokines (IL-1α, IL-1β, IL-6, IP-10, IL-7, MKC, TNF-α) Levels (pg/mL) after 
24 h Exposure with TFV Loaded HA-NPs and HA-SH-NFs in Female C57BL/6 mice CVL 
and CV Tissues. Results are given as mean ± SD, n = 3. 
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The IL-1α and IL-1β are efficient inducers of the pro-inflammatory signals, released by 
injured epithelial tissues and enhance the HIV replication process (217). IL-6 enhance the HIV 
replication process and act as a growth factor for HIV virus. It has been recently shown that 
IL-7 facilitates HIV transmission to CV tissues (243). In addition, IL-7 also promotes HIV 
persistence during antiretroviral treatment by enhancing residual levels of viral production and 
inducing the proliferation of latently infected CD4+ T cells (244). Thus, it is important to check 
the levels of IL-7 after a microbicide formulation application. IP-10 is significantly associated 
with high vaginal viral load and its higher level decreases the T-cell functions in HIV infected 
individuals on retroviral therapy (39). MKC is equivalent to human IL-8 cytokine which 
stimulates the HIV replication process (245). TNF-α is one of the most important pro-
inflammatory cytokines that induces the levels of IL-6 and IL-8 and helps in upregulation of 
HIV replication (217).  
It was observed that the levels of most of the cytokines was not significantly induced 
after HA-NPs or HA-SH-NFs treatments for 24 h compared to the control CVL and genital 
tissue samples (Figure 48). The levels of few cytokines was found to be higher than the control, 
samples however, the values were well below than their standard values. The cytokine release 
data supported that HA-NPs and HA-SH-NFs were potentially non-immunogenic for vaginal 
application. 
Identification of Inflammatory Cells in CV Tissues 
Following 24 h exposure, negative control (Figure 49A), HA-NPs (Figure 49D) and 
HA-SH-NFs (Figure 49E) treated mice tissues did not show any significant immune cell 
infiltration in the genital tract which suggested the lack of vaginal inflammation but, few 
surface and luminal lymphocytes were observed. However, a significant number of immune 
cells infiltrate were noted in BZK (Figure 49B) and N-9 (Figure 49C) treated mice (indicated 
by red arrows). Very few, but not significant CD45 cells were observed after 7 days treatment 
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with HA-SH-NFs compared to BZK or N-9 treated groups. Overall, the cytokine and 
immunohistochemistry data supported that HA-NPs and HA-SH-NFs were potentially safe for 
vaginal application. 
 
Figure 49. Immune Cells (CD45) Infiltration on Female C57BL/6 Mice Vaginal Tissues after 
24 h and 7 Days Exposure. (A) Control. (B) BZK. (C) N-9. (D) TFV Loaded HA-NPs at the 
Dose of 25 mg/kg (equivalent to the drug dose of ~6.5 mg/kg). (E) TFV Loaded HA-SH-NFs 
at the Dose of 275 mg/kg (equivalent to the drug dose of ~46 mg/kg). Red Arrows Showed the 
CD45 Cells Infiltration in C57BL/6 mice CV Tissues. 
 
In Vitro Anti-HIV Activity of Nanoformulations (HA-NPs and HA-SH-NFs) 
Pseudotyped Virus Particle Generation and Characterization 
The pseudotyped HIV virus particles were generated using plasmid transfection method 
(Figure 43) and analyzed using nanoparticle tracking analysis (NTA) measurements (Figure 
50). The mean diameter of the virus particles was found to be 128.00 ± 15.53 nm (n = 6). The 
virus titer (number of particles/mL) was determined to be 3.07 × 1010 ± 0.30/mL (n = 6) in cell 
culture media. A clear difference between the background and the sample containing 
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pseudotyped virus particles was observed (Figure 50) which also confirmed the presence of 
pseudotyped HIV virus particles and they are successfully generated. 
 
Figure 50. Characterization of Pseudotyped HIV Virus Particles Generated by Plasmid 
Transfection Method Using Nanoparticle Tracking Analysis (NTA) Measurements. 
 
In Vitro Anti-HIV Activity of HA-NPs 
The HIV virus replication inhibition efficacy of HA-NPs was analyzed at the 
concentration that is equivalent to the TFV dose of 0.035-35 µM and at the MOI of 10,000 
(Figure 51A), 5,000 (Figure 51B) and 1,000 (Figure 51C).  
Results showed that the HA-NPs have significantly higher anti-HIV activity against the 
pseudotyped virus replication compared to the free TFV (n = 3) at the MOI of 5,000 and 1,000 
in all concentrations except the 35 µM. However, the efficacy of NPs was not significantly 
different compared to the free TFV at the MOI of 10,000. This could be due to the presence of 
very high number of virus particles compared to the number of cells at the MOI of 10,000. The 
HA-NPs were found to be non-cytotoxic to MT-4 cells and there was no statistically significant 
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effect (p > 0.05) on the viability of MT-4 cells, compared to the cell culture medium is observed 
(n = 3) (Figure 52). 
 
Figure 51. In vitro Anti-HIV Activity of TFV Loaded HA-NPs: (A) At the MOI of 10,000 (B) 
At the MOI of 5,000. (C) At the MOI of 1,000. Results are given as mean ± SD, n = 3. Asterisk 
(*) indicated the significant effect (p ˂ 0.05) of NPs compared to free TFV at the same dose. 
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Figure 52. Cytotoxicity assay and effect of HA-NPs on the viability of MT-4 cell line analyzed 
by MTS assay. Results are given after 48 h of incubation as mean ± SD, n = 3. 
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In Vitro Anti-HIV Activity of HA-SH-NFs 
The in vitro anti-HIV activity data (n = 3) of HA-SH-NFs at the MOI of 10,000 (Figure 
53A), 5,000 (Figure 53B) and 1,000 (Figure 53C) showed that the NFs effectively inhibited 
the virus replication process. The in vitro anti-HIV activity of free TFV and TFV loaded HA-
SH-NFs was significantly increased as the MOI was lowered from 10,000 to 1,000. This could 
be due to the presence of fewer virus particles exposed to the native TFV or TFV loaded HA-
SH-NFs as MOI was lowered. However, the anti-HIV effect was not significantly different 
compared to that of the free TFV at all MOIs. This could be due to the facts that the cell 
treatment with the pseudotyped HIV virus was performed after the 24 h treatment with HA-
SH-NFs and by that time, most of the encapsulated drug was released out of the NFs as shown 
in their release profile graphs (Figure 38). This probably led to have an equal amount of free 
TFV in the HA-SH-NFs treated cells as in free TFV treated cells and thus, produced almost the 
similar anti-HIV activity. These observations were consistent with recent studies by other 
researchers where they also observed that the anti-HIV activity of TFV encapsulated in 
nanofibers was similar to that of unformulated or free TFV (246). 
Although, the anti-HIV activity of free TFV and TFV in HA-SH-NFs was not 
significantly different, the results suggested that the drug maintained its structural integrity, 
and the activity of TFV was unaffected by composite geometry of HA-SH-NFs. In addition, 
drug formulations such as NFs have several advantages compared to the free drug, including 
sustained and controlled release system, leading to better drug delivery than free drugs in 
solution, with a potential reduction in the side effects, and drug instability issues. In this respect, 
anti-HIV activity assay needs to be perform at different time points after HA-SH-NFs treatment 
in the presence and absence of HAase enzyme to determine the enzyme responsiveness of these 
nanoformulations (NPs and NFs). Comparing the anti-HIV activity of TFV loaded HA-NPs 
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and HA-SH-NFs, HA-NPs seemed to have higher efficacy. This was due to the several facts as 
explained below. 
 
Figure 53. In Vitro Anti-HIV Activity of TFV loaded HA-SH-NFs: (A) At the MOI of 10,000. 
(B) At the MOI of 5,000. (C) At the MOI of 1,000. Results are given as mean ± SD, n = 3. 
Asterisk (*) indicated the significant effect (p ˂  0.05) of TFV loaded HA-NPs compared to free 
TFV at the same dose concentration. 
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Tenofovir used as a model microbicide in this study, belongs to the category of anti-
retroviral drugs under the sub-category of nucleotide RT inhibitors. The nucleotide analogues 
must undergo a series of phosphorylation steps by intracellular kinases to transform into their 
active triphosphate metabolites. Thus, they need to get inside the cells either through passive 
diffusion or carrier-mediated transport to produce their antiviral effects. Usually, the nucleotide 
analogues such as tenofovir are highly hydrophilic in nature and have limited cell membrane 
permeability. The NPs has been proven to have a higher cellular uptake by several pathways 
because of their small diameter, targeting efficiency, and surface chemistry (247). It has been 
previously reported that the particle size contributes to the cellular internalization pathways 
and particles with a diameter < 200 nm enter cells preferentially via clathrin-mediated 
endocytosis (248). The HA-NPs formulated (chapter 3) with a mean diameter of ~70-80 nm 
supposed to have a higher cellular uptake compared to the NFs formulation due to the longer 
structure, non-spherical geometry, and mucoadhesive properties. These all helped NFs to stay 
longer at the cell surfaces rather than being up taken by the cells. All of these factors caused 
the low amount of TFV that has been up taken by cells and thus hindered the antiviral effect of 
TFV in case of NFs compared to the NPs. 
In this dissertation, stimuli-sensitive nanoformulations have been developed those 
supposed to be stayed at the vaginal surface until the arrival of seminal fluid including the 
hyaluronidase enzyme. In this respect, the NFs is an appropriate model since, it will have higher 
bio-retention and less cellular uptake due to the facts as explained above compared to the NPs 
design. However, this remains to be elucidated in the future in vivo time-responsiveness and 
bio-retention of these nanoformulations in the presence of seminal fluid and hyaluronidases.  
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Bio-retention and Distribution of FITC labelled HA-NPs in the Mouse Vagina 
The bio-retention and distribution of the HA-NPs in the vaginal tract was investigated 
after intravaginal application of FITC-labelled HA-NPs (25 mg/kg) using a female C57Bl6 
mice. The mice were sacrificed at 15min, 30min, 8h, and 24 h post-treatment immediately 
before dissecting out the vagina. After dissection, the entire vagina was slit open lengthwise 
and flat-mounted on microscope slides. Images of the flat-mounted vagina was viewed and 
captured using a Nikon Labophot-2 microscope (Nikon Instruments, Inc., Melville, NY) 
equipped with a PAXCam digital microscope camera and analyzed using PAX-it image 
management and analysis software (Midwest Information Systems, Inc., Villa Park, IL).  
 
Figure 54. Vaginal Distribution of FITC-labelled HA-NPs (25mg/kg) in Female C57BL/6 
Mice. 
The results demonstrated the HA-NPs were distributed throughout the vaginal lumen. 
However, the bio-retention was very low as after 24 h, very few HA-NPs were observed in the 
vaginal tract (Figure 54). The results showed that the HA-NPs did not have a long residence 
time in mice vagina and leaked-out quickly due to their low or negligible mucoadhesion 
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properties and small diameter. In this respect, mucoadhesive HA-SH-NFs developed in Chapter 
4, would have a better bio-retention in mice vagina due to their thiolated surface chemistry and 
non-spherical geometry to fulfill the goal of stimuli-sensitive formulation development in this 
dissertation. However, this remain to be analyzed in the future studies.  
 
5.4. Conclusion 
 
In this study, preclinical evaluation of HA based nanoformulations (HA-NPs and HA-
SH-NFs) was performed in C57BL/6 mice model. Histological analyses confirmed the safety 
of NPs and NFs in mice genital tract tissues and other organs. The HA-NPs or HA-SH-NFs did 
not induce any CD45 immune cell infiltration in genital tract tissues. The cytokine release 
levels were not significantly changed for most of the tested cytokines in CVL and CV tissues. 
The in vitro anti-HIV activity data showed that the drug loaded HA-NPs and HA-SH-NFs were 
able to inhibit the pseudotyped HIV virus replication and the anti-HIV activity of TFV was 
preserved after the nanofabrication processes. Results showed that the HA-NPs have 
significantly higher anti-HIV activity against the pseudotyped virus replication compared to 
the free TFV at the MOI of 5,000 and 1,000 for most of the concentrations tested. However, 
the efficacy of NPs was not significantly different compared to the free TFV at the MOI of 
10,000. The in vitro anti-HIV activity data of HA-SH-NFs showed that the NFs effectively 
inhibited the virus replication process. Although, there was no significant difference was 
observed compared to the free TFV. Overall, the data presented here highlight the potential of 
developed NPs and NFs templates for the vaginal delivery of anti-HIV/AIDS microbicides. 
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CHAPTER 6 
SUMMARY, CONCLUSION AND FUTURE DIRECTIONS 
 
6.1. Summary and Conclusion 
 
In this dissertation, two different kinds of nanoformulations templates (nanoparticle and 
mucoadhesive nanofiber) have been developed. These formulations were loaded with an anti-
HIV topical microbicide (tenofovir) and designed to have a stimuli-sensitive effect in the 
presence of semen hyaluronidase enzyme for HIV virus vaginal transmission prevention in 
women. The physicochemical properties such as mean diameter, drug loading, surface 
morphology, stability, in vitro drug release profile and drug release kinetics were evaluated. 
The in vitro cytotoxicity, preclinical safety, and anti-HIV activity of these formulations were 
also performed. 
In chapter 3, hyaluronic acid based nanoparticles (HA-NPs) were designed and 
formulated using surfactant free cross-linking method to test the hypothesis that a triggered 
release of a microbicide (tenofovir) from HA-NPs can be achieved under the influence of 
seminal hyaluronidase enzyme. The Fractional Factorial Experimental Design was employed 
to examine the effect of various formulation and process variables on NPs. The HA-NPs were 
characterized for their particle mean diameter, size distribution, surface morphology, cross-
linking chemistry, in vitro enzymatic degradation, stability, and in vitro drug release profile. 
HA-NPs exhibited a spherical shape with mean diameter of ~75 nm. The HAase enzyme 
notably triggered the drug release and HA degradation from the NPs after 24 h (~90% w/w and 
65% w/w, respectively); whereas, in its absence, these values were ~39% w/w and 26% w/w, 
respectively. The HAase triggered drug release from the HA-NPs took about 24 h to reach 
~90% w/w and was the major limitation of this design. Moreover, these HA-NPs systems found 
151 
 
to have a short vaginal retention time in vivo as analyzed using C57BL/6 mice model and 
explained in chapter 5. The NPs were found to be non-cytotoxic to human vaginal VK2/E6E7 
and End1/E6E7 cells and had no effect on Lactobacillus bacteria viability. These data 
suggested the possibility of using HA-NPs as a delivery system for intravaginal delivery of 
topical microbicides for the prevention of HIV transmission after successful improvement of 
the HAase enzyme effectiveness and bio-retention time. Overall, the NPs provided a better 
control over drug release compared to the HA-gel. The study suggested that ultimately 
suspending the TFV loaded NPs in TFV loaded HA-gel formulation might be an alternative 
formulation for effective prevention of the HIV virus transmission. In this case, the gel would 
provide a bolus dose for immediate drug release before the HIV virus crosses the CV mucosa 
(in about 2-6 h) followed by a semen-triggered drug release from NPs for at least 72 h after the 
sexual intercourse. 
Based on the knowledge gained in chapter 3, stimuli-sensitive and mucoadhesive 
thiolated nanofibers loaded with a vaginal microbicide (tenofovir) were formulated in chapter 
4 for the prevention of HIV virus vaginal transmission in women. A novel thiolated sulfhydryl 
(-SH) group modified HA (HA-SH) was first synthesized and characterized to fabricate the 
TFV loaded HA-SH-NFs (mean diameter ~75 nm) using coaxial electrospinning method. The 
synthesized HA-SH-NFs were characterized for their physicochemical properties including 
size distribution, surface morphology, surface chemistry, crystallinity, mucoadhesion property, 
and in vitro drug release profile. Mucin interaction and ellipsometer measurements confirmed 
the higher mucoadhesion of HA-SH-NFs compared to native HA. A triggered drug release 
(~87 %w/w) from HA-SH-NFs compared to the HA-NPs was observed after 1 h of incubation 
in the presence of seminal HAase enzyme. This could be due to the porous surface geometry 
and absence of any cross-linking chemistry at the HAase enzyme target size (carboxylic acid 
groups) compared to the HA-NPs. Moreover, the large surface areas to volume ratios of NFs 
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provided a larger area for drug interaction with the surrounding medium which facilitated the 
mass transfer and thus, a fast release of therapeutic molecules was observed. The HA-SH-NFs 
were non-cytotoxic to vaginal VK2/E6E7 and End1/E6E7 cells and L. crispatus bacteria 
analyzed up to for 48 h. In addition, NFs confirmed to have a higher mucoadhesion due to the 
presence of thiol groups on their surface. Collectively, the results suggested that TFV loaded 
HAase sensitive HA-SH-NFs templates developed in this study have the potential of vaginal 
delivery of microbicides for the prevention of HIV transmission. 
In chapter 5, the developed HA-NPs and HA-SH-NFs formulations were evaluated in 
vivo for their preclinical safety, immunogenicity in female C57BL/6 mice. The histological 
analysis on the female C57BL/6 mice genital tract and other organs did not show any signs of 
damage upon once-daily administration of these nanoformulations up to 7 days. Following 24 
h of exposure, HA-NPs or HA-SH-NFs did not show any significant CD45 cell infiltration in 
mice vaginal tissues. The cytokines levels in CVL and CV tissues were not significantly 
changed compared to control (treated with PBS) mice groups analyzed after 24 h. The in vitro 
anti-HIV activity data showed that the TFV loaded HA-NPs and HA-SH-NFs were able to 
inhibit the pseudotyped HIV virus replication and the anti-HIV activity of TFV was preserved 
after the nanofabrication processes. Results showed that the HA-NPs have significantly higher 
anti-HIV activity against the pseudotyped virus replication compared to the free TFV at the 
MOI of 5,000 and 1,000 for most of the concentrations tested except at 35 µM equivalent of 
drug dose. However, the efficacy of NPs was not significantly different compared to the free 
TFV at the MOI of 10,000. The in vitro anti-HIV activity data of HA-SH-NFs showed that the 
NFs effectively inhibited the virus replication process, although there was no significant 
difference was observed compared to the free TFV. This could be due to the facts that the cell 
treatment with the pseudotyped HIV virus was performed after the 24 h treatment with HA-
SH-NFs and by that time, most of the encapsulated drug was released out of the NFs as shown 
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in their release profile graphs. This probably led to have an equal amount of free TFV in the 
HA-SH-NFs treated cells as in free TFV treated cells and thus, produced the similar anti-HIV 
activity. These observations were consistent with recent studies by other researchers where 
they also observed that the anti-HIV activity of TFV encapsulated in nanofibers was similar to 
that of unformulated TFV. The anti-HIV activity results suggested that the drug TFV has 
maintained its structural integrity during the nanofabrication processes either in NPs or NFs.  
The developed HA-NPs and HA-SH-NFs formulations are compared here;  
Parameters HA-NPs HA-SH-NFs 
Manufacturing feasibility √ √ √ 
Scalability √ √ 
Cost-effectiveness √ √ 
Drug compatibility/loading √ √ √ 
Stability √ √ √ 
Enzyme sensitiveness √ √ √ 
Bioretention √ √ √* 
Preclinical safety √ √  
In vitro anti-HIV activity √ √* √ 
√: High; √√: Very High; *: remains to be elucidated. 
Overall, the dissertation work presented here demonstrated the applicability of two 
different kinds of stimuli-sensitive nanoformulations for the topical vaginal delivery of anti-
HIV/AIDS microbicide candidates. These formulations are promising delivery systems and 
offered a safe delivery of anti-HIV microbicide candidates.  
 
154 
 
6.2. Future Directions 
 
 Expand the application of nanoformulations templates to other topical microbicides 
(fusion/entry inhibitors) alone or in combination with reverse transcriptase inhibitors. 
 Optimize the scalability and cost-effectiveness of developed nanoformulations to 
eventually meet the actual needs of third world countries. 
 Address the potential in vivo time-responsiveness and drug release in the presence of 
seminal fluid and hyaluronidase enzyme. 
 Analyze the in vivo anti-HIV efficacy of developed nanoformulations in an appropriate 
animal model. 
 Biodistribution and pharmacokinetic profiling of nanoformulations in animal model. 
 In vivo retention and mucoadhesion studies in animal model. 
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